Targeting the interaction between p38α and TAB1 by Thapa, Dibesh
This electronic thesis or dissertation has been 











The copyright of this thesis rests with the author and no quotation from it or information derived from it 
may be published without proper acknowledgement. 
 
Take down policy 
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing 
details, and we will remove access to the work immediately and investigate your claim. 
END USER LICENCE AGREEMENT                                                                         
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 
International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ 
You are free to: 
 Share: to copy, distribute and transmit the work  
 
Under the following conditions: 
 Attribution: You must attribute the work in the manner specified by the author (but not in any 
way that suggests that they endorse you or your use of the work).  
 Non Commercial: You may not use this work for commercial purposes. 
 No Derivative Works - You may not alter, transform, or build upon this work. 
 
Any of these conditions can be waived if you receive permission from the author. Your fair dealings and 




























Targeting the interaction between 















Department of Cardiology 
Cardiovascular Division 
Rayne Institute, BHF Centre 
4
th
 Floor Lambeth Wing 
St Thomas’ Hospital 

















p38α, a member of the mitogen activated protein kinase family, is a stress activated 
serine/threonine kinase which plays an important role in signalling pathways mediating 
fundamental processes such as inflammation, apoptosis, autophagy, and cell division, 
differentiation and death. Over the last two decades, its prominence in ischaemic heart disease 
has risen rapidly with several studies providing overwhelming evidence that p38α activation 
aggravates lethal injury during myocardial ischaemia. Several inhibitors have been tested to 
prevent p38α activation and although they have performed well in the laboratory; unfortunately 
the results have not translated to clinical trials in patients. This has mainly been due to toxicity 
such as liver injury, skin rashes, gastrointestinal disorders, and flares-ups of rheumatoid 
arthritis. These adverse effects are shared by different inhibitors, the majority of which belong 
to the ATP-mimetic, type I group, suggesting they result from an on-target effect of inhibiting 
ubiquitously expressed p38α. As a result, an alternative therapeutic strategy, other than the 
blanket inhibition of p38, is required. TAB1 mediated p38α activation appears to be the culprit 
behind the detrimental p38α signalling during myocardial ischaemia and selectively targeting 
this branch of p38α activation, without affecting prototypical p38α activation, is highly 
desirable. In this thesis I studied the structural features of p38α and TAB1 which contribute to 
the TAB1-mediated p38α autoactivation mechanism. Using various biochemical and 
biophysical tools in in-vitro and ex-vivo systems, I have identified the key residue in p38α, and 
TAB1, which contribute to the auto-activation of p38α by TAB1. The results from my 
investigations suggest that targeting these residues impairs the autoactivation process and these 
structural features may be exploited to elucidate p38α’s role in myocardial ischaemia. 
Ischaemic heart disease continues to be the biggest killer in the world, and the search for p38α 
inhibitors still continues without any fruitful outcomes. A new direction and strategy focusing 
on circumstance selective inhibition is required in p38α therapeutics, and hopefully the results 
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1.1 Ischemic Heart Disease  
Ischemic heart disease (IHD) is a pathological condition caused by an inadequate supply of 
blood to the myocardium. IHD also known as coronary artery disease (CAD) or coronary heart 
disease comprises a group of diseases which includes angina, myocardial infarction and sudden 
cardiac death. IHD along with heart failure, arrhythmias, cardiac arrest and stroke contributes to 
cardiovascular diseases (CVD). In 2010, more than 17 million deaths globally were caused by 
CVD; 7 million of which were caused by IHD (Lozano et al, 2012). 80,000 of the 7 million 
deaths were in the UK and together with 49,000 deaths from Stroke, it resulted in cardiovascular 
disease being the most common cause of death in the UK with almost 180,000 deaths in 2010 
(BHF statistics, 2010). The morbidity and mortality from IHD is substantial and chronic CVD 
affects a significant portion of the population. It not only decreases quality of life but also causes 
an enormous pressure on an already limited NHS budget. In 2009 alone, it cost the UK’s 
healthcare system £8.7 billion (BHF statistics, 2010).   
 
The hallmark of ischaemic heart disease, as the name suggest, is ischaemia of the heart, i.e. lack 
of an adequate supply of blood. This prevents delivery of sufficient oxygen and nutrients to, 
and/or removal of the metabolites from, cells within the heart muscle. The cells cannot function 
or survive without oxygen that is required for aerobic respiration and metabolic imbalance 
triggers several biochemical reactions which can lead to myocyte death (Ferrari, 2000). There 
are many risk factors for IHD with the most common being smoking, hypertension, obesity, 
diabetes mellitus, high cholesterol and unhealthy lifestyle; consequently, 90% of IHD may be 
preventable (McGill et al, 2008). The current management for IHD is medication with Statins, 
which reduce cholesterol levels in the blood and anti-platelet therapy such as aspirin that 
prevents the risk of thrombus formation and Myocardial Infarction following erosion or rupture 




1.2 Atherosclerosis  
Atherosclerosis, a vascular disease, is the main underlying cause of ischaemic heart disease 
(IHD). It is a chronic condition in which over time the artery wall thickens, stiffens and looses 
elasticity due to the build-up of atherosclerotic plaques. The atherosclerotic plaque is a fatty 
streak (cholesterol and lipids) that builds up along the inner lining of the arteries in the heart. 
According to the response-to-injury hypothesis, atherosclerosis begins with the dysfunction of 
endothelial cells which can be caused by several factors such as smoking, elevated level of LDL 
due to unhealthy lifestyle choices, hypertension, diabetes mellitus, viral infections, or genetic 
alterations (Ross et al, 1973). The insult of endothelial dysfunction then starts a chain of 
reactions, beginning with the accumulation of lipids and low-density lipoprotein beneath the 
endothelium (Hollander et al, 1979). This incites an inflammatory response with increased 
leukocyte, monocytes infiltration from the blood into the blood vessel. The LDL accumulation 
increases beneath the endothelium in the intima layer and free radicals and oxidizing enzymes, 
such as lipoxygenase, begin to oxidize the LDL (Yoshida et al, 2010). The oxidized LDL further 
enhances the inflammatory response as infiltrating monocytes differentiate into macrophages 
(Zhang et al, 2017). The macrophages engulf the oxidized LDL, via scavenger receptors, in an 
attempt to clear these particles. The intracellular LDL persists and in the process the 
macrophages turn into foam cells. The damage to the endothelial layer stimulates the 
proliferation and migration of the smooth muscle cells to form a fibrous cap. The process 
continues slowly and the vicious cycle of inflammatory response results in the growth of the 

























Figure 1.2 Progression of atherosclerosis: The figure shows the mechanism of atherosclerosis as it 
progresses from one stage to another. The disease starts with endothelial dysfunction that causes an 
inflammatory response resulting in the formation of fatty streaks. A fibrous cap forms around the lesion 
and fatty streaks as a healing response but over time it can become unstable and rupture to cause 
thrombosis. The thrombus may occlude the artery which can result in Myocardial Infarction (Ross, 1999). 
 
 
Over time, the size of the atherosclerotic plaque increases, hardening the artery wall and 
obstructing the blood flow in the lumen of the artery. The lack of proper supply of the blood 
(oxygen and nutrients) leads to a condition known as angina pectoris – chest pain caused by 
cardiac ischemia. There are two types of angina; stable angina and unstable angina. Stable 
angina is a chest discomfort that is only felt during an activity such as walking, running or other 
physical or mental stress, but not during rest. In unstable angina however, chest pain symptoms 
occur during rest and are unpredictable. The difference between the two types of angina is 
determined by the pathophysiology of the atherosclerotic plaque within the coronary artery 
22 
 
(Chen et al, 2009). In stable angina, the atheromatous plaque restricts the full supply of the 
blood flow in the heart but the plaque itself is protected by a fibrous cap. The demand for blood 
by the heart is not high during rest; as a result myocardial ischaemia does not occur under resting 
conditions, so the patient is asymptomatic and angina-free. However, on exercise, the heart has 
to work harder to meet the body’s demands and as a result its own oxygen demand increases. 
The increased demand cannot be met due to the atheromatous plaque obstructing the conduit 
epicardial artery, and preventing the increase in myocardial blood flow. As a consequence of the 
mismatch between myocardial demand for blood and coronary artery supply; ischaemia ensues 
which the person fells as chest discomfort. In unstable angina, the atheromatous plaque is 
unstable, causing variable obstruction/embolization which impedes flow to the heart muscle at 
rest. The processes contributing to instability include platelet aggregation and formation of blood 
clot/thrombus. The thrombus can occlude the residual lumen of the artery and block the vessel 
completely or it can travel down the artery and then block the smaller blood vessels within the 
myocardium. Unstable angina can therefore lead to Myocardial Infarction (Rajpurohit et al, 
2015). The likelihood of this progression is diminished by drugs and mechanical disruption of 
the plaque by balloon angioplasty and stent insertion (Clarkson et al, 1999).   
 
1.3 Myocardial Infarction (MI)  
Myocardial Infarction (MI) occurs when a thrombus blocks an epicardial coronary artery, or 
smaller distal blood vessels, to impede myocardial blood flow. Without blood, the oxygen and 
nutrients cannot be delivered to the region of the heart and metabolites cannot be washed out, as 




















Figure 1.3 Myocardial infarction: The diagram shows the damage to the heart caused by Myocardial 
Infarction. The atheromatous plaque and blood clot blocks the blood flow in the coronary artery which 
results in the necrosis of the distal region of myocardium supplied by the blocked coronary artery 
(National Institute of Health- https://www.nhlbi.nih.gov/health/health-topics/topics/heartattack).     
 
 
The immediate consequence of the thrombus is the creation of a hypoxic environment in the 
subtended myocardium. Without oxygen, the krebs cycle and oxidative phosphorylation ceases, 
which results in a dramatic fall of ATP production. In an attempt to maintain the ATP:ADP 
ratio, the cell switches to anaerobic respiration and glycogen breakdown and glucose uptake 
increase to stimulate glycolysis. The glycolysis converts a glucose molecule into 2 pyruvates and 
2 ATPs. Due to the lack of oxygen, pyruvate cannot be oxidized to acetyl-coenzyme A (Acetyl-
CoA) to feed into the Krebs cycle, making glycolysis the sole source of ATP. To increase the 
ATP production the cell speeds up glycolysis by converting pyruvate to lactate through lactate 
dehydrogenase, which in turn produces NAD
+
 from NADH that is required for glycolysis (Guth 
et al, 1990; Marshall et al, 1981). Glycolysis however only produces around 5% of energy 
compared to aerobic respiration (2 ATP compared to 38 ATP per glucose) which is not enough 
to sustain proper cellular functions (Stanley, 2001). The cycle continues and lactate build-up 
overwhelms cell as it cannot be washed out due to lack of perfusion. The consequence is low 
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cellular pH which has two significant effects; first, it slows down glycolysis by inhibiting 
phosphofructokinase 1 (PFK), one of the enzymes in glycolytic pathway and second, it disrupts 
cellular haemostasis which triggers a host of downstream event that cause the cellular 
dysfunctions apparent in acute myocardial infarction (AMI) (Jennings, 1991).  
 
The acidic environment caused by build-up of lactic acid activates the sodium-hydrogen 
exchanger, which in an attempt to normalise pH, causes intracellular sodium accumulation 
(Huber et al, 2012). The increase in intracellular sodium in turn causes activation of the sodium-
calcium exchanger, thereby causing the intracellular calcium concentration to rise. These 
abnormal biochemical changes can disrupt the heart’s rhythm and chronotropic state (Murphy et 
al, 2002). For example, the rise in intracellular calcium can overload the mitochondria, and 
sarcoplasmic reticulum (SR) which causes calcium leakage into the cytosol (calcium sparks). 




 exchanger that results in a net inward depolarizing 
current, which can trigger delayed after depolarisation. The low ATP caused by ischaemia 
affects the ion pumps such as sodium/potassium ATPase which causes imbalance in ionic 
gradient and results in increased extracellular potassium concentration (Fozzard et al, 1985). 
This in turn decreases the resting membrane potential of the cardiac cells and affects their 
excitation. The high extracellular potassium also causes reduction in duration of the action 
potential which makes its susceptible to re-excitation. The high potassium permeability can 
trigger early repolarisation and shorten refractory period which all may contribute to re-entry. 
Sodium channels responsible for the action potential exist in three forms; open, inactivated and 
closed. During ischaemic depolarization, the cell shifts the balance towards the inactivated state 
of these sodium channels which greatly reduces the number of channels available to be opened 
resulting in reduced excitation and conduction velocity (Fozzard et al, 1985). Additionally, the 
low pH increases the resistance of gap junctions and slows electrical conduction through the 
ischaemic myocardium (De Mello, 1982). All these ionic/electrophysiological perturbations in 




Ischaemia also affects the ionotropic function of the heart. Under normal perfusion of the cells, 
1/3 of ATP produced in the cell is used by ATPase pumps such as Na/K ATPase and the calcium 
pump (SERCA) in the sarcoplasmic reticulum, whereas 2/3 of ATP is used during 
contraction/relaxation by myosin ATPase to achieve crossbridge recycling (Stanley, 2001). So, 
the shortage of ATP during ischaemia means the ATPase channels cannot function properly 
which leads to the accumulation of sodium and calcium in cells which affects myocytes 
excitation, which in turn affects excitation -contraction coupling. The process of contraction is 
profoundly perturbed since the reduction in the concentration of ATP:ADP prevents myosin 
from detaching from actin at the end of the power stroke. This is exacerbated by the high 
intracellular calcium concentration which sensitises the myofilaments by binding to troponin C. 
The end result is rigor bond formation and a stiff non-contractile heart.  This will affect 
excitation-contraction coupling and prevent the proper contraction of the heart.  
 
With prolonged starvation of blood, cells in the heart will start to die by necrosis and apoptosis. 
Apoptosis is an event whereby cells under-go programmed cell death characterized by nuclear 
fragmentation and generation of apoptotic bodies (Arbustini et al, 2008). Necrosis on the other 
hand is a premature cell death caused by an external insult such as ischaemia that results in 
degradation of cell membranes and release of cellular products into the extracellular space which 
triggers an inflammatory reaction. During myocardial infarction, cardiac myocytes in the 
ischaemic region die by both apoptosis and necrosis, although it is unclear how much each 
pathway contributes to the infarction (James, 1998). Apoptosis is an energy-dependent event; as 
a result the energy depleted cells in the centre of the infarct are believed to die via necrosis, 
whereas the less energy-compromised cells in the border region of the infarct are believed to die 
via apoptosis (Webster, 2012). Early ischaemic stress may induce apoptosis but with prolonged 
ischaemia converts to necrosis as ATP concentration drops (Cruchten et al, 2002). With 
prolonged ischaemia, there is a significant rise in ADP, AMP and phosphate concentration in the 
cells. The increased AMP is converted into adenosine which is converted to inosine and xanthine 
through the purine degradation pathway. In the presence of residual oxygen, xanthine reductase 
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can be oxidized to xanthine oxidase which produces superoxide and other damaging reactive 
oxygen species (ROS) (Haelstrap et al, 2009). Additionally, nitric oxide synthase and NADPH 
oxidase also contribute towards the formation of harmful ROS and superoxides during ischaemia 
(Murphy, 2009). The rise in intracellular calcium resulting from low pH causes the mitochondria 
to take up calcium. The flooding of calcium in mitochondria, with increased phosphate and ROS 
triggers the opening of the mitochondrial permeability transition pore (mPTP) (Webster, 2012). 
The mPTP opening means the inner mitochondrial membrane no longer maintains a proton 
barrier which completely stops oxidative phosphorylation. Another major consequence of mPTP 
opening is the leakage of molecules smaller than 1.5kDa from the mitochondria (Seidlmayer et 
al, 2015). This not only imbalances the metabolic gradient between the mitochondria and cytosol 
but it also causes the swelling of mitochondria due to colloidal osmotic pressure caused by 
inflow of small osmolytes. Eventually, as the matrix expands the outer membrane cannot sustain 
the pressure leading to its rupture. This releases cytochrome c and other pro-apoptotic proteins to 
initiate apoptotic cell death (Halestrap et al, 2009). With prolonged ischaemia, the mPTP 
opening will drive necrosis and cause infarction of the myocardium. If an extensive area of the 
heart is affected its ability to pump blood is compromised and the consequence is maladaptive 
remodelling which eventually causes immediate or delayed heart failure. The mPTP opening is 
triggered by a combination of high intracellular calcium and ROS, and as ROS production is 
highest at the point of reperfusion due to the availability of oxygen, it may accelerate damage at 
the beginning of reperfusion, which is commonly known as ischaemia-reperfusion injury.  
 
1.4 Cardiac hypertrophy  
Cardiac hypertrophy is a physical change where the heart grows in size with thickening and/or 
lengthening of cardiac myocytes. There are two types of cardiac hypertrophy; physiological and 
pathological (Bernardo et al, 2010). Physiological cardiac hypertrophy is a uniform growth of 
ventricular wall and septum matched by an increase in chamber dimension (eccentric 
hypertrophy) that results in increased myocardial muscle mass and pumping ability. For 
example, during pregnancy or in trained athletes the myocardial wall and cavity enlarge as 
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myocytes increase in length which helps enable the necessary increase in cardiac output 
(Shimizu et al, 2015). Pathological hypertrophy however, is characterized by an uneven growth 
of cardiac myocytes with a net decrease in the ventricular chamber dimension (concentric 
hypertrophy) and wall thickening and is accompanied by an extensive fibrosis that does not 
result in an increased cardiac output (Heineke et al, 2006). Pathological hypertrophy is caused 
by hypertension, outlet valve stenosis, MI, or genetic mutations.  
 
After the ischaemic insult of MI, the heart may undergo a compensatory change in an attempt to 
restore normal cardiac function (Zaino et al, 1963). For example, a prolonged duration of 
ischaemia can result in a large amount of necrosis and myocardial cell loss. This will affect the 
ability of the myocardium to pump blood properly and result in a reduced cardiac output for any 
given filling pressure. In order to compensate for the loss of cardiac output, the heart undergoes 
a process of pathological cardiac hypertrophy. Pathological cardiac hypertrophy results in 
further dysfunction of myocardium and with increased interstitial fibrosis the cardiac function 
progressively deteriorates and causes heart failure (Kerkela et al, 2006).  
 
1.5 Heart Failure  
Chronic heart failure, also known as congestive heart failure (CHF), is a condition where the 
heart is unable to pump and supply enough blood to meet the body’s demand. It is characterized 
by shortness of breath, especially during exercise, and tiredness due to the lack of adequate 
perfusion of tissues with oxygen and nutrients from the blood. The most common cause of heart 
failure is coronary artery disease and previous myocardial infarction (CHF guideline). 
Hypertension, atrial fibrillation, and diabetes mellitus can also contribute to heart failure.  
 
Patients that survive an episode of MI can go on to suffer from chronic heart failure if there is 
extensive damage to the myocardium. After MI, the heart undergoes remodelling to compensate 
for the damage caused by MI, in an attempt to maintain proper heart function. It is characterized 
by cardiomyocyte apoptosis, interstitial fibrosis, thinning of the ventricular wall and enlargement 
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of the ventricular chamber, and hypertrophy (Konstam et al, 2011). The immediate phase of 
remodelling can begin as quickly as a few hours after an infarct and involves the repair/clearance 
of necrotic tissue and replacement with fibrotic tissue that results in scar formation, elongation 
and the thinning of the infarct zone (Korup et al, 1997). This causes a significant increase in LV 
volume and in the short term is associated with improved cardiac output. However, if prolonged 
the latter phase of the remodelling is dominated by extensive fibrosis and pathological 
hypertrophic growth of the cardiac myocytes that results in a change in the shape of the left 
ventricular cavity from elliptical to spherical (Mitchell et al, 1992). Fibroblasts increase collagen 
synthesis and cause fibrosis in both infarcted and non-infarcted regions of the heart (Volders et 
al, 1993). Over time, with thin ventricular walls, the systolic and diastolic stress increases and 
results in further dilation with pathological cardiac hypertrophy. The end-systolic volume 
increases and the ejection fraction decreases progressively contributing to reduced cardiac output 
(Cohn et al, 2000). With ongoing interstitial fibrosis and pathological cardiac hypertrophy, the 
cardiac function deteriorates further and eventually causes heart failure.  
 
CHF is a long, debilitating, multimechanistic, complex disease and there are multiple 
pathophysiological processes involved that lead from the fatty streak to the ruptured complex 
atherosclerotic plaque that causes myocardial infarction. Following this event are the immediate 
and delayed consequences of infarction that ultimately lead to heart failure. For the purposes of 
my research I will focus on the biochemical changes at the cellular level that follow the onset of 










1.6 Mitogen-activated protein kinases (MAPKs)  
 
MAPKs or mitogen activated protein kinases are a family of serine/threonine protein kinases 
responsible for relaying extracellular signals into cellular responses. They mediate their function 
by phosphorylating targets to regulate gene expression and protein function. MAPKs are 
activated by a wide range of stimuli such as mitogens, growth factors, inflammatory cytokines, 
pathogens, osmotic stress, heat shock, UV irradiation, ischaemia etc (Ono et al, 2000). As a 
result, MAPKs are involved in a host of cellular functions from gene expression and cell 
growth/division to survival and cell death. Their involvement in a plethora of signalling events 
has made MAPKs an attractive target for therapeutic intervention. 
 
The MAPK family is made up of four members; Extracellular regulated kinases (ERK1/2), p38, 
c-Jun N-terminal kinase (JNK), and ERK5 (Fig 1.6). ERK1/2s’ are mainly involved in cellular 
growth/division (mitosis/meiosis) whereas p38, JNK, and ERK5 are primarily involved in stress 
signalling pathways involving cytokines, heat shock proteins, ischaemia etc. MAPKs are 
activated via a 3-tier kinase cascade where the most upstream kinase (MAPKKK) activates an 
intermediate kinase (MAPKK), which then activates the MAPK. In the case of ERK, RAF 
proteins activate the intermediate kinase MEK1/2 which then activates ERK1/2. p38 is activated 
via intermediate kinases MEK3/6, which are activated via MAPKKKs such as TAK1 and ASK1. 
JNK is activated via intermediate kinases MEK4/7, which are activated via MAPKKKs such as 
MAPKKK1/2 and ZAK. MAPKs are activated when the dual-intermediate kinase 
phosphorylates its characteristic T-X-Y motif in the activation loop (T-E-Y in ERK, T-G-Y in 
p38, and T-P-Y in JNK). The phosphorylation of the T-X-Y motif causes structural 
rearrangement of the kinase that increases the catalytic activity and facilitates substrate binding, 
resulting in an increased kinetic activity of the kinase, thus an active kinase (Yurtsever et al, 

















Figure 1.6 The classical MAPK activation pathway: The diagram shows the classical 3-tier activation 




p38MAPK is a 38kDa stress activated protein kinase that was discovered in monocytes that 
became tyrosine phosphorylated in response to lipopolysaccharide  (LPS) (Han, 1994). p38 is 
made up of 2 main domains; the N-terminal domain (135 residues) mainly made up of β-sheets, 
and the C-terminal domain made up of α-helices (Fig1.7A). The p38MAPK family consists of 
four different isoforms; p38α, p38β, p38γ, and p38δ. These isoforms have a high degree of 
sequence homology, with 75% similarity between p38α (MAPK14) and p38β (MAPK11) 
isoforms, both of which are sensitive to inhibition by the pyridinyl imidazole molecule 
SB203580, the archetypal/model inhibitor. SB203580 belongs to the class of classical type I 
inhibitors which compete with ATP for p38’s catalytic site and as a result causes reduced kinetic 
activity. p38γ (MAPK12) and p38δ (MAPK13) are 70% identical with each other but only 60% 
identical with p38α. The gatekeeper residue of Thr106 present in p38α/β that is crucial to the 
binding of these ATP-competitive drugs is replaced by a larger methionine in p38γ/δ, which 
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renders them resistant to type I inhibitors such as SB203580 (Risco et al, 2012). The p38α and 
p38β isoforms are expressed ubiquitously, p38γ expression is mainly in skeletal muscle and 
cardiac muscle, and p38δ is highly expressed in endocrine system such as kidney, pancreas, 

















Figure 1.7A The crystal strucutre of p38α in a complex with SB203580: The crystal structure of p38α 
(blue) with SB203580 occupying the ATP binding site. The Thr106 (yellow) is the gatekeeper residue and 
crucial in binding of SB203580 and other ATP-competitive inhibitors. The long activation loop illustrated 
in red contains the Thr180 and Tyr182 and phosphorylation of these residues makes the kinase active. 
Illustrated in green is Thr185, which we have hypothesized plays a role in the autoactivation mode of 
p38α caused by TAB1. The upper, N-terminal lobe, is comprised mainly of beta-pleated sheets (arrows) 
and the lower, C-terminal lobe, is comprised mainly of alpha helices (Honndorf VS, 2008; PDB:1A9U) 
 
MAPKs are activated by dual phosphorylation of a conserved Thr-X-Tyr motif on the activation 
loop by upstream kinases, as described earlier. In p38α, Thr180 and Tyr182 are phosphorylated 
by the dual specificity kinases, MKK3 and MKK6, and in some cases by MKK4. MKK3/6 in 
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turn are activated by upstream MAPKKKs such as -TAK1 and ASK1 completing the tri-kinase 
activation sequence. This describes the classical activation pathway of MAPKs. However in the 
case of p38, alternative activation mechanisms have been discovered (Fig 1.7B). In T-cells, p38 
can become phosphorylated via ZAP70, a tyrosine kinase, on residue Tyr323 (Salvador, 2005). 
The phosphorylation of Tyr323 induces autophosphorylation of p38’s T-G-Y motif, activating 
p38. Another mode of p38 activation is specific to p38α and it involves a scaffold protein, 
Transforming growth factor -β –activated protein kinase 1 binding protein 1 (TAB1). The 
interaction of p38α with TAB1 causes the auto-phosphorylation of T-G-Y motif in cis, thus 
activating p38α (Ge et al, 2002). The TAB1 mediated autoactivation of p38α has gained a lot of 













Figure 1.7B Activation mechanisms of p38α: The schematic illustrates the 3 different activation 
mechanisms of p38. 1 is the classical activation pathway where MKK3/6 transphosphorylates p38. 2 is the 
TAB1- mediated autoactivation of p38α which is SB203580 sensitive. 3 shows the activation of p38 in T-
cells where a tyrosine kinase ZAP70 causes phosphorylation of Tyr323 which in turn leads to 
autoactivation of p38. Once activated, p38 phosphorylates TAB1 which suppresses the ability of TAB1 to 
activate TAK1 and that in-turn reduces the activation of MKK3/6 and p38, which completes the feedback 






1.8 TAB1  
Transforming growth factor -β –activated protein kinase 1 binding protein 1 (TAB1) is a 
scaffold protein and as the name suggest it binds and activates TAK1. The C-terminal region of 
TAB1 directly interacts with the N-terminal region of TAK1 to cause autophosphorylation of 
Thr184, Thr187 and Ser192 in the activation loop and induce TAK1’s kinetic activity (Shibuya 
et al, 1996; Brown et al, 2005).  In addition to regulating the TAK1 signalling pathway, TAB1 
also plays a role in WNT-1, and interleukin 1 signalling pathways, as a result TAB1 is a vital 
protein in cellular signalling (Ninomiya et al, 1999). In fact its importance is attested by the fact 
that genetic deletion of TAB1 causes embryonic lethality in mice (Komatsu et al, 2002). In 
2002, Ge and his group discovered that TAB1 also plays a role in p38α activation (Ge et al, 
2002). They showed through a series of well-designed experiments that TAB1 binds to p38α and 
induces p38α autoactivation. The molecular mechanism behind this activation has been 
unknown for several years until our lab resolved the crystal structure of a p38α-TAB1 complex, 
and I will discuss this in further detail later in the thesis.  
 
TAB1 is made up of 3 domains; PP2C-like pseudophosphatase domain, p38α binding domain 
and TAK1 binding domain (Fig1.8). The C-terminal region of TAB1 houses several 
phosphorylation sites which are important in its regulation; S423, T431, S438, S452, S453, 
S456, S457. The phosphorylation of S423 and T431 by p38α suppresses the ability of TAB1 to 
activate TAK1 (Shin et al, 2009). There are 4 members in the TAB family; TAB1, TAB2, 
TAB3, TAB4 (Takaesu et al, 2000; Cheung et al, 2004; Prickett et al, 2008). In this study we 
focus on TAB1 which is involved in p38α signalling. TAB1 has 2 different isoforms; TAB1α 
and TAB1β. The TAB1β isoform is approximately 10kDa smaller as it lacks the TAK1 binding 














Figure 1.8 TAB1 domains: The schematic shows TAB1 with its 3 main domains of PP2C-like domain, 
p38α-binding domain and TAK1-binding domain. TAB1β lacks the C-terminal TAK1 binding domain and 
as a result cannot activate TAK1. The C-terminus contains several phosphorylation sites which regulate 
TAB1 activity. CM and NCM regions are the sites responsible for interacting with p38α and induce p38α 
activation (Pelin Arabacilar).  
 
 
1.9 p38’s cellular function  
p38 is ubiquitously expressed and involved in a myriad of cellular signalling events. Its 
functional role starts as early as the embryonic developmental stage as the genomic deletion of 
p38α causes death (Adams et al, 2000). Belonging to the stress activated protein kinase family; 
p38 is primarily involved in the stress signal pathways such as inflammation, ischaemia, heat 
shock, osmotic stress, and apoptosis.  
 
p38 causes the production of proinflammatory cytokines such as tumour necrosis factor alpha 
(TNF-α), interleukin 6 (IL-6), and interleukin -1 beta (IL-1β) (Zarubin et al, 2005). In fact, p38’s 
role in inflammation was evident by the use of inhibitors which caused the reduction in the 
inflammatory markers in diseases such as rheumatoid arthritis, chronic obstructive pulmonary 
disease, coronary vascular disease etc (Westra et al, 2004; Armstrong et al, 2011; Medicherla et 
al, 2008). Additionally, p38 causes recruitment of adherent proteins such as VCAM-1 and plays 
a role in the regulation of immune cells (Pietersma et al, 1997; Aicher et al, 1999). It is widely 
accepted that p38 plays a role in apoptosis and promotes cell death however some studies have 
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shown that p38 promotes survival (Sarkar et al, 2002; Porras et al, 2004; Park et al, 2002). p38 
has been shown to promote skeletal muscle differentiation, rescue neurons from cell death 
during neuronal differentiation, and arrest the cell cycle at G2/M under UV exposure (Bulavin et 
al, 2001; Zetser et al, 1999; Mao et al, 1999). p38 plays a role in proliferation and differentiation 
of lung epithelial cells as its inhibition was shown to affect lung homeostasis (Ventura et al, 
2007). p38 has also been shown to play important role in early cardiogenesis during 












Figure 1.9 Physiological function of p38: The schematic on the left shows the several signalling 
pathways p38 is involved in, and the schematic on the right shows the various physiological functions of 
p38 in different organ system (Caudrado et al, 2010).   
 
 
The evidence from the literature shows that p38 plays a role in a plethora of cellular signalling 
events and physiological functions (Fig 1.9). p38 interacts with a range of proteins that are 
kinases, phosphatases, scaffold proteins, structural proteins, membrane proteins, transcription 
factors etc to mediate its effect.  For the purpose of my investigation, I will focus the discussion 





1.10 p38 cellular localization  
There is contrasting evidence in the literature on the subject of p38’s cellular localization. Some 
have said that p38 translocates into the nucleus from cytoplasm once activated whereas others 
have said that p38 translocates into the cytosol once activated (Raingeaud et al, 1995: Ben-Levy 
et al, 1998). The discrepancy could arise from the fact that there are 4 different isoforms of p38 
and they may interact differently with scaffold proteins depending upon stimulus which could 
determine its location in the cell. For example, in early phase of pressure overload hypertrophy, 
p38α and p38β were found in both cytoplasm and nucleus with no signs of p38γ and p38δ. 
However, in the late phase of hypertrophy the appearance of p38γ increased in the nucleus 
whereas the p38α’s distribution remained unaffected (Dhanmendra et al, 2010).  
 
One of the problems in determining the mechanism behind p38’s cellular localization is the fact 
that unlike other MAPK’s, p38 does not have a nuclear localization signal. For example in 
ERK2, during pathological cardiac hypertrophy ERK2 translocates into the nucleus after it 
autophosphorylates itself and unlocks the nuclear localization signal (Lorenz et al, 2008). In my 
study, I will investigate if p38α has a similar characteristic.  
 
1.11 p38MAPK signalling in IHD  
As mentioned earlier, ischemia in the heart causes several intricate biochemical changes within 
the cell that can lead to detrimental outcomes. This is where the p38 signalling comes into play, 
the p38α isoform to be more specific. MAPKs are well-known for their function in cell growth 
and division, with their associated pathological conditions of cancer and tumour formation. As a 
result, a huge amount of effort has been concentrated in studying MAPKs in the field of cancer 
biology. However with stress activated p38, MAPK’s prominence in CVD is increasing rapidly, 
especially in ischemic heart disease. Studies in our lab and by several other groups have shown 
that there is an activation of p38α during myocardial ischemia and that this could be central to 
the damage caused under this circumstance. Ma et al showed that inhibiting p38 using 
SB203580 decreased apoptotic events and increased cardiac function in Langendorff perfused 
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rabbit hearts (Ma et al, 1999). Barancik and his group showed inhibition of p38α by SB203580 
delayed ischaemic cell death in pig hearts (Barancik et al, 2000). Kaiser showed p38 works as a 
pro-death signalling molecule in both cultured myocytes and intact heart in rats (Kaiser et al, 
2004). Gray’s group showed p38α inhibitor SB239063 reduced apoptotic events and infarct size, 
and improved cardiac function (Gray et al, 2011). There are 100 additional publications from 
independent labs which collectively suggest that p38α aggravates the lethal injury to the heart. 
Therefore, appropriate controlled regulation of p38α might provide an opportunity to limit or 
inhibit the damage caused by p38α, and prevent the injury that occurs during and following MI. 
Such a therapy could limit myocardial infarction and its sequelae such as arrhythmia, 
pathological cardiac hypertrophy and heart failure.  
 
p38α can be activated via three different routes as discussed earlier and interestingly, it is not the 
classical activation of p38α that occurs during myocardial ischemia. In a study carried out using 
a transgenic mouse model of wild-type MKK3 and knockout MKK3 -/- hearts, after 30 minutes 
of global ischemia, both WT MKK3 and MKK3 -/- hearts produced similar levels of p38 
phosphorylation and infarction (Tanno et al, 2003). The study demonstrated activation of p38 
despite the knockout of its activator MKK3, indicating p38 activation was not mediated via the 
canonical MAPKKK cascade. Instead, this unique activation of p38α was induced by interaction 
with the non-enzymatic scaffold protein TAB1. The interaction of p38α and TAB1 increases 
p38α’s affinity for ATP, which results in increased catalytic activity and autophosphorylation of 
its Thr180 and Tyr182 residues, thus activating p38α (Ge et al, 2002). SB203580, an ATP-
mimetic, inhibits this event by interacting with the gatekeeper residue Thr106 to occupy the ATP 
binding site which prevents ATP from binding, consequently inhibiting autophosphorylation of 
the T-G-Y motif (Eyers et al, 1999; Barancik et al, 2000). Recently, the molecular details of the 
interaction between p38α and TAB1 which leads to autophosphorylation of p38α were 
elucidated (De Nicola et al, 2013); it revealed that TAB1 makes a direct contact with p38α at 




1.12 p38α and TAB1  
The interaction between p38α and TAB1 that leads to p38α’s autophosphorylation is a true 
enigma in the field of biology. Firstly, p38α is a serine/threonine kinase and yet it 
autophosphorylates itself on the Tyr182 residue of the activation loop. Secondly, for p38α to be 
activated, the T-G-Y motif needs to be phosphorylated by an upstream kinase which then 
induces the structural changes to increase ATP affinity and open the substrate binding cleft. 
However, in the case of TAB1-induced autophosphorylation, the ATP binding precedes the 
phosphorylation of the T-G-Y motif (De Nicola et al, 2013). This paradox has been likened to a 
“catch 22”, and although being an unusual event this phenomenon has also been observed in 
other mammalian kinases (Lochhead et al, 2009; Shrestha et al, 2012).  In 2013, our lab resolved 
the crystal structure of a p38α-TAB1 complex which answered the conundrum behind the catch 
22 paradox. The crystal structure of p38α complexed with a chemically synthesized region of 
TAB1 peptide (384-412) responsible for the interaction revealed that the action of TAB1 binding 
mimics the effect of phosphorylation of the T-G-Y motif by MKK3/6, which causes an increased 
affinity of p38α towards ATP. The activation loop swings towards the catalytic site bringing the 
T-G-Y motif near ATP to facilitate autophosphorylation and make p38α kinetically active. The 
phosphorylation of Tyr182 residue however, still remains a mystery. The crystal structure and 
NMR data showed that TAB1 binds to p38α in a bipartite manner. The N-terminal region of 
TAB1 peptide binds to the lower hydrophobic pocket of p38α created by the αF and αH helices 
and the loop connecting helix α21.4 to helix αH (noncanonical lower site). The C-terminal 
region of the TAB1 peptide binds within the groove created by αD and αE helices and the 




















Fig1.12 Structural overview of p38α with TAB1 peptide (384-412): The crystal structure revealed p38α 
binds to TAB1 in a bipartite manner as seen in this figure. The zoomed in section on right highlights the 
residues that are involved in the interactions (De Nicola et al, 2013) 
 
 
1.13 p38 inhibitors and clinical trials  
One of the reasons why the studies on p38α took off over the last decade was due to the 
availability of several inhibitors especially those belonging to the Type I class, based on the 
pyridinyl imidazole backbone (Fig 1.12). These inhibitors compete with ATP for the catalytic 
site which results in reduced kinetic activity of the kinase and as a result inhibits the 
phosphorylation of its substrates. The crystal structure of the p38α-pyridinyl imidazole complex 
revealed that these inhibitors bind to an aryl-specificity pocket located behind the active site 
which is normally occupied by ATP’s adenine ring. The 4-pyridinyl moiety of the drug interacts 
with the Thr106 (gatekeeper residue) in the hydrophobic pocket of p38α (Fig1.6A). In p38γ and 
p38δ the Thr106 is replaced by a bulkier methionine which prevents the drug accessing the 














Figure 1.13: A) The image shows the chemical structure of SB203580 (molecular weight: 377.43) which 
belongs to the Type I class of ATP competitive inhibitors. B) The image shows the chemical structure of 
BIRB796 (molecular weight: 527.66) which belongs to the Type II class of inhibitors.  
 
 
The majority of clinical trials of p38 inhibition were carried out for inflammatory diseases such 
as arthritis, chronic obstructive pulmonary diseases, psoriasis, and atherosclerosis. The initial 
success of these inhibitors in animal models had promised a positive outcome in clinical trials 
but it was not to be the case as almost all inhibitors failed. RWJ-67657, a p38α and p38β specific 
inhibitor, was one of the few inhibitors that promised positive results as several groups showed 
that it was good at lowering inflammatory biomarkers with minimal toxicity suggesting it could 
be useful in treating rheumatoid arthritis and sepsis (Fijen et al, 2001; Faas et al, 2002; 
Parasrampuria et al, 2003). It was in a phase I clinical trial for the treatment of arthritis and 
inflammatory bowel disease but it failed, and this turned out to be a trend that was followed by 
most inhibitors. VX-745 was shown to suppress the release of inflammatory mediators such as 
interleukin (IL)-1beta and tumour necrosis factor (TNF) alpha but it caused an elevation in liver 
transaminases (Haddad et al, 2001). Pamapimod, a selective inhibitor of p38α, was shown to 
have limited efficacy and cause adverse side effects like infection, skin disorders and dizziness 
(Cohen et al, 2009). VX702 was shown to reduce the inflammatory biomarkers but was 
associated with severe infections (Damjanov et al, 2009).  A randomised study on the effect of 
BIRB-796 in Crohn disease found no efficacy and it caused liver toxicity (Schreiber et al, 2006). 
SCIO-469 had poor potency and patients suffered from rashes, dizziness, constipation, and 
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arthralgias, which were dose related (Genovese et al, 2008). More recently, the LATITUDE-
TIMI 60 study was carried out after promising data from a phase 2 trial in non-ST elevation MI 
patients had indicated that Losmapimod attenuated inflammation and may improve outcome. 
But after the initial study in 3503 patients showed no difference in the reduction of major 
ischaemic cardiovascular events in 18 months, the second part of the trial involving 
approximately 22000 patients was then suspended (O’Donoghue et al, 2016).  
 
At least 22 different p38 inhibitors have been investigated in PhaseI/II of clinical trials and the 
few that reached the phase III stage also failed (Hammaker et al, 2010). The lack of efficacy and 
selectivity, and the profound adverse side effects have significantly hampered the progression of 
p38α inhibitors in clinical trials. An alternative solution is therefore required to inhibit p38α, one 
of which could be not to target p38 directly but indirectly. Targeting other proteins involved in 
the p38 signalling pathway, and not p38α itself which is ubiquitously expressed and involved in 
a plethora of signalling events, could be the way forward.    
 
1.14 Targeting the p38α-TAB1 interaction 
The race to discover an effective inhibitor for p38α has been futile as discussed above and it is 
not surprising considering the nature of the target. Firstly, p38α belongs to the kinase family that 
comprises over 500 members, where the majority of them share some homology which makes 
achieving selectivity extremely difficult. Next, p38α is ubiquitously expressed and involved in 
several physiological events. Along with the detrimental role it plays in myocardium during MI 
and HF, it is also vital in maintaining physiological homeostasis and is involved in a plethora of 
cellular responses. Finally, there are 4 different isoforms of p38 in p38α, p38β, p38γ, and p38δ 
and all four isoforms are associated with variety of functions in different cell types. So 
selectively targeting p38α in the heart during MI is an inherently difficult task.  
 
As a result the TAB1-mediated p38α autoactivation occurring in MI provides a new opportunity 
to target p38α therapeutically. The fact that p38α is activated via TAB1 during ischaemia means 
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we can selectively target this branch of p38α activation without affecting the classical activation 
pathway that is involved in very many other important signalling cascades. It allows us to 
achieve the circumstance-specific inhibition of p38α just in the event of MI. And as we are 
avoiding the blanket inhibition of p38α, it could potentially eradicate the toxicity problems seen 
with p38α inhibitors, which has been the Achilles heel in the clinical trials. The involvement of 
TAB1 in other important signalling pathways such as the TAK1 pathway also means that TAB1 
cannot be targeted. Therefore, the best approach is to specifically target the interaction between 
p38α and TAB1. That could be achieved by either preventing the interaction between the two 
proteins or breaking the p38α-TAB1 complex once it forms.  
  
In order to target the interaction between p38α and TAB1 a better understanding of the intricate 
structural details of the p38α-TAB1 complex is required at an atomic level. To address this, our 
lab recently published the crystal structure of p38α and the interacting region of TAB1 which 
revealed key residues involved in the binding between the two proteins (De Nicola et al, 2013). 
In this thesis, we examine the interaction between p38α and TAB1 in further detail and 
investigate the changes in the complex that are critical to the autoactivation process in a bid to 
develop small inhibitor molecules which can interfere with it.  
 
1.15 Aim of the thesis  
The ultimate aim of this thesis is to study the interaction between p38α and TAB1 in order to 
develop a small molecule to target it. However, specific aims are:   
1. To confirm the TAB1 mediated p38 autoactivation. 
2. To study the structural details of p38-TAB1 interaction  
a. Investigate the role of Thr185 in p38α’s autoactivation mechanism 
b. Investigate the role of Thr185 in p38α’s cellular localization signalling 
3. To study the TAB1 KI mouse in the setting of myocardial ischaemia and determine 
p38α’s signalling mechanism. 
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2 Material and Methods   
 
In this chapter, I have described the principles and the general protocols for the common 
techniques used in my thesis. Full details of the protocols specific to individual experiments are 
described in the relevant result chapters.  
 
All analytical-grade laboratory reagents were purchased from Sigma-Aldrich Chemical 
Company (Poole, UK) or ThermoFisher Biosciences (Hempstead, UK) unless stated otherwise. 
 
2.1 Cell culture  
Cell culture is a biological system in which cells are grown under a controlled environment. It is 
a laboratory technique for maintaining and growing cells (primary and immortalised) in a 
specific medium suitable for their survival. In my study, I have used 3 different cell lines and a 
primary cell line; Human Embryonic Kidney 293 (HEK293) cells, HELA cells, H9C2 cells, and 
Mouse Embryonic Fibroblasts (MEF), which were isolated from mouse embryos. All cell types 
were grown in a humid, 37
o
C incubator in room air supplemented with 5% CO2. 
 
2.1.1 Human Embryonic Kidney cells 
Human Embryonic Kidney 293, also known as HEK293, cells are a specific cell line derived 
from human embryonic kidney cells. HEK293 cells were transformed in 1977 by exposing them 
to sheared fragments of adenovirus type 5 DNA (Graham et al, 1977). Because of the 
transformed background, HEK293 cells are not an ideal model for normal or cancer cell studies. 
However, they are very easy to maintain in culture and straightforward to transfect with foreign 
DNA. Since they contain all the necessary machinery for gene expression and post-translational 




In my studies, I used HEK293 cells extensively as an over-expression system. I cultured these 
cells in T75 flasks with full growth medium (Dulbecco’s modified Eagle’s medium containing 
584mg/l L-glutamine, 10% v/v foetal bovine serum, 1% v/v penicillin/streptomycin) at 37
o
C, in 
room air supplemented with 5% CO2 in a water saturated incubator. The cell culture was 
maintained and upon reaching 80-90% confluency, they were transferred into new flasks with 
fresh full growth medium. For the purpose of the experiments, cells were split onto 6-well 
plates. 
 
2.1.2 HELA cells 
HELA cells are an immortal cell line derived from the cervical cancer cells of Henrietta Lacks. 
George Gey derived the cell in 1951 by expanding an isolated tumour cell, and named the cell 
line after Henrietta Lacks, HELA (Scherer, 1953). HELA cells are the first and the oldest 
immortal cell line grown in a lab. It is one of the most commonly used cell lines in biological 
and medical research. The vaccine for polio was developed by growing the virus in these cells 
(Brownlee, 1955). 
 
Just like HEK293 cells, HELA cells are easy to transfect to express the protein of interest, and 
cells contain all the machinery required for post-translational modifications. HELA cells have a 
more abundant cytoplasm than HEK293 cells and as a result are more suited for 
immunofluorescence assays. HELA cells were grown in T75 flasks with full growth medium 
(Dulbecco’s modified Eagle’s medium containing 584mg/l L-glutamine, 10% v/v foetal bovine 
serum, 1% v/v/ penicillin/streptomycin) at 37
o
C, in room air supplemented with 5% CO2 in a 
water saturated incubator. Once they were reached 80% confluence, cells were either split into 






2.1.3 H9C2 cells  
H9C2 cells are a cardiac cell line derived from embryonic BDIX rat (strain used in cancer 
model) heart tissue (Kimes & Brandt, 1976). Although having a cardiac origin, these cells also 
exhibit features of skeletal muscle since they were immortalised through fusion with 
mononucleated myoblasts and consequently express nicotinic receptors and synthesize a muscle-
specific creatine phosphokinase isoenzyme. As a result H9C2 cells are used in both cardiac and 
skeletal muscle studies. Although H9C2 cells lack morphological properties of adult 
cardiomyocytes, they still exhibit many cardiac-specific features such as electrical and hormonal 
signalling pathways and are shown to have morphological similarities to immature embryonic 
cardiomyocytes (Hescheler et al, 1991).  
H9C2 cells were grown under the same conditions as HEK293 and HELA cells, as described 
above. The cells were cultured in T75 flasks with full growth medium (Dulbecco’s modified 
Eagle’s medium containing 584mg/l L-glutamine, 10% v/v foetal bovine serum, 1% v/v 
penicillin/streptomycin) at 37
o
C, in room air supplemented with 5% CO2 in a water saturated 
incubator. Upon reaching 80-90% confluency, the cells were transferred into new flask with 
fresh growth medium. For the purpose of experiments, they were split onto 6-well plates. 
 
2.2 Transfection  
Transfection is the process of introducing foreign genetic material into a cell. It is a common 
laboratory technique used to insert DNA into a cell so that encoded genes can be expressed to 
study the protein of interest. Transfection involves opening transient holes in the cell membrane 
to allow the uptake of DNA into the cell where it can undergo transcription/translation. There 
are several kinds of transfection such as viral, electroporation and chemical. The most 
commonly used method is the chemical based transfection that utilizes lipid polymers. Lipid 
based transfection uses lipid polymers to form a complex with DNA which is then taken up by 
cells. The DNA containing liposome complexes are positively charged on their surface which 
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fuses with the negatively charged plasma membrane to facilitate its transportation inside the cell 
via endocytosis. For my project, I used Turbofect
TM
 reagent, which is similar to lipid-based 
transfection, but is not a lipid polymer. Turbofect
TM
 is composed of a cationic polymer in sterile 
water. The polymer forms positively charged complexes with DNA which protects it from 
degradation and facilitates its delivery into the cells.   
 
There are two types of transfection; transient and stable. In transient transfection, the persistence 
of the foreign DNA is limited by degradation and/or diluted through cell division. In stable 
transfection, the persistence of the foreign DNA is not limited since it integrates with the cell’s 
genomic DNA (which is rare) or it confers an advantage to transfected cells by co-expressing a 
resistance gene (more common). The easiest method to achieve stable transfection is to use a 
vector containing a selective marker gene such as Geneticin or Blasticidin. When cells are grown 
in the medium containing the antibiotic, only the cells that have had successful transfection and 
taken up the foreign DNA containing the marker gene will survive. These cells can be cultured 
using the selective marker as long as needed.  
 
 
2.3 In vitro kinase assay  
An in-vitro kinase (IVK) assay is a method developed to test the ability of a protein kinase to 
phosphorylate its substrate. In a typical IVK reaction, a kinase and its substrate are mixed 
together in a tube with ATP and MgCl2 at 37
o
C to allow the kinase to phosphorylate the 
substrate. The phosphorylation status of the substrate can then be tested using phospho-specific 
antibodies with western blotting.  
 
In our investigations, we carried out IVK reactions with p38α and TAB1 peptide, p38α and 
ATF2, and MKK6 and p38α. The recombinant p38α and MKK6 were produced in E.coli, 
whereas TAB1 peptide and ATF2 fusion protein were bought from Activotec and Cell Signalling 
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Technology respectively. TAB1 (371-416) was a 46mer peptide that contained the residues 
(V390, Y392, V408, M409) responsible for binding to p38α.  
 
TAB1 peptide:  
NH2- EMSQPTPTPAPGGRVYPVSVPYSSAQSTSKTSVTLSLVMPSQGQMV-COOH.  
 









Table 2.3 IVK reagents: The table lists the amount of each reagent used in a typical IVK reaction, unless 
stated otherwise (The reagent concentrations as used before in paper published in NSMB, De Nicola et al, 
2013)  
  
The proteins were incubated in 1X kinase buffer (25mM Tris/HCl, pH7.5, 5mM β-
glycerolphosphate, 2mM dithiothreitol, 0.1mM Na3VO4 and 1mM MgCl2), with 550µM ATP for 
an appropriate amount of time at 37
o
C. At the end of the reaction 2X SDS buffer was added to 
the mixture to terminate the reaction, and 5µl of the reaction mix was used to run on an SDS-gel 
for western blotting.   
 
2.4 Western Blot   
Western/immuno blotting is a widely used analytical technique that allows the detection of 
protein in a sample of cells/tissues. It is made up of 3 main steps; electrophoresis, transfer, and 




TAB1 peptide 15 
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detection. The electrophoresis involves separation of proteins in the sample based on their mass 
or their intrinsic charge and mass. The transfer involves the transfer of the separated protein 
from the gel onto a membrane, and the final detection phase involves detecting the protein of 
interest on the membrane using an antibody.  
 
2.4.1 Sodium dodecyl sulphate polyacrylamide gel electrophoresis  
Sodium dodecyl sulphate polyacrylamide gel electrophoresis or SDS-PAGE is an 
electrophoresis system which separates proteins based on their mass in a polyacrylamide gel 
once its denatured by sodium dodecyl sulphate, hence the name SDS-PAGE. SDS is an anionic 
detergent which breaks the non-covalent bonds in proteins that causes the protein to lose its 
native tertiary/quaternary structure. Additionally, SDS completely covers the protein with its 
strong anionic charge which is significantly stronger than the protein’s native charge. The strong 
electrostatic repulsion of SDS forces the protein into a linear rod shape which allows for uniform 
movement of the protein through the gel during electrophoresis. The negative charge of the 
denatured protein moves towards the positively charged anode during electrophoresis. The 
smaller, lighter and shorter proteins will move faster through the gel than the bigger, heavier and 
longer proteins; as a result proteins are separated based on their mass. A known standard 
(molecular marker) is run alongside the samples as the reference.  
 
For my projects, I used Mini Protean III one-dimensional gel electrophoresis system from Bio-
rad to run SDS-PAGE gels. Almost all of the proteins I was investigating were between 25kDa 
and 70kDa, so I used 10% polyacrylamide gel unless stated otherwise (constituents in the table 
below). Polyacrylamide gels were poured into the 1mm space between the glass plates and left 
to set for 20 minutes. Also known as resolving gel, this part of the gel is responsible for the 
separation of the proteins. 2cm of stacking gel was layered above the resolving gel with a comb 
to form wells, where the samples are loaded and it ensures they migrate in a single compressed 




Reagent 7.5% gel 10% gel 12.5% gel 15% gel Stacking gel 
(4%) 
MW range   10-100 kDa 5-70kDa  
DI H2O 9ml 5(7.5)ml 4(6)ml 3(4.5)ml 7ml 
30% Acrylamide 4.5ml 4(6)ml 5(7.5)ml 6(9)ml 2ml 
1.5M Tris-HCL (pH 8.8) 4.5ml 3(4.5)ml 3(4.5)ml 3(4.5)ml - 
0.5M Tris-HCL (pH6.8) - - - - 3ml 
10% Ammonium persulphate 90µl 60(90) µl 50(75) µl 50(75) µl 100µl 
TEMED 22.5µl 15(22.5) µ 15(22.5) µl 15(22.5) µl 10µl 
 
Table 2.4.1: Composition of SDS-PAGE gels.  
 
Once fully set, the gels were stacked into the electrophoresis tank and filled with running buffer 
(Tris-base, 0.025mol/L; glycine, 0.192mol/L; SDS, 0.1% w/v). The samples were loaded (5-
15µl) into the wells and separated by electrophoresis with a voltage of 100V (Powerpac 300 
Biorad, Herts, UK) for the first 15 minutes until the samples had migrated through the stacking 
gel into the resolving gel, after which the voltage was increased to 120V for the rest of the 
electrophoresis run. Upon completion of electrophoresis, gels were carefully disassembled from 
the glass plates and readied for the transfer.   
 
2.4.2 Transfer  
The transfer stage of western blotting involves transferring the separated proteins from the SDS 
gel onto a membrane. There are two types of membrane; nitrocellulose and polyvinylidene 
difluoride (PVDF) and I used the latter for my experiments. PVDF membranes are highly 
hydrophobic and ideal for detecting small amount of protein, as little as 10 pmoles 
(ThermoFisher Scientific). Because of their highly hydrophobic nature, they must be pre-soaked 
with methanol or ethanol prior to soaking them in the transfer buffer. Additionally, unlike the 
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nitrocellulose membrane, PVDF membrane can be stripped and re-probed several times. During 
transfer, the gel is placed on top of the membrane and sandwiched by blotting paper. The 
proteins are transferred by electrophoresis and the principle is the same as the one in SDS PAGE 
electrophoresis whereby an electric current is applied to move the negatively charged proteins 
towards the positively charged anode and in the process the proteins move from the gel onto the 
membrane.  
 
I used a semi-dry transfer technique to transfer proteins from the gel onto a membrane. The 
PVDF membrane was pre-soaked in methanol for 1-2 minutes for activation before being soaked 
in transfer buffer (Tris-base, 25mmol/L; glycine, 150mmol/L; 20% (v/v) methanol) along with 
the SDS-polyacrylamide gel containing separated proteins. 12 pieces of 3M chromatography 
paper (Fisher Scientific, UK) were used as sandwich for transfer and soaked briefly in the 
transfer buffer. The gel was rested on the top of the PVDF membrane and sandwiched between 
the filter papers (6 on each side). Any air bubbles were removed and transfer was started by 




The final stage of western blotting is the detection phase where we detect the protein of interest 
using a specific antibody against the desired protein on the membrane. After completing the 
transfer of protein onto a membrane, the membrane is blocked with 4% milk +1% BSA in TBST 
for 1 hour to prevent any nonspecific binding of the antibody to the membrane. The membrane is 
designed to have a high affinity for proteins so antibody can also easily bind to the remaining 
binding surface that has not been occupied by the proteins in the sample during electrophoresis. 
This will give non-specific binding and a high background signal. So to prevent this, the 




Following blocking, the membrane is incubated with primary antibody overnight at 4
o
C. The 
antibody solution I used was prepared in 1% BSA-TBST and unless stated otherwise primary 
antibodies were prepared at a dilution of 1:1000 and secondary antibody at a dilution of 1:5000. 
The following day the membrane was washed 3 times in 15ml TBS-(Tween-0.01%) for 10 
minutes to remove any unbound primary antibody. The secondary antibody which is linked to an 
enzyme horseradish peroxidase (HRP) was then incubated for 1 hour at room temperature. The 
membrane was washed again 3 times with 15ml of TBST for 10 minutes to remove any unbound 
secondary antibody.  
 
Finally, the protein is detected using an enhanced chemiluminescence technique (Amersham, 
England). The membrane is blocked with an equal amount of stable peroxide solution and an 
enhanced luminol solution for two minutes. The HRP enzyme conjugated to the secondary 
antibody catalyses the reaction which produces light and the photons are detected by 
photographic film. The amount of specific protein on the membrane correlates with the amount 
of primary/secondary antibody bound to it and that correlates with the reaction catalysed by 
HRP which produces the band on the film, i.e. more protein in the sample means the band 
produced on the film will be darker and larger. The developed films were scanned using GS-800 
scanner (Biorad) and the band densities were measured using Quality One program (Biorad).   
 
2.5 Immunofluorescence  
Immunofluorescence, also known as IF, is a light microscopy technique that uses fluorophore 
conjugated antibody to visualise the target antigen in a cell/tissue sample. The fluorophore 
allows visualization of the distribution of the target molecule within a sample using 
epifluorescence and confocal microscopes. There are two types of IF; Direct IF and Indirect IF. 
In direct IF, the primary antibody is directly conjugated to a fluorophore which allows 
visualization of target without the use of a secondary antibody. Indirect IF does not use a 
fluorophore-conjugated primary antibody, instead a secondary antibody conjugated with 
fluorophore is used for visualization. There are fewer steps in direct IF which saves time and 
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makes it the quicker protocol to complete. Additionally, the lack of the secondary antibody 
means there is no cross-reactivity and as a result it produces lower levels of non-specific 
background signal compared to the indirect IF. However, direct IF is less sensitive compared to 
indirect IF, as in indirect IF the signal is amplified as multiple secondary antibodies can bind to a 
primary antibody which significantly enhances the signal. As a result of this, less primary 
antibody is required with indirect IF making it the more affordable option. On the downside, 
indirect IF is more labour intensive and increases non-specific binding, but this can be controlled 
with optimization of the conditions.   
 
2.6 Polymerase chain reaction  
Polymerase chain reaction (PCR) is a technique used in molecular biology that allows the 
amplification of a single copy of DNA by several orders of magnitude. PCR, developed by Kary 
Mullis in 1983, uses thermal cycles of repeated heating and cooling to produce millions of 
copies of the DNA sequence from a single copy (Bartlett, 2003). This simple and cheap 
technique has revolutionised bio/medical research and is routinely used in DNA cloning, genetic 
fingerprinting, medical tests, phylogeny test etc. A PCR set-up requires four components; a 
DNA template that is to be amplified, forward and reverse primers complementary to the 5’ and 
3’ end, heat stable DNA polymerase, and buffer containing deoxynucleoside triphosphates 
(dNTPs). A typical PCR reaction is run in a volume of 20-50µl with approximately 20-40 
thermal cycle and consists of 3 main steps: 
 
1. Initialization step: This initial step involves raising the temperature to 95oC for couple of 
minutes to activate the DNA polymerase. 
2. Thermal cycle step (20-40 cycles) 
 Denaturation: This step involves raising the temperature to 90-98oC for 20-30 
seconds to break the double stranded DNA into single strands by breaking the 
hydrogen bonds between the base pairs. 
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 Annealing: This step involves lowering the temperature to 50-65oC for 20-30 
seconds to allow the primers to stick to its complementary region on the single 
strands of DNA. The temperature and length of the annealing step depends on the 
individual primers. 
 Extension: The final step of thermal cycle involves raising the temperature to 70-
80
o
C for optimum activity of polymerase so that it can start the synthesis of double 
stranded DNA using the dNTPs in the buffer. The length of this step depends on 
the length of the DNA extension and also on the type of polymerase as different 
polymerases have different activities. 
3. Final extension: The final extension step involves raising the temperature to 70-80
o
C for the 
final 5-10 minutes after the thermal cycle has completed to ensure that all remaining single 
stranded DNA is extended to form double strands. 
 
After the final extension, the reaction can be kept on final hold where the temperature is set at 4-
10
o
C for short term storage of the reaction.  
 
2.7 DNA agarose gel electrophoresis  
Agarose gel electrophoresis is a gel electrophoresis technique that is used to separate DNA by its 
mass. Agarose gels range from 0.7%-2%, are easy to cast, and when an electric field is applied, 
the negatively charged DNA molecule moves toward the positively charged anode, resulting in 
separation of DNA by size. Agarose gel is a 3-dimensional matrix formed of helical agarose 
molecules in super-coiled bundles that forms channels/pores through which DNA can move. 
 
The agarose gels were run in Tris-Acetate-EDTA buffer (40mM Tris, pH7.6, 20mM acetic acid, 
1mM EDTA), supplemented with 0.01% (v/v) Gel Red
TM
 Stain (Biotium) for 1hour at 100V. 
The bands on the gel were viewed and photographed with a UV transilluminator (Syngene, 




2.8 Transformation for plasmid DNA amplification and protein production 
Transformation is a technique where an exogenous genetic material is introduced into bacteria. 
For a successful transformation, bacteria must be competent i.e. they must be modified to have 
the ability to uptake foreign DNA. The commonly used technique is preparing the cells in a 
solution containing divalent cations (calcium chloride).  The divalent cations assist in attaching 
the DNA to bacterial membranes at around 0
o
C, and then a brief heat shock (37-42
o
C) 
permeabilizes the membrane, subsequently the DNA is taken up inside the cell (Mandel & Higa, 
1970). The bacteria is grown in a selective antibiotic medium so that only the transformed 
bacteria that have taken up the foreign DNA containing the antibiotic resistance gene can grow, 
allowing for selective growth.   
 
In my experiments I used 100ng of DNA to transform 100µl of competent bacteria. For DNA 
production I used E.coli - DH5α cells, whereas for protein production I used E.coli – RosettaTM 2 
cells. After adding the DNA, the cells were incubated on ice for 30 minutes. The cells were heat 
shocked at 42
o
C for 30 seconds to allow the entry of the DNA into the cells. Then cells were 
immediately put back on ice and incubated for 5 minutes. 900µl of fresh LB (Luria-Bertani) 
media was added to the transformed cells and incubated at 37
0
C in a shaker for 1 hour. 50µl of 
transformed cells were inoculated by streaking onto LB plates with appropriate antibiotics and 
incubated overnight at 37
0
C. On the next day, a single isolated colony was picked to start a large 












Table 2.8: Constituents of Luria Bertani medium  
 
2.8.1 Mini Prep 
A Mini prep kit (Macherey-Nagel) was used to purify the small amounts of DNA (nanogram) 
required for cloning, sequencing and transformation. All the reagents were provided in the kit 
and the isolation was done at room temperature. The transformed bacteria were grown in 1-5ml 
LB culture overnight at 37
o
C. The next day the culture was centrifuged at 11,000g for 30 
seconds to pellet the cells and supernatant was discarded. The pellet was re-suspended in 250µl 
of Buffer A1 (re-suspension buffer) by either pipetting up and down or using a vortex. Then 
250µl of Buffer A2 (lysis buffer) was added and mixed gently by inverting the tube 5-6 times.  
The cells were incubated for 5 minutes and 300µl of Buffer A3 (neutralization buffer) was 
added. Then samples were mixed again by gently inverting the tube a couple of times. The cells 
were centrifuged at 11,000g for 5 minute and the supernatant was transferred to the 
NucleoSpin
(R)
 Plasmid Columns. Columns were centrifuged at 11,000g for 1 minute and the 
supernatant was discarded as the DNA attaches to the silica membrane of the column. The DNA 
in the column was washed with 600µl of Buffer A4 (wash buffer) and centrifuged at 11,000g for 
1 minute. The flowthrough was discarded and the column was centrifuged at 11,000g for 2 min 
to dry the membrane on the column. 50µl of nuclease free water was added to the column to 




Bacto-yeast extract 5 
NaCl 10 
Add the constituents in a 950ml de-ionized water, adjust pH to 7 and top it up to make 1L of LB. Add 





2.8.2 Maxi Prep 
Maxi prep (QIAGEN HiSpeed
(R)
) was carried out to purify large quantities of plasmid DNA 
(milligrams) required for transfection of mammalian cells. After growing the 5ml culture of 
transformed cells overnight it was transferred to a 150ml of LB media with appropriate 
antibiotic. The culture was grown overnight at 37
o
C in an orbital incubator shaking at 200rpm. 
The bacterial culture was centrifuged at 6000g for 15 minutes at 4
o
C. The supernatant was 
discarded and cells were re-suspended in 10ml of Buffer P1 and mixed thoroughly by pipetting 
up and down. 10ml of lysis buffer, Buffer P2 was added and mixed gently by inverting tubes 
couple of times. Cells were incubated for 5 minute and 10ml of neutralization buffer, Buffer P3 
(pre-chilled) was added and mixed gently. The lysate solution was transferred into the barrel of a 
QIAfilter Cartridge and incubated for 10 minutes. During incubation, HiSpeed Maxi Tips were 
equilibrated with 10ml of Buffer QBT. After 10 minute incubation, the precipitated lysate was 
filtered with QIAfilter Cartridge into the equilibrated HiSpeed Maxi Tip by gravitational flow. 
The HiSpeed Maxi Tip was washed with 60ml of Buffer QC, and DNA was eluted with 15ml of 
Buffer QT into a 50ml falcon tube. DNA was precipitated by addition of 10.5ml of isopropanol 
and incubated for 5 minutes. The QIAprecipitator Maxi Module filter was attached onto the 
outlet nozzle of 30ml syringe and the precipitated DNA-isopropanol solution was filtered 
through it at a constant pressure. The filter was washed with 2ml of 70% ethanol and air dried by 
passing air through the filter using the empty syringe a couple of times. The QIAprecipitator was 
attached to the outlet nozzle of a 5ml syringe and DNA was eluted into a 1.5ml tube with 1ml of 
nuclease free water.  
 
2.8.3 Agarose gel purification 
PCR products after amplification are run on agarose gel to confirm identity by their mass and to 
separate and extract them for sequencing. The isolation/purification of PCR products from the 
agarose was carried out using the High Pure PCR Product Purification kit (Roche Diagnostics). 
After the agarose gel electrophoresis was completed, the desired DNA band from the agarose gel 
was excised using a scalpel. The excised gel was weighed and put in a 1.5ml eppendorf tube. 
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300µl of Binding Buffer per 100mg of agarose gel slice was added into the tube and incubated at 
56
o
C for 10-15 minutes with regular vortexing. Once the agarose gel was fully dissolved, 150µl 
of isopropanol per 100mg of agarose gel was added into the tube and vortexed thoroughly. The 
suspension was transferred into a High Pure Filter Tube and centrifuged for 30 seconds. The 
flowthrough was discarded and the tube was washed with 500µl of Wash Buffer and centrifuged 
at 16,000g for 1 minute. The flowthrough was discarded and washed again with 200µl of Wash 
buffer. The High Pure Filter Tube was inserted into a new eppendorf tube, and 50µl of nuclease 
free water was added and centrifuged at 16,000g for 1 minute to elute the DNA.  
 
2.9 Recombinant protein expression in E.coli   
Ever since the first human protein was expressed in E.coli in 1977, bacteria have been 
extensively used to express proteins in native and mutant forms (Itakura, 1977). The reasons 
behind E.coli’s popularity are numerous. For example, E.coli can be transformed easily with 
different types of plasmids and exponential growth ensures a large protein yield in a short period 
of time. Additionally there are various strains of E.coli and this provides a range of options when 
trying to optimize the condition for better growth and yield.  
 
In my project, I used Rosetta
TM
 BL21 (DE3) strain of E.coli to express p38α and its mutant. 
pETDuet plasmid, containing two multiple cloning sites (MCS), lac repressor gene (lac I), T7 
promoter and ampicillin resistance gene, was used as a vector. p38α was cloned into the first 
multiple cloning site just downstream of the T7 promoter and lac operator; by Dr. Gian De 
Nicola. After successful transformation, the cells were grown in a 1.5L of LB media with 
appropriate antibiotic. Initially the cells were grown at 37
o
C until the OD600 reached 0.5, after 
which the temperature was lowered to 21
o
C and cells were induced with isopropyl-beta-d-
thiogalactopyranoside (IPTG). IPTG is a galactose analogue that binds to the lac repressor and 
disrupts its ability to bind to the lac operator. This in turn induces the expression of T7 
polymerase. T7 polymerase then activates the T7 promoter and starts the transcription of the 
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gene downstream of it. After induction, cells were grown at 21
o
C for 5 hours, centrifuged to 
collect the cells and then stored at -20
o
C until further use.  
 
2.10 Protein purification  
Protein purification is the process of collecting and purifying a specific protein from cells. The 
first part of purification involves separating the protein from non-protein complexes, and the 
second part involves isolating the desired protein from all other groups of proteins. The first part 
is fairly simple which involves breaking the cells apart and centrifuging to separate proteins 
from heavier molecules such as cellular organelles and debris. After growing the bacteria 
expressing the desired protein, cell pellets are lysed using a sonicator in a lysis buffer. A typical 
lysis buffer contains a detergent or an enzyme to break the cell membrane, and protease 
inhibitors to prevent endogenous proteases breaking down the protein of interest. After 
sonication, cells are centrifuged to separate the soluble fraction containing proteins, and non-
soluble fraction containing the rest of the cellular debris. The non-soluble fraction is discarded 
and the soluble fraction is used to purify the desired protein.   
 
The second stage of purification is more complicated and there are different types of purification 
techniques available. Each purification type utilizes different properties of the protein to achieve 
separation. In my project I have used three types of protein purification; affinity 
chromatography, ion-exchange chromatography, and size-exclusion chromatography. Affinity 
chromatography involves purifying the protein based on its high affinity for another protein, for 
example antibody to antigen, enzyme to substrate or ligand to receptor. In our case, we cloned 
p38α with a histidine tag which has a very high affinity for nickel. So, we have used nickel resin 
in a column to separate p38 from the rest of the cellular proteins. Ion-exchange chromatography 
involves separating proteins based on the ionic strength. Anion exchange resins have a negative 
charge so they are used to separate positively charged proteins, whereas cation exchange resins 
have a positive charge so they are used to separate the negatively charged proteins. Finally, the 
size-exclusion chromatography also known as gel filtration chromatography separates proteins 
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based on their size. The gel filtration column in made up of porous beads stacked in a column. 
The smaller proteins will enter these beads easily so will spend more time retained on the 
column. The larger proteins do not spend much time within the beads and as a result are eluted 
faster. This way the proteins are separated based on their size.   
 
2.11 Isothermal titration calorimetry 
ITC or isothermal titration calorimetry is a biophysical tool used to study the interaction between 
two biological molecules such as protein-protein, protein-DNA, and protein-inhibitor. ITC 
characterizes the thermodynamics of the interaction between two molecules to determine the 
binding affinity, enthalpy changes and stoichiometry of the interaction. It is a simple yet 
powerful technique that produces readout on how the two molecules interact with each other and 
how strong the interaction is. ITC is a very sensitive physical tool and the experiment is 
significantly dependent on the correct concentration of the two molecules, buffer, and the 
temperature of the environment.  
 
An ITC machine can be either a single or dual injection variety (Duff et al, 1999). In a single 
injection instrument the titrant is added to the cell containing protein. In a separate control 
experiment the titrant is added to the buffer without the protein. In the dual injection instrument, 
the titrant is simultaneously added to the cell containing the protein and another cell containing 
the buffer. To run a typical ITC experiment, one protein is loaded into a cell and another into a 
syringe. Using a syringe, the protein is loaded and titrated into the calorimetric cell containing 
the other protein in a stepwise manner. This triggers the binding reaction and as the two proteins 
interact, the heat is either released or absorbed depending upon the type of reaction. The 
apparatus quickly changes the temperature of the cell to return it to the baseline after each 
injection; before the heat change from next injection is measured again, and the process 
continues until the end. With every injection, the amount of protein in the cell that is left to bind 
decreases and with it the heat release/absorbed also diminishes until only the background heat of 
dilution is observed. This change in the heat is detected and based on this change, the enthalpy 
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change, entropy, binding affinity, stoichiometry, and the binding constant; can be calculated. I 
carried out ITC experiments with the help of Dr Gian De Nicola and more details are provided in 
chapter 4.   
 
2.12 Mass spectrometry  
Mass spectrometry is an analytical tool that allows the identification of chemical constituents of 
a substance. It measures the mass-to-charge (m/z) ratio of ions to identify and quantify molecules 
in a sample. Mass spectrometry consists of 5 different stages 
 
1.  Vaporization 
2.  Ionization 
3.  Acceleration 
4.  Deflection 
5.  Detection 
 
 
In a typical mass spectrometry procedure, a sample (solid/liquid/gas) is vaporized and ionized by 
bombarding it with electrons from an ion source. This causes the molecules in the samples to 
break into charged fragments. These ions are then accelerated through a magnetic field which 
causes them to deflect before they are detected by a detector. The amount of deviation depends 
on the mass-to-charge (m/z) ratio, i.e. the ions with same mass-to-charge ratio will undergo the 
same amount of deflection whereas ions of different mass-to-charge will deviate by different 
amounts. The computer software analyses the ion detector data and produces a graph in the form 
of spectra with the individual m/z ratio and relative abundance. The result is processed through a 
database to predict the identity of the molecule based on the m/z. 
 
Protein mass spectrometry has revolutionized the field of proteomics and made significant 
contributions to the discovery of protein structure, function, modification and global protein 
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dynamics. The development of electrospray ionization (ESI) and matrix assisted laser 
desorption/ionization (MALDI) was the key to the advancement of mass spectrometry in 
proteomics (Domon et al, 2006). It allows the measurement of molecular masses of polypeptides 
and determination of additional structural features such as posttranslational modifications like 
phosphorylation. The mass spectrometry technique that allows the determination of 
posttranslational modifications is known as Tandem mass spectrometry, also known as MS/MS 
or MS2. It involves multiple mass spectrometry steps where the first stage (MS1), involves 
normal separation of the ions based on the mass-to-charge ratio. The second stage (MS2) 
involves selection of the precursor ions of the particular mass-to-charge ratio to create new 
fragment ions (product ions). These ions are separated again and the masses from these new 
fragment ions can be used to deduce any modification in the structural feature. 
 
2.13 Simulated Ischaemia 
Simulated ischaemia is an in-vitro technique developed to simulate the conditions that occur 
during tissue ischaemia, but in cultured cells. There are different versions of this technique and 
we have adapted ours based on the method developed by Kimio Esumi (Esumi et al, 1991). It is 
impossible to reproduce exactly the same conditions that cells are exposed to during myocardial 
infarction. However, our model of simulated ischaemia has many of the key features. One of the 
hallmarks of myocardial infarction is deprivation of oxygen or hypoxia and the ischaemic buffer 
simulates that with addition of an oxygen scavenger, sodium dithionite. However, it is important 
to note that sodium dithionate can cause causes oxidative stress, which should be considered 
whilst interpreting the results. The buffer also mimics the extracellular milieu of reversible 
myocardial ischaemia by modelling the hypoxic environment with addition of lactate, low 
glycolytic flux with 2-DOG, disruption of the membrane potential and electrical activity with 
high potassium, and acidic condition with low pH.  
 
The ischaemic buffer (table C) and control buffer (table B) were made from the basic stock 
buffer shown in table A. For ischaemic buffer, all compounds were added except for sodium 
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dithionite, filter sterilized with 0.2µm filter, and warmed to 37
o
C in water bath. At this stage pH 
of the buffer is approximately 6.8. After the buffer reaches 37
o
C, sodium dithionite was added 
and it caused the pH of the buffer to drop further to approximately 6.3.The buffer is then 
immediately added onto the cells for an appropriate amount of time.  
 
         
Table 2.13A: Composition of basic stock buffer 
 
Control buffer, pH7.4 
Reagent Amount (Total 50ml) 
10X basic stock buffer 5ml 
Sterile ddH2O 45ml 
20mM D-glucose 0.225g 
1mM Na pyruvate 5.5 
 






Basic stock buffer, pH7.4 
Reagent Concentration (mM) 1X (g/L) 10X (g/0.2L) 
NaCl 137 8 16 
KCl 3.58 0.27 0.54 
MgCl2.6H2O 0.49 0.10 0.2 
CaCl2.2H2O 1.8 0.264 0.528 




Simulated Ischaemia/Reperfusion buffer, pH6.3 
Reagent Amount (Total 50ml) 
10X basic stock buffer 5ml 
Sterile ddH2O 45ml 
10mM 2-DOG 82.1mg 
20mM Na lactate 172µl 
1mM Na dithionite 8.7mg 
 
Table 2.13C: Composition of ischaemia/reperfusion buffer 
 
2.14 Langendorff perfusion of isolated mouse hearts  
Langendorff retrograde perfusion of isolated hearts was pioneered by Oscar Langendorff in 1895 
and since then it has been routinely used to study the patho/physiology of the heart (Bell, 2010). 
Langendorff perfusion is an ex-vivo technique which involves cutting out the heart from an 
animal and attaching it to a fixed cannula via the aorta through which the heart is perfused with a 
nutrient rich oxygenated buffer such as KREBs. The perfusate enters the heart via the aorta in a 
retrograde direction which causes the aortic valve to shut. This forces the perfusate to enter the 
left and right coronary arteries which supply blood to the heart muscle. This continuous delivery 
of oxygen and nutrients to the heart muscle enables the heart to beat continuously for several 
hours even outside an animal. The apparatus for Langendorff perfusion is water-jacketed, the 












Table 2.14: Composition of modified Krebs-Henseleit buffer 
 
The Langendorff technique allows the measurement of different functions of the heart such as 
coronary flow, heart rate, contractile function etc. The other advantage of the technique is it 
allows pharmacological investigation by measuring the effect of drugs on the heart. The 
Langendorff technique can also be used to harvest the cardiac myocytes from the heart and 
culture them for studies. The contractile function of heart is measured by inserting a deflated 
intra-ventricular balloon. Once inside, the balloon is inflated to 5-10mm Hg to provide a pre-
load stretch of myocytes to optimise systolic isovolumaemic pressure.  
 
Langendorff perfusion requires practice and to ensure consistency the following inclusion 
criteria had to be met  
  
1. Time from thoractomy to aortic cannulation must be less than 3 minutes.  
2. Coronary flow must be between 1.5ml/min to 4ml/min 
3. Unpaced heart greater than 300 beats/min 
 Concentration (mM) 5L 2L 1L 
NaCl 118.5 34.63 13.85 6.93 
NaHCO3 25 10.5 4.20 2.10 
KCl 4.7 1.77 0.71 0.35 
MgSO4.7H2O 1.2 1.47 0.59 0.29 
KH2PO4 1.2 0.8 0.32 0.16 
Glucose 11 9.9 3.96 1.98 
Mix and bubble the solution with 95%O2 + 5% CO2 for 15 minutes before adding calcium 
chloride 
CaCl2.2H2O 1.4 1.04 0.42 0.21 
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4. LVEDP less than 10mm Hg 
5. LVDP must be greater than 60mm Hg with no persistent arrhythmia 
 






















3 TAB1 induces p38α autoactivation  
 
3.1 Introduction  
The prototypical activation mechanism of a MAPK involves a 3-tier kinase cascade where the 
most upstream kinase (MAPKKK), activates an intermediate kinase (MAPKK); which then 
activates the MAPK. In the case of p38α, MAPKKKs such as TAK1 and ASK1 activate the 
dual-specificity intermediate kinases MEK3/6 and MEK4 which then activate p38α. In 2002 an 
alternative activation mechanism of p38α was discovered by Ge and co-workers when they 
showed TAB1, a scaffold protein, caused autoactivation of p38α (Ge et al, 2002). This study 
provided a new mechanism of p38α activation where they proposed the alternative activation 
pathway could operate in parallel with the canonical kinase cascade to regulate important 
signalling events. Subsequent studies in the last decade have shown that this mode of TAB1-
mediated p38α activation could be harmful to the heart in ischaemic stress such as MI, and 
preventing its activation could be therapeutically beneficial (Barancik et al, 2000; Mackay et al, 
1999, Ma et al, 1999; Saurin et al, 2001). The studies in our lab have revealed similar findings 
and with that we have focused our time and tools in studying the TAB1 induced mode of p38α 
activation with the aim of disrupting the p38α-TAB1 interaction. In this chapter, we look at the 
TAB1-mediated autoactivation of p38α. Using purified recombinant proteins in in-vitro kinase 
assays and endogenous proteins in mammalian cells, we study the mechanism of p38α 
autoactivation. Recently, we published the crystal structure of a p38α-TAB1 complex which 
revealed that TAB1 binds to p38α in a bipartite manner (De Nicola et al, 2013). Here, we 
explore that p38α-TAB1 crystal structure in detail and study the key residues involved in the 






3.2 Specific Methods 
 
3.2.1 cDNA constructs for mammalian cell over expression  
pCDNA3 was used as a plasmid vector for expression in mammalian cells. The plasmid contains 
cytomegalovirus immediate early (CMV) promoter and SV40 polyadenylation sequence for high 
level expression in mammalian cells.  It has an ampicillin resistance gene for selective cloning. 




Table 3.2.1Plasmids used for mammalian cell transfection 
 
3.2.2 Culture of HEK293 cells   
HEK293 cells were used as the over-expression system to study TAB1 induced p38α activation. 
The cells were cultured in T75 flasks with full growth medium (Dulbecco’s modified Eagle’s 
medium, supplemented with 10% v/v foetal bovine serum, 1% v/v penicillin/streptomycin) at 
37
o
C in room air supplemented with 5% CO2 in a water saturated incubator.  Upon reaching 80-
cDNA Plasmid 
backbone 
Resistance  Tag Expected 
molecular weight 
(kDa) 
Details & Source 
 
WT p38α pCDNA3 Ampicillin HA 40 Full length WTp38α (DR Y 
Wang, UCLA, USA) 
WT TAB1 pCDNA3 Ampicillin CFP 83 Full length WT TAB1 (Gian 
De Nicola) 
TAB1 mutant    
(V390A, Y392A, 
V408G, M409A) 
pCDNA3 Ampicillin CFP 83 Full length mutant TAB1 
(Gian De Nicola) 
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90% confluency, the cells were transferred into new T75 flask with fresh full growth medium. 
For the purpose of experiments, they were split onto 6-well plates.     
 
3.2.3 Transfection 
HEK293 cells were seeded on 6-well plates in full growth medium at 37
o
C and transfected upon 
reaching 60% confluency as described in chapter 2. The transfection was mediated using 
Turbofect reagent. Turbofect is a solution of cationic polymer in water, which binds with DNA 
to form a compact, stable, positively charged complex. This complex protects DNA from 
degradation and also facilitates its delivery into the cells by fusing with the negatively charged 
cell membrane.  
 
The reagent mixture was prepared in eppendorf tubes. 100µl of Optimem solution was added 
into the tube followed by 1µg of DNA sample. 2µl of Turbofect reagent (2µl Turbofect per 1µg 
of DNA) was added to the tube, mixed gently and left for 30 minutes for complex formation. An 
appropriate volume of Optimem was added into the tube to make 1ml total volume. The tube 
was inverted gently for complete mixture of the transfection reagents which were then pipetted 
onto the cells in 6-well plates, in a drop-wise manner. The cells were incubated for 24hrs at 37
o
C 
after which the transfection media was replaced with serum free media (SFM). In the 
experiments with inhibitors, drugs were incubated with SFM for the appropriate amount of time 
as needed. For western blot analysis the SFM was removed and the cells were washed with PBS. 
200µl of 2X SDS-sample buffer (120mM Tris, pH 6.8, 6% w/v SDS, 20% v/v glycerol, 10% β-
mercaptoethanol and 0.01% bromophenol blue) was added to each of the wells of the 6-well 
plate and cells were scraped into eppendorf tubes. The samples were heated to 95
o
C for ten 






3.2.4 In vitro kinase assay  
WTp38α, TAB1 (371-416) peptide, and double mutant TAB1 (371-416) peptide were used for 
IVK assays in the presence and absence of SB203580. The residues mutated on TAB1 peptide 
were: V390A Y393A (on the lower non-canonical site) and V408G M409A (on the upper 
canonical site). 3µM of p38α and 15µM of TAB1 peptide were incubated in 1X kinase buffer 
(25mM Tris/HCl, pH7.5, 5mM β-glycerolphosphate, 2mM dithiothreitol, 0.1mM Na3VO4 and 
1mM MgCl2). 5µl of 10mM ATP was added to the incubation mixture to start the reaction at 
37
o
C. 10 µM SB203580 was added in the reaction mixture to examine the sensitivity of the 
reaction to p38 inhibition. The samples were collected at four different time points of 30min, 
1hr, 2hr, and 4hr. 2X sample buffer was added to the sample, heated to 95
o
C for 10 minutes and 
used for western blot analysis. 
 
3.2.5 Western Blot   
Western/Immuno- blotting is a widely used technique that allows the detection of proteins on a 
membrane by an antibody after they are separated by electrophoresis. Samples were analysed by 
western blot as described in chapter 2. In brief, samples were lysed with 2X SDS sample buffer 
and boiled at 95
o
C for 10 minutes. 10µl samples were run on 10% SDS polyacrylamide gel for 
1hr 30 min and transferred to a PVDF membrane. The membrane was then blocked with 
phospho p38 antibody (Thr180/Tyr182) at a dilution of 1:1000 and total p38 antibody at a 
dilution of 1:1000 at 4
o
C overnight. The membrane was washed three times with 15ml of TBST 
for 10 minutes each and blocked with rabbit secondary antibody conjugated with HRP (at 
1:5000 dilution) for 1 hour at room temperature. The membrane was washed three times with 
15ml TBST for 10 minutes each and developed by chemiluminescence technique.   
 
3.2.6 Statistical analysis  
 
Data sets were analysed by one way ANOVA (Analysis of Variance) and groups were compared 
using Tukey’s test as a post-hoc. p value of less than 0.05 was considered significant.  
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3.3 Results  
 
3.3.1 TAB1 induces p38α autoactivation  
An in-vitro kinase assay was carried out using recombinant p38α and 29mer TAB1 peptide (384-
412) at 37
O
C in a kinase buffer with ATP for 2 hours as described in section 3.2.4. The western 
blot analysis of the IVK product showed that in the presence of TAB1, phospho-p38 signal at the 
T-G-Y motif increased, suggesting TAB1 promotes activation of p38α (Fig 3.3.1). The phospho-
p38 signal was completely abolished in the presence of SB203580, an ATP-competitive inhibitor 
of p38 catalytic activity. Thus, the result indicates SB203580 is competing with ATP to block 












Figure 3.3.1 TAB1 causes p38α autoactivation:  Representative western blot figure of the IVK products 
probed with dual specificity phospho p38 (Thr180/Tyr182) antibody and total p38 antibody. The addition 








3.3.2 TAB1 induces p38α autoactivation in HEK293 cells 
To complement our IVK experiment we used an over-expression system in mammalian cells 
where we transfected HEK293 cells with p38α and TAB1 as described in 3.2.3. Transfection of 
p38α caused a small increase in phospho-p38 signal (T-G-Y motif) compared to the control. 
Transfecting TAB1 had no effect on p38α activation. Co-transfection of p38α and TAB1 
together however caused a marked increase in phospho p38 signal (T-G-Y motif), which was 
completely blocked by 10µM SB203580 treatment. The result suggests TAB1 causes 
















Figure 3.3.2 Co-transfection of p38α and TAB1 in HEK293 cells with SB203580 exposure: The western 
blot figure shows a marked increase in phospho p38 signal at the T-G-Y motif in cells co-transfected with 
p38α and TAB1. 10µM SB203580 treatment completely abolished that signal. Arrow represents the 
ectopic band which runs higher than the endogenous band on an SDS-PAGE gel as it is heavier because 
of the hemagglutinin tag. The graphic representation above the western blot figure shows a significant 
difference in p38 activation when co-transfected with TAB1. Data represented as mean+/-SEM from 3 




3.3.3 TAB1 interacts with p38α in a bipartite manner 
In 2013 our lab published the crystal structure of a p38α-TAB1 complex (De Nicola et al, 2013) 
which revealed TAB1 binds to p38α in a bipartite manner.  NMR, X-ray crystallography and 
ITC data pointed out residues 385-394 and 404-412 on TAB1 to be the two regions involved in 
binding with p38α. To test this we mutated four of these key residues to produce a mutant TAB1 
(V390A/Y392A/V408G/M409A). An in-vitro kinase assay was carried out with p38α, WT 
TAB1 and mutant TAB1 at 37
0
C for 4 hours as described in section 3.2.4. The sample from the 
IVK reaction analysed by western blotting showed that WT TAB1 activated p38α at all four 
time points as evident by the phospho-p38 signal (T-G-Y motif) which got stronger with time 
(Fig 3.3.3). The mutant TAB1 was however, not similarly able to activate p38α with a faint 
phospho-p38 signal seen only at the 2 and 4hrs time point. In fact the signal with mutant TAB1 
was even lower than the signal observed without TAB1. The result confirms that these residues 












Figure 3.3.3 TAB1 binds to p38α in a bipartite manner: Figure shows the western blot result of an IVK 
performed with p38α, WT TAB1 (371-416) peptide and mutant TAB1 (V390A/Y392A/V408G/M409A) 
peptide, as described in section 3.2. The western blot shows the IVK products at four different time points 
30min, 1hr, 2hr and 4hr probed with dual phospho (Thr180/Tyr182) p38 antibody and total p38 antibody. 
WT TAB1 causes an increase in phospho-p38 signal at all 4 time-points; mutated TAB1 does not cause a 




3.3.4 TAB1 interaction with p38α leads to p38α autoactivation in HEK293 cells 
The IVK result showed that TAB1 binds to p38α in a bipartite manner and without the 
interaction, autoactivation does not happen. We sought to examine whether we could 
recapitulate this result in mammalian cells. We used an over-expression system in HEK293 cells 
and transfected p38α, WT TAB1 and mutant TAB1 (V390A/Y392A/V408G/M409A). 24hrs 
later, we saw an increased phospho p38 (T-G-Y) signal when p38α and WT TAB1 were co-
transfected, as expected from the IVK with the corresponding peptide forms of TAB1. But co-
transfection of p38α and mutant TAB1 did not lead to a similar increase in phospho p38 (T-G-Y) 
signal suggesting mutant TAB1 is unable to cause p38α autoactivation. The result supports the 
outcome from IVK assay and confirms a similar effect when the residues are mutated in full-




































Figure 3.3.4 p38α-TAB1 interaction in HEK293 cells: The western blot figure showed HEK293 cells 
transfected with p38α, WT TAB1 and mutated TAB1 as described in section 3.2. In samples transfected 
with p38+TAB1 there was a dramatic increase in phospho-p38 signal (T-G-Y), but not in cells transfected 
with p38+mutated TAB1. The graph above shows the quantification from western blot analysis which 
shows a significant difference in phospho-p38 signal between p38+TAB1 and p38+mutated TAB1. 
(Quantification from three separate experiments with data represented as mean+/-SEM. * = P<0.05 vs 









3.4 Discussion  
In this chapter, we investigated the TAB1 induced activation mechanism of p38α. Using an over 
expression system in mammalian HEK293 cells and recombinant proteins in in-vitro kinase 
assays, we showed that TAB1 interacts with p38α in a bipartite manner which causes p38α 
autoactivation.  
 
3.4.1 TAB1 causes p38α autoactivation 
The western blot analysis of IVK assay with recombinant p38α and 29mer TAB1 peptide (384-
412) showed that phospho p38 signal increased markedly in the presence of TAB1 (Fig 3.3.1). 
This was completely abolished with 10µM SB203580, an ATP mimetic Type I inhibitor. 
SB203580, which belongs to a family of pyridylimidazole, competes with ATP for the ATP 
binding pocket of a kinase and diminishes its catalytic ability (Young et al, 1997). Thus, the 
IVK result of SB203580 inhibiting p38α activation suggests that TAB1 is causing p38α 
activation via an auto-activation mechanism. The result is in line with other studies in our lab 
where we have found that a kinase dead p38α that is unable to bind ATP cannot be activated via 
TAB1. The surprisingly high level of phospho p38 signal seen in the absence of TAB1 could be 
the result of incubating p38α in a tube with a high concentration of ATP at 37oC for 2hours 
which causes it to auto-activate itself. The IVK result showed that TAB1 augments the p38α 
autoactivation. Next, we carried out a similar experiment in mammalian cells to see if we could 
replicate this result in a biological experimental model. We transfected HEK293 cells with p38α 
and TAB1 and looked at the activation profile of p38α. 24hrs after transfection, there was a 
significant increase in the phospho p38 signal in cells transfected with p38α and TAB1 
compared to the cells transfected with just p38α or TAB1 alone (Fig 3.3.2). This signal was, as 
expected, completely blocked with a 2 hour treatment of 10µM SB203580. The result 
recapitulates the outcome produced from IVK assay in 3.3.1 confirming that TAB1 induces 
p38α autoactivation which is sensitive to SB203580, and supports the findings from the original 
study of Ge and co-workers (Ge et al, 2002).     
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3.4.2 TAB1 binds to p38α in bipartite manner to cause its activation  
After confirming TAB1 mediates p38α autoactivation, we went on to investigate this activation 
mechanism in further details. The crystal structure of p38α and the interacting region of TAB1 
in a complex was resolved by our lab recently which showed that TAB1 binds to p38α in a 
bipartite manner (De Nicola et al, 2013). The crystal structure showed that the C-terminal 
region of the TAB1 binds to the canonical region of p38α (where other p38α partners such as 
MKK3/6 and p38α substrates bind) while the N-terminal region binds to the non-canonical 
region. This interaction results in the structural re-arrangement of p38α that leads to p38α 
autoactivation. Originally, TAB1 (373-418) was believed to be the region interacting with p38α, 
however subsequent studies narrowed it down to a much shorter region of 29mer TAB1 (384-
412) and suggested pro412 to be the key residue required for binding (De Nicola et al, 2013; Ge 
et al, 2002; Zhou et al, 2006). To confirm this, we ordered a 29mer WT TAB1 peptide and 
29mer mutant TAB1 peptide with mutations in the four key residues that interact with the 
canonical and non-canonical region. We hypothesized that the WT TAB1 peptide will bind and 
auto-activate p38α but the mutant TAB1 peptide will not be able to bind to p38α and as a 
consequence cannot induce p38α autoactivation. The mutant TAB1 was created with 4 point 
mutations; V390A, Y392A (to disrupt the noncanonical site), V408G, M409A (to disrupt the 
canonical site).  
We performed an IVK assay with recombinant p38α in the presence of WT TAB1 peptide 
(NH2- RVYPVSVPYSSAQSTSKTSVTLSLVMPSQ-COOH) and the mutated TAB1 peptide 
(NH2- RVYPVSAPASSAQSTSKTSVTLSLGAPSQ-COOH). The western blot analysis of the 
IVK product showed that there was a marked increase in the phospho p38 signal in the presence 
of WT TAB1 but in the presence of the mutated TAB1, there was not. The phospho p38 signal 
was enhanced with longer incubation in the reaction mixture with WT TAB1 as expected, but 
not with the mutated TAB1. The result showed that even with a 4 hour long reaction time, 
mutated TAB1 was unable to activate p38α. A very faint phospho p38 signal is observed at the 
4 hour time point. A high phospho p38 signal seen at 2 hour and 4 hour time points in the 
77 
 
absence of TAB1 was also not surprising due to the high ATP concentration at 37
o
C which 
causes p38α to auto-activate itself, as seen previously in result 3.3.1. A lower p38 activation 
observed in the presence of mutated TAB1 than the one observed without TAB1 was unusual 
and may have arose due to mutated TAB1 protein interfering with the auto-activation of p38 
that takes place in the presence of high ATP concentration without any other proteins to 
physically interfere. The IVK result suggests that our hypothesis is correct and the four mutated 
residues in TAB1 are necessary to bind to p38α which causes the structural re-arrangement 
within p38α that promotes p38α autoactivation. We also tested this in an over expression system 
in HEK293 cells and transfected p38α with WT TAB1 and mutated TAB1 where the same 4 
residues are mutated. There was an increase in phospho p38 signal in all transfected cells 
compared to the untransfected cells (Fig 3.3.4). More importantly, there was a significant 
increase in phospho p38 signal when cells were co-transfected with p38α and WT TAB1 but not 
when cells were co-transfected with p38α and mutated TAB1. In fact the phospho p38 signal 
observed in cells co-transfected with p38α and mutated TAB1 was similar to the ones observed 
in cells transfected with p38 or TAB1 alone. The result showed that the mutated TAB1 is unable 
to augment p38α activation suggesting it cannot bind to p38α, unlike WT TAB1. The results 
from IVK assay and transfection experiment in HEK293 cells confirm that 29mer TAB1 peptide 
is the region of TAB1 that is responsible for interacting with canonical and noncanonical region 
of p38α; thus supporting our hypothesis that TAB1 binds to p38α in a bipartite manner.  
The results from this chapter offer insights into the interaction between p38α and TAB1, which 
could impact on developing an inhibitor to prevent the interaction between p38α and TAB1. The 
canonical region of p38α is shared by upstream kinases of traditional activation pathway and 
designing a small molecule to target this region could lead to a blanket inhibition of p38α. This 
will cause the disastrous side effects we have seen in the clinical trials (Marber, 2011). 
However, to our knowledge there are no known molecules that bind to the noncanonical region 
of p38α, which makes it an ideal target for a small molecule. An inhibitor that blocks only the 
noncanonical region of p38α could potentially result in a selective inhibition of p38α caused by 
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TAB1, without affecting the MKK pathway or other p38α binding partners. It could achieve the 
much yearned selective inhibition of p38α that is so highly desirable in p38α therapeutics. 

























4 Thr185 plays a key role in the auto-activation process of p38α 
 
4.1 Introduction  
In the third chapter we discussed the activation of p38α mediated via TAB1. Using an over-
expression system in HEK293 cells and recombinant proteins in in-vitro kinase assays, we 
showed that TAB1 robustly induced the dual phosphorylation of p38α at the T-G-Y motif.  The 
phosphorylation was sensitive to an ATP-mimetic, SB203580 which led us to confirm that 
TAB1 is causing autoactivation of p38α. We and various other groups have shown that this 
mode of p38α activation during myocardial infarction (MI) is harmful to the heart and as a 
result preventing TAB1 mediated p38α autoactivation would be therapeutically beneficial. To 
date the studies of p38 inhibition in the setting of MI have used ATP-competitive inhibitors. 
Unfortunately, these inhibitors have repeatedly failed in clinical trials despite the availability of 
different scaffolds and mechanisms of binding to p38. In large part this failure is attributable to 
toxicity (Marber et al, 2011) which is common between inhibitors suggesting it is an “on-target” 
effect. Such toxicity is not entirely surprising considering the ubiquitous nature of p38α and its 
involvement in a plethora of cellular responses.  In cardiomyocytes for example, p38 plays a 
protective role during ischaemic preconditioning but is lethal in myocardial infarction (Clark et 
al, 2007; Sicard e al, 2010).  Targeting TAB1 would be an alternative strategy but its knockout 
results in embryonic lethality and it plays an important role in the TAK1 signalling pathway 
(Komatsu et al, 2002). Therefore, ischaemia selective TAB1 dependent auto-activation of p38α 
provides a better opportunity for circumstance-selective inhibition of p38α which could 
potentially reduce the toxicity seen in clinical trials, making it a very attractive therapeutic 
target to pursue.   
 
To target TAB1 induced auto-activation of p38α, a greater depth of understanding of the 
molecular interaction between these two proteins is required. To address this, we recently 
published the crystal structure of p38α and the interacting region of TAB1 which revealed key 
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residues involved in the binding between the two proteins (De Nicola et al, 2013). The crystal 
structure showed that TAB1 binds to p38α in a bipartite manner which causes structural changes 
that result in an increased affinity for ATP. The N-terminus and the C-terminus lobes of p38α 
move towards each other, this movement swings the activation loop (Leu171-Val183) 
containing the T-G-Y motif towards the catalytic site which facilitates its auto-phosphorylation, 
rendering the kinase active. Closer inspection of the crystal structure revealed the formation of a 
hydrogen bond between the side chains of Thr185 on the activation loop and Asp150 of the 
HRD domain (Figure 1). This hydrogen bond appeared to orientate the activation loop into a 
position that enabled the T-G-Y motif to access the catalytic site thereby promoting auto-
phosphorylation. Therefore, we hypothesised that the inability to form this hydrogen bond 
would deprive p38α of the free-energy required to reorientate the activation loop and thereby 

































Figure4.1: The crystal structure of WTp38α on the left, and the WTp38α- TAB1 peptide (yellow) on the 
right. In the WTp38α, the Thr185 and Asp150 (green) are 5.647Å apart which prevents the formation of 
hydrogen bond and the T-G-Y motif (blue) is facing away from the catalytic groove preventing 
autophosphorylation. When the TAB1 is bound, the Tyr182-Thr185 forms an alpha helical segment which 
is stabilized by the hydrogen bond formation between Thr185 and Asp150 and in the process the 













4.2 Specific methods –  
 
4.2.1 cDNA constructs 
4.2.1.1 cDNA constructs for bacterial over expression   
pETDuet was chosen as a bacterial expression vector to clone the insert of mutant p38αT185G. 
p38αT185G was cloned in the first multiple-cloning site. The C-terminus and the N-terminus 
fragments of p38αT185G were produced by two separate PCRs with complementary internal 
primers containing the required mutations. The PCR products from these reactions were then 
combined to form a template for the second PCR reaction with external primers to form the 
complete cDNA of p38αT185G harbouring the desired mutation.  
 
 
Table 4.2.1.1 Plasmids used for transformation  
 
4.2.1.2 cDNA constructs for mammalian cell over expression  
pCDNA3 was used as the plasmid for expression in mammalian cells. The plasmid contains 
cytomegalovirus immediate early (CMV) promoter and SV40 polyadenylation sequence for 
high level expression in mammalian cells.  It has an ampicillin resistance gene for selective 




cDNA Plasmid backbone Resistance  Details 
 
WT p38α pETDuet Ampicillin Full length WT p38 α-MAPK 






Table 4.2.1.2 Plasmids used for mammalian cell transfection 
 
4.2.2 Bacterial transformation and growth 
4.2.2.1 Transformation and plasmid DNA growth   
100ng of plasmid DNA encoding the mutant p38αT185G containing the ampicillin resistance 
gene was added to 50µl of E. coli strain Rosetta
TM
 2 cells and incubated on ice for 30 minutes 
(The Rosetta
TM
 2 are specifically designed to enhance the expression of eukaryotic proteins). 
The cells were heat shocked at 42
0
C for 30 seconds to facilitate the entry of the DNA. The cells 
were immediately put back on the ice and incubated for 5 minutes.  950µl of fresh LB (Luria-
Bertani) media was added to the transformed cells and incubated at 37
0
C in a shaker for 1 hour. 
Following 1 hour, 30µl of LB culture was spread onto LB plates (ampicillin) and incubated 
overnight at 37
0
C. A single colony was picked and used to make a starting culture (15ml) 
overnight at 37
0
C incubator.  
 
4.2.2.2 Protein production in bacteria  
The starting culture containing the transformed cells was added to 800ml LB containing 
ampicillin (100µg/ml) and grown in a 37
0
C incubator until the absorbance measured at OD600 
was 0.6. The culture was cooled down to room temperature and induced with IPTG (Isopropyl 
β-D-1thiogalactopyranoside) at 1mM final concentration for induction of protein expression. 
The culture was left to grow in a shaker for 5 hours at 25
0
C. The culture was spun using a JLA-
cDNA Plasmid backbone Resistance  Details 
 
WT p38α pCDNA3 Ampicillin Full length WT p38 α-MAPK 




8.1000 rotor (Avanti series, Beckman Toulter) at 6238 RCF (5000 RPM) for 30 minutes at 4
0
C 
to pellet the cells.  
 
4.2.3 Protein Purification  
The bacterial pellet was re-suspended in 25ml of cold lysis buffer (Buffer A made up of 500mM 
NaCl, 50mM Tris, 20mM Imidazole, supplemented with 0.1g of lysozyme, 160µl of 100mM 
PMSF, 2mM DTT and a tablet of cOmplete
TM 
protease inhibitor cocktail (Roche). The lysate 
was sonicated at 33% amplitude with a Vibra-cell
TM 
sonicator (Sonics) for a pulse sequence of 4 
seconds on, 25 seconds off on ice until the entire pellet broke down and lysate was clear. The 
lysate was then centrifuged using a JA20 rotor (Avanti
TM
 series, Beckman Coulter) at 35000 
RCF for 45 minutes at 4
0
C. The soluble fraction of the lysate which contains the protein of 
interest was transferred into a new tube and passed through a 0.45µM filter and kept on ice 
ready for purification.  
 
4.2.3.1 Nickel column affinity purification  
A nickel-affinity column was used as the first purification step as our protein is expressed with a 
polyhistidine tag. Prior to its use, the nickel column was washed with 2 column volumes (CV) 
of deionised water to remove the ethanol in which it is stored. The column was washed with 2 
CVs of Buffer B (500mM NaCl, 50mM Tris, 150mM Imidazole –pH7.5) to remove residual 
contaminants. The column was washed with 2 CVs of Buffer A (500mM NaCl, 50mM Tris, 
20mM Imidazole –pH7.5) to equilibrate it before the addition of the soluble fraction. As the 
soluble fraction passes through the column, our protein with the histidine tag binds to the nickel 
resin while the unbound debris and other proteins passes through and is collected as the flow 
through. The column was washed with 5 CVs of Buffer A (with 2mM DTT) to remove any 
residual impurities that were bound to the column. Buffer B (with 2mM DTT) was added to 
elute our protein from the nickel column as the high concentration of Imidazole in buffer B acts 
to displace and elute the bound protein off the column. The eluted protein was dialysed in a 
6000-8000 MWCO dialysis tube overnight in 2 litres of dialysis buffer (100mM NaCl, 20mM 
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Tris, 2mM DTT –pH7.5) in order to remove the high concentration of imidazole in which the 
protein was eluted.   
 
4.2.3.2 Ion exchange chromatography  
Ion exchange chromatography was used as the second purification step. Ionic exchange 
chromatography separates protein based on their charge at a given pH and takes advantage of 
the affinity of molecules to the given ion exchanger. We used a Mono Q 5/50 GL column (GE 
Healthcare Life Sciences), a strong anion exchange column within the ÄKTA purification 
system. Before starting the purification, the column was washed with 2CVs of deionised water, 
2CVs of Buffer B (1M NaCl, 50mM Tris, 2mM DTT –pH7.5, filtered/degassed) to remove 
contaminants and 2CVs of Buffer A (50mM Tris, 2mM DTT –pH7.5, filtered/degassed)  to 
equilibrate the column. The dialysed protein from the Nickel column purification was filtered 
using a 0.45µM filter and automatically loaded onto the Mono Q column using a 50ml 
superloop. Initially, roughly 10 CVs of Buffer A was applied to the column to remove bound 
contaminants then a gradient of 0-60% of elution buffer (Buffer B) was applied, totalling 40 
CVs to elute the protein with flow collected at 0.5ml per fraction. The sample (protein) 
concentration was measured as it was eluted into fractions by a UV detector (280nm), and a 
chromatograph (relevant peak), representing the fractions with the greatest protein concentration 
(Unicorn software), was produced by the program. The fractions containing the eluted protein, 
represented by the peak, were collected in a falcon tube and the protein concentration was 
measured using a nanodrop at an absorbance of 280nm. 20µl of sample was also taken to run on 
an SDS-PAGE gel and coomassie stained to confirm the protein identity by its molecular 
weight. The rest of the protein sample was kept on ice and used either for the activation of the 
protein or dialysed overnight in 2 litres of Dialysis buffer (100mM NaCl, 20mM Tris, 10mM 
DTT –pH7.5) to get rid of the excess salt and ready it for the final purification step of size-





4.2.3.3 Size Exclusion Chromatography  
The final step of purification was carried out using a gel filtration column in the ÄKTA 
purification system.  The gel filtration column separates molecules based on their size with high 
purity yield and is often used as the final purification step (polishing step). The dialysed protein 
from the previous purification step was filtered using 0.45µM filter and concentrated to 
10mg/ml using a 10,000 MWCO centricon. The reason for concentrating the sample was to 
reduce the total volume of protein as the maximum capacity of the column (HiLoad 26/60 
Superdex 75- Ge Healthcare Life Sciences) is limited to 12 ml. The column was washed with 1 
CV of deionised water and equilibrated with 1CV of buffer (100mM NaCl, 20mM Tris, 10mM 
DTT –pH7.5, filtered/degassed). Once the sample was loaded into the column using a 50ml 
superloop, the column was pumped with 1.5 CV of buffer and 0.5 ml of sample per fraction was 
collected. The samples from different fractions were pooled as represented by the peak given by 
a UV detector (280nm) and their constituent protein concentration was measured using a 
nanodrop at 280nm absorbance. The samples were divided into aliquots, flash frozen using 
liquid nitrogen and stored at -80
0
C for future use.  
 
4.2.4 Isothermal titration calorimetry (ITC) 
ITC was carried out in an ITC200 microcalorimeter from Microcal (GE Healthcare Life 
Sciences). 70µl of 180µM p38α was loaded into a syringe and 320µl of 20µM TAB1 peptide 
was loaded into the cell. Prior to loading, both syringe and cell were rinsed extensively with de-
ionized water. After loading the samples, the temperature for the reaction was set at 25
0
C, the 
number of injections was set at 13 with 3µl sample per injection with spacing of 400 seconds 
between each injection to enable the system to reach equilibrium. The reaction was started and 
the first addition was done after achieving the baseline stability. After completion of the 
experiment, Microcal Origin 7.0 data software was used to analyse the result. Integrated heat 
data obtained for the titrations corrected for heats of dilution were fitted with a nonlinear least-
squares minimization algorithm to a theoretical titration curve. The heat of the first injection 
was discarded from the analysis to avoid artefacts due to diffusion through the injection port 
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that occur during the long equilibrium period which affects the local protein concentration near 
the syringe. The data fitting gave us the values for binding stoichiometry (n), binding affinity 
(K), molar enthalpy change (ΔH). The molar entropy (ΔS) was calculated using ΔS = ΔH- ΔG, 
where ΔG= -RT x lnK (R=1.987 cal mol-1 K-1, T=298K).  
 
4.2.5 Crystallization and structure determination  
The p38αT185G-TAB1 complex at 12mg/ml was preincubated with 1mM SB203580 and 
crystallized by sitting-drop vapour diffusion at 4
o
C. The complex crystals grew in two different 
conditions yielding two different forms; 1, p38α-TAB1 tetragonal, 20%w/v PEG3350, 0.2M 
Na/K tartrate, 0.1M bis-Tris propane, pH6.5. 10% ethylene glycol, and 2, p38α-TAB1-S04 
tetragonal, 25% w/v medium-molecular-weight PEG smears, 0.2M ammonium sulphate, 0.01M 
CdCl2, 0.1M HEPES, pH7.5.  The crystals were cryoprotected with mother liquor supplemented 
with 20% ethylene glycol. The diffraction data were collected using beamline I03 and I04 at 
Diamond Light Source and processed and scaled with MOSFLM and SCALA. The structure 
was solved by molecular replacement with a p38α monomer and PHASER45 as a search model.   
 
4.2.6 In-vitro Kinase assay  
An in-vitro kinase assay was performed to activate p38α by MKK6, and ATF2 by p38α. 1mg of 
p38α was activated with 0.2mg of MKK6dd. The reaction was supplemented with 3.3ml of 
EGTA at 1mM, 3.3ml of MgCl2 at 100mM and 360µl of ATP at 20mM. The final reaction 
volume of 33ml was made up using buffer (100mM NaCl, 20mM Tris, 2mM DTT –pH7.5). The 
samples were mixed gently and the reaction tube was incubated at 37
0
C for 2 hours. After 2 
hours, 300µl of amylose resin was added to the reaction tube to remove MKK6 (MKK6 was 
tagged with Maltose binding protein which has high affinity for amylose). The sample was 
centrifuged for 5 minutes to pellet the amylose resin bound with MKK6 and rest of the sample 
was separated and filtered through a 0.45µM filter. The sample was passed through the Mono Q 
column for another step of purification to remove the impurities from the activation process of 
in-vitro kinase assay. Once purified, the sample was dialysed overnight in the dialysis buffer 
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(100mM NaCl, 20mM Tris, 10mM DTT –pH7.5) to get the end product of active p38α. The 
IVK for ATF2 was carried out for 30 minutes using 0.86µM ATF2, 0.2µM p38α and 550µM 
ATP in a kinase buffer.   
 
To carry out the TAB1 mediated activation of mutant p38αT185G; 3µM of p38α was used with 
15µM of TAB1 peptide (384-412) and incubated in 1X kinase buffer (25mM Tris/HCl -pH7.5, 
5mM β-glycerolphosphate, 2mM DTT, 0.1mM Na3VO4 and 1mM MgCl2). 5µl of 10mM ATP 
was added to the incubation mixture to start the reaction at 37
o
C. The samples were collected at 
four different time points of 30min, 1hr, 2hr, and 4hr. 2X sample buffer (20% glycerol, 6% SDS 
in 0.12M Tris –pH6.8, 10% 2-mercaptoethanol and 0.4% Bromophenol Blue) was added to the 
sample, heated to 95
o
C for 10 minutes and used for western blot analysis as described 
previously in the second chapter (2.1.4). The samples were run on a 10% SDS-PAGE gel, 
transferred onto a membrane and probed with dual monoclonal phospho p38 (Thr180/Tyr182) 
antibody (Sigma), total p38 antibody (Cell Signalling), phospho ATF2 antibody (Cell 
signalling).   
 
4.2.7 Ischaemic buffer 
The recipe for Ischaemic buffer has been adapted from Esumi et al, 1991 which is described in 
Punn et al, 2000. 50ml of Ischaemic buffer (127mM NaCl, 3.58mM KCl, 0.49mM 
MgCl2.6H2O, 1.8mM CaCl2.2H2O, 4mM HEPES, pH7.4) was made up using 5ml of 10X basic 
stock solution  and 45ml of sterile deionised H2O. 10mM 2-DOG and 20mM Na lactate was 
added to the 50ml solution and filter sterilised using a 0.2µm syringe, warmed to 37
O
C. pH of 
the solution at this point is 6.8. Once the solution was warmed up, 1mM Na dithionite was 
added to the solution (pH drops to 6.3) and mixed before quickly adding it onto the cells for 
10mins. Cells were washed with PBS prior to the addition of ischaemic buffer. After 10mins, 





4.2.8 Western Blot   
Western blotting was done as described earlier in chapter 2. Briefly, samples were lysed with 2X 
SDS sample buffer and boiled at 95
o
C for 10 minutes. 5µl of IVK samples and 10µl of cell 
samples were run on 10% SDS polyacrylamide gel for 1hr 30 min and transferred to a PVDF 
membrane. The membrane was then blocked with 4% milk and 1% BSA in TBST for 1 hour at 
room temperature. The membrane was then probed with appropriate antibody (see table below) 
overnight at 4
o
C. The membrane was washed three times with 15ml of TBST for 10 minutes 
each and blocked with rabbit secondary antibody conjugated with HRP for 1 hour at room 
temperature. The membrane was washed three times with 15ml TBST for 10 minutes each and 
developed by chemiluminescence technique.   
 
Table 4.2.8 Antibodies used for western blot 
 
4.2.9 Statistical analysis  
 
Data sets were analysed by one way ANOVA (Analysis of Variance) and groups were compared 
using Tukey’s test as a post-hoc. p value of less than 0.05 was considered significant.  
 
 Cell samples IVK samples 
Phospho p38 antibody (T180/Y182) 1/1000 1/5000 
Total p38 antibody 1/2000 1/10000 
Phospho TAB1 (Ser423) 1/1000 N/A 
Total TAB1 1/2000 N/A 
Phospho MKK3/6 1/1000 1/5000 
Phospho ATF2 N/A 1/2000 
Total ATF2 N/A 1/10000 
Secondary antibody 1/5000 1/8000 
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4.3 Results  
 
4.3.1 First purification step: Nickel column affinity purification of p38αT185G  
After carrying out the large scale growth of transformed bacteria (Rosetta
TM
 2) expressing the 
protein of interest, several purification techniques were employed. Bacteria were lysed as 
described in section 4.2 and the soluble fraction containing protein was used for purification. 
Since the protein was cloned with a polyhistidine tag at the C-terminal end, a nickel column was 
used for the first purification. At each step of the nickel column purification, 20µl of samples 
were collected to run on 10% SDS-PAGE gel and stained with Coomassie Brilliant Blue to 
provide a visual estimate of purity. As evident from the image of the gel in figure 4.3.1, the 
protein purity increases at each step of Nickel column purification with a single band seen on 
the elution fraction around 38kDa molecular weight. The total fraction represents the soluble 
fraction of the lysate; Flow-through fraction represents the flow through collected after passing 
the soluble fraction through the nickel column where the protein binds to the column and 
remaining contaminants pass through the column; wash represents washing of the column with 
buffer A (low salt); and finally the elution fraction represents our protein p38αT185G which is 
























Figure 4.3.1 Coomassie Brilliant Blue staining of SDS-PAGE gel: The image shows the SDS-PAGE gel 
following coomassie staining of samples from each step of Nickel column purification and the samples 
collected from different fractions of the subsequent MonoQ anion exchange purification. As highlighted, 
the relevant band is seen around molecular weight of 38kDa, which is the molecular weight of the protein 
p38 (although the protein runs a little higher on the gel (~40kDa) due to polyhistidine tag). As seen, the 
p38α band gets cleaner after each stage of Nickel column purification and a clean single band is seen on 
the fractions collected from the anionic exchange chromatography column.  
 
 
4.3.2 Second purification step: Ionic-exchange chromatography of p38αT185G 
After the Nickel affinity column purification, the elution fraction was purified further using ion 
exchange chromatography to improve the purity level. We used an anionic exchanger Mono Q 
5/50 GL column (GE Healthcare Life Sciences).  With pI value of 5.4, p38αT185G is negatively 
charged at pH7.5 and will initially bind to the column. But as the gradient of high salt buffer B 
increases during purification, p38αT185G’s affinity is diminished by the increasing 
concentration of negatively charged chloride ions which results in the displacement of p38α. 
Thus p38αT185G gets eluted off the column with higher purity, separating it from other 
contaminating proteins and residues. As seen in figure 4.3.1, the fractions collected under the 
main peak of chromatogram (Fig 4.3.2) contain a single band representing our protein 
92 
 
p38αT185G. This step removed the faint bands that were seen on the elution fraction of the 
















Figure 4.3.2 Mono Q anionic exchange purification: The chromatograph shows the absorbance at 
280nm (blue peak) which represents the elution of protein from the column. The dominant peak around 
1000mAU represents p38αT185G and corresponding fractions under this peak were collected and ran on 
the SDS gel shown in figure 4.3.1. The subsequent small peaks represent the elution of trace proteins with 
different phosphorylation states, as the column separates protein based on ionic strengths which varies 
according to the phosphorylation state (negative charge), and were discarded.  
 
 
4.3.3 Third purification step: Size exclusion chromatography of p38αT185G  
Finally, a gel filtration column was used as the last step of protein purification; this polishing 
step increased the purity close to 100%. The samples collected after this step were either 
immediately used for our experiments or stored at -80
0
C for future use. The purity of samples 
can be seen in figure 4.3.3A which shows the elution fraction from the size-exclusion 
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chromatography purification. It is also reflected in the chromatograph in figure 4.3.4B with a 








Figure 4.3.3A Coomassie Brilliant Blue staining of the SDS gel: The SDS gel after coomassie staining 
of the fractions eluted from the gel filtration column. The samples were taken from the fractions under the 
peak on the chromatograph as seen in figure 4.3.4B. A single clean band is seen around 38kDa molecular 














Figure 4.3.3B Chromatograph of gel filtration column:  The chromatograph shows a single blue peak at 
280nm absorbance, representing a single pure protein being eluted from the column. The other coloured 
line represents different parameters of purification; brown line represents the conductivity, light blue 





4.3.4 Isothermal titration calorimetry  
p38α autoactivation is the consequent result of TAB1 interacting with p38α, i.e. without the 
p38α-TAB1 interaction, the auto-phosphorylation of p38α’s T-G-Y motif cannot happen. So 
before testing our hypothesis that the p38αT185G mutation impairs TAB1-induced p38 auto-
activation, we needed to confirm that the p38αT185G mutant kinase is able to bind TAB1. ITC 
was performed with recombinant p38αT185G and 29mer TAB1 peptide (384-412) as described 
in section 4.2.4. The results showed that p38αT185G was able to bind to TAB1 and the 
mutation did not affect its ability to interact with TAB1 (Fig 4.3.4). Data analysis confirmed 
that the mutant protein p38αT185G was interacting strongly with TAB1 similar to WTp38α 

























Figure 4.3.4 ITC titration profile of p38αT185G on the left and WT p38α on the right with TAB1 
peptide (384-412) and a table summarizing the thermodynamic parameters of the interaction: The top 
figures shows the raw data traces of differential power recorded (µcal/sec) over time generated by 
formation of a complex between p38αT185G and TAB1 peptide (384-412) (left) and WTp38α and TAB1 
peptide (384-412) (right), with sequential injections of p38αT185G into TAB1 peptide. The plot of the 
heat evolved per injection over molar ratio calculated from integration of the data, corrected for the 
dilution. The bottom figure represents the thermodynamic parameters of the interaction which is 
summarized in the table below it, from 3 independent experiments with standard deviation.  
 
 
4.3.5 Crystal structure of p38αT185G and TAB1 peptide (384-412) 
Following the confirmation of interaction between p38αT185G and TAB1 with ITC, we 
crystallized the p38αT185G-TAB1 complex in order to see its structure and compare it with the 
WTp38α-TAB1 (This was carried out by Dr Gian De Nicola and Dr Charles Nichols). The 
crystal structure revealed many shared features between these complexes with the notable 
exception of the activation loop confirmation. The crystal structure showed that without the 
hydrogen bond between Thr185 and Asp150, the activation loop (Leu171-Val183) of 
p38αT185G is not able to adopt the orientation observed in WTp38α. The helical extension of 
the c-terminal portion (Tyr182-Thr185) of the activation loop of WTp38α that orientates T180 
towards the catalytic cleft, is absent in p38αT185G. This crystal structure indicates that our 
hypothesis could be correct and without the hydrogen bond between Thr185 and Asp150, the 
activation loop cannot orientate towards the catalytic site, which would be predicted to impair 
the auto-phosphorylation of T-G-Y motif.  With this encouraging finding, we proceeded to test 
our hypothesis.  
 
 N Kd (M
-1





































Figure 4.3.5 Crystal of p38αT185G-TAB1 peptide (384-412) complex. 1) Representative p38α 2fo-fc 
electron density maps at 1.0σ, residue 185 highlighted in CPK format (1a shows p38αT185G, 1b shows 
WTp38α). 2a) Cartoon format illustrates the structural comparison of wild-type (WT) in red and T185G 
(TG) in blue p38α co-crystallised with TAB1 peptide and ATP-analogue SB. 2b) Close-up of loop 
containing residue Thr185 and its H-bonds with Asp150 in the WT. The Thr185 residue in T185G trace is 
not shown but its relaxation can be seen compared to the WT (blue trace compared to red). The 
relaxation of the C-terminal end of activation loop in T185G trace caused high B factor (100 compared 
to 40 in WT) indicating a very mobile activation loop, which as a result could not be resolved in the 
crystal structure. Side-chain atoms of residue D150, K152 and T/G185 are shown in liquorice (WT) or 
CPK (TG) formats. Lattice constraints prevent complete loss of helical structure, but the B-factor 










4.3.6 p38αT185G’s autoactivation is impaired  
To test our hypothesis of impaired autoactivation of the p38αT185G mutant, we carried out an 
in-vitro kinase assay (IVK) with recombinant p38αT185G and 29mer TAB1 peptide (384-412). 
The IVK assay was carried out in an eppendorf tube with p38αT185G (3µM), TAB1 peptide 
(15µM) and ATP (550µM) in 1X kinase buffer for 4 hours at 37
o
C. The product of the reaction 
was collected at four different time points for analysis by western blot. The western blot result 
shows TAB1 caused autoactivation of WTp38α at 4 different time points but was not able to 
cause autoactivation of the p38αT185G mutant as seen by the lack of phosphorylation at T-G-Y 
motif (Fig 4.3.6). This result suggests that the hydrogen bond that forms between Thr185 and 













Figure 4.3.6 In-vitro kinase assay with WTp38α, p38αT185G and TAB1. The western blot analysis of 
kinase assay performed with WTp38α and p38αT185G mutant in the absence and presence of TAB1 
peptide (384-412) at 4 different time points. Phospho p38 signal can be seen in the sample with WTp38α 
and TAB1 which becomes stronger with time. The phospho p38 signal in sample with p38αT185G and 







4.3.7 p38αT185G autoactivation is impaired in HEK293 cells  
The IVK result suggested that the hydrogen bond that forms between Thr185 and Asp150 is 
essential in TAB1 induced p38α autoactivation which supports our hypothesis. To further 
examine this mechanism, we used an over-expression system in mammalian HEK293 cells and 
ectopically expressed p38αT185G in HEK293 cells together with TAB1. 24hrs after 
transfection there was a significant increase in phospho-p38 (T-G-Y) signal in cells transfected 
with WTp38α and TAB1, however no such increment was observed in cells transfected with the 
p38αT185G mutant and TAB1 (Fig 4.3.7). The result mirrors the outcome from IVK and 
provides another strand of evidence to support our hypothesis that the hydrogen bond formation 
between Thr185 and Asp150 is a prerequisite step for TAB1 induced p38α autoactivation and 







































4.3.7 Western blot analysis of HEK293 cells transfected with WTp38α, p38αT185G and TAB1. Western 
blot result of HEK293 cells co-transfected with WTp38α or p38αT185G and TAB1 treated with SB203580 
(10µM). There was a significant difference between the wtp38α and p38αT185G activation when co-
transfected with TAB1. The phospho-p38 signal was reduced by SB203580 treatment indicating the mode 
of activation to be autoactivation. The result clearly illustrates the impaired autoactivation in 
p38αT185G compared to WTp38α. The arrow represents the ectopic p38 which runs higher than the 
endogenous p38 as it is heavier because of the polyhistidine tag. At the bottom is the graphic 
representation of the quantification of 3 independent experiments which shows a significant difference 
between WTp38α and WTp38α+TAB1 (*), and WTp38α+TAB1 and p38αT185G+TAB1 (#). Data 








4.3.8 Simulated Ischaemia does not cause autoactivation of p38αT185G 
In order to provide a more physiologically relevant stimulus to test our hypothesis of TAB1-
induced p38α autoactivation, we decided to use ischaemic stress. We transfected HEK293 cells 
with either WTp38α or p38αT185G, and subjected cells to simulated ischaemia using simulated 
ischaemia buffer (relying on endogenous TAB1 to cause p38α autoactivation). After 10 minute 
incubation in ischaemic buffer, we saw increased phospho p38 (T-G-Y) signal in cells 
transfected with WTp38α compared to the control baseline (Fig 4.3.8), which was SB203580 
sensitive confirming the mode of p38 activation to be autoactivation. In cells transfected with 
the p38αT185G mutant, we did not see an increased phospho-p38 signal compared to the 
control baseline with ischaemia indicating impaired autoactivation. The result recapitulates the 





































4.3.8 Western blot analysis of HEK293 cells subjected to simulated ischaemia. Western blot result of 
HEK293 cells transfected with WTp38α or p38αT185G exposed to ischaemia buffer for 10 minutes in the 
presence of SB203580. There was a significant increase in phospho-p38 signal compared to control 
baseline when treated with ischaemic buffer in cells transfected with WTp38α. This was inhibited was 
SB203580 at 10µM. In cells transfected with p38αT185G, no increment in phospho-p38 signal was 
observed with ischaemic buffer compared to the control. The arrow represents the ectopic p38α. Below 
the blot is the graphic representation of the quantification of 3 independent experiments which shows a 
significant difference between wtp38α and p38αT185G autoactivation caused by ischaemic buffer. Data 






4.3.9 p38αT185G and WTp38α are similarly activated by upstream kinases  
Having obtained results to support our hypothesis that the hydrogen bond between Thr185 and 
Asp150 plays an important role in p38α’s autoactivation process, we asked ourselves whether it 
had a similar role in p38α’s classical activation pathway. To investigate this we carried out an 
in-vitro kinase assay with p38α and the dual specificity kinase MKK6, an upstream activator of 
p38. The IVK assay was carried out as described earlier with p38α, the constitutively active 
MKK6dd and ATP at 37
O
C in a kinase buffer. After 2 hours of IVK reaction, the constitutively 
active MKK6 was able to activate the p38αT185G mutant in a similar way to WTp38α (Fig 
4.3.9). The result suggested that hydrogen bond between Thr185 and Asp150, unlike in p38α’s 
autoactivation mechanism, has no impact on p38α’s trans-activation mechanism involved in the 











Figure 4.3.9 Activation of p38αT185G and WTp38α by upstream kinase MKK6. Western blot of the 
product of the IVK reaction between WTp38α/p38αT185G and MKK6dd. MKK6dd was able to equally 






4.3.10 p38αT185G and WTp38α are similarly activated by upstream kinase in 
HEK293 cells 
Following the IVK result, we next examined whether these differential effects could be 
recapitulated in mammalian cells. We used an over-expression system to transfect HEK293 
cells with WTp38α or p38αT185G, TAB1 and MKK3, another upstream activator of p38α. 
24hrs following transfection, we saw an increased phospho-p38 signal in cells transfected with 
WTp38α and TAB1 compared to control but not in cells transfected with p38αT185G and 
TAB1. In cells transfected with WTp38α and MKK3, we saw a significant increase in phospho-
p38 signal which was expected but we also saw similar level of increased phospho-p38 signal in 
cells transfected with p38αT185G and MKK3. The result suggests there is no difference 
between WTp38α and p38αT185G transphosphorylation by upstream kinases, paralleling the 











Figure 4.3.10 Activation of p38αT185G and WTp38α by TAB1 and MKK3. Western blot figure shows 
the result of HEK293 cells transfected with WTp38α/p38αT185G, TAB1 and MKK3. There was increased 
phospho-p38 signal in cells transfected with WTp38 and TAB1 compared to control but not in cells 
transfected with p38αT185G and TAB1. There was a marked increase in the phospho p38 signal in cells 
transfected with both WTp38 and TAB1, but not p38αT185G and TAB1. Phospho-MKK3 signal can be 
seen in cells transfected with MKK3 indicating active MKK3. Arrow heads represents ectopic band which 






4.3.11 p38αT185G and WTp38α are similarly able to phosphorylate downstream 
substrates. 
The results so far suggest that the hydrogen bond between Thr185 and Asp150 plays an 
important role in p38α’s auto-activation by TAB1 but not in p38α’s ability to be trans-activated 
by MKK3/6. Next we wanted to investigate whether the hydrogen bond would have an impact 
on p38’s ability to phosphorylate its downstream targets. We carried out an in-vitro kinase assay 
with WTp38α, p38αT185G and activating transcription factor -2 (ATF2) which is a well known 
substrate of p38 as described in 4.2.5. The IVK result showed that both WTp38α and 
p38αT185G mutant were able to phosphorylate ATF2 similarly (Fig 4.3.11). The result suggests 











Figure 4.3.11 Activation of ATF2 by WTp38α and p38αT185G: Western blot of the product of the IVK 
reaction between recombinant WTp38α/p38αT185G and ATF2. A clear phospho ATF2 signal was 








4.3.12 Activation of TAB1 by WTp38α and p38αT185G in HEK293 cells  
To further confirm the previous IVK result which suggested no difference in p38αT185G’s 
ability to phosphorylate its substrate compared to WT, we carried out an over-expression 
experiment in HEK293 cells to look at another of p38’s prominent substrates, TAB1. WTp38α, 
p38αT185G and TAB1 were transfected in HEK293 cells and 24hrs later analysed by western 
blotting. The result showed that the cells transfected with p38αT185G had a similar level of 
phospho-TAB1 signal compared to the cells transfected with WTp38α (Fig 4.3.12). Although 
the result recapitulates the IVK outcome carried out with ATF2, this result is surprising. In the 
IVK assay, the active p38αT185G had been pre-activated with MKK6 so there was an equal 
amount active WTp38α and p38αT185G. However, in this case the active p38αT185G is lower 












Figure 4.3.12 Activation of TAB1 by p38αT185G and WTp38α. Western blot of the HEK293 cells 
transfected with WTp38α, p38αT185G, and TAB1. There was increased phospho-p38 signal in cells 
transfected with WTp38 and TAB1 compared to control but not in cells transfected with p38αT185G and 
TAB1. There was a similar level of increment in phospho TAB1 signal in both WTp38 and p38αT185G 
transfected cells indicating both WTp38α and p38αT185G are able to activate TAB1 equally. Arrows 





4.3.13 The T185G mutation makes a difference at lower enzyme concentrations. 
From our results in 4.3.9 we concluded that the hydrogen bond between Thr185 and Asp150 
does not have an impact on p38α’s phosphorylation by MKK3/6. The same conclusion was 
made on p38α’s catalytic ability based on the ATF2 (Fig 4.3.11) and TAB1 (Fig 4.3.12) data. 
However, the IVK experiments carried out were performed using high enzyme concentration 
which is not ideal. The high enzyme concentration not only makes the reaction conditions 
unphysiological, but it also leads to artefactual stoichiometry which can give rise to misleading 
results when trying to interpret enzymatic activity. Therefore in order to address this deficiency, 
we carried out a kinetic assay where we lowered the concentration of enzyme to the low 
nanomolar range. The IVK was carried out at a constant p38α concentration and varying 
concentrations of MKK6 for 20 minutes. There was no difference between WTp38α and 
p38αT185G mutant transphosphorylation by MKK6 above 0.02µM (20nM) concentration of 
MKK6. Below 6.6nM concentration, MKK6 was able to activate WTp38α much more 
efficiently than the p38αT185G mutant (Fig 4.3.13 A). Similarly in the IVK assay with p38α 
and ATF2, there was no significant difference in p38αT185G mutant’s ability to activate ATF2 
compared to WTp38α until 0.006µM (60nM) concentration of p38α (Fig 4.3.13 B). From 20nM 
concentration and onwards, p38αT185G’s ability to phosphorylate ATF2 was significantly 


































Figure 4.3.13A Kinetics of WTp38α and p38αT185G activation by MKK6.Western blot of the product of 
the IVK reaction between WTp38α/p38αT185G and different concentrations of MKK6dd. There was a 
significant difference in phosphorylation of WTp38α and p38αT185G phosphorylation by MKK6 below 
0.02µM MKK6dd. The graph below represents the quantification from 3 independent experiments, data 





























Figure 4.3.13B Kinetics of activation of downstream substrate ATF2 by WTp38α and 
p38αT185G.Western blot of the product of the IVK reaction between ATF2 and different concentrations 
of WTp38α and p38αT185G. There was a significant difference in phosphorylation of ATF2 by WTp38α 
and p38αT185G below 0.02µM. The graph below represents the quantification from 3 independent 
experiments, data represented as mean +/-SEM, p<0.05.  (* = significant against the WTp38α at that 





4.4 Discussion  
 
In this chapter we investigated the potential role played by Thr185 in the TAB1 induced p38α 
autoactivation mechanism. We hypothesized that the hydrogen bond that forms between the side 
chains of Thr185 and Asp150 provides energy to hold the activation loop in its new orientation 
that facilitates the T-G-Y autophosphorylation. To test our hypothesis we created a mutant 
p38αT185G which cannot form a hydrogen bond between Thr185 and Asp150.  
 
4.4.1 p38αT185G binds to TAB1 
Before we tested our hypothesis, it was necessary to confirm that the mutant p38αT185G was 
able to bind to TAB1. The autoactivation of p38α is the consequence of TAB1 binding to p38α, 
so to test the effect of T185G mutation on the autoactivation mechanism, we needed to make 
sure that p38αT185G can also bind to TAB1. To investigate this, we carried out an isothermal 
titration calorimetry experiment with recombinant p38αT185G and 29mer TAB1 peptide (384-
412). The ITC data showed that p38αT185G was indeed able to bind to TAB1, similar to 
WTp38α as seen in figure 4.3.3. Both the WTp38α and the mutant p38αT185G were interacting 
with TAB1 in a strong manner with a binding affinity of 4.35 X 10^
5 
/mol and 9.76 X 10^
5 
/mol 
respectively. The result indicates that the hydrogen bond between Thr185 and Asp150 does not 
impact p38α’s ability to interact with TAB1. The result is expected as the crystal structure of 
WTp38α-TAB1 complex clearly illustrates the residue Thr185 structurally far away from the 
two interacting regions (De Nicola et al, 2013). The raw data analysis showed the stoichiometry 
(n) of the WTp38α and the mutant p38αT185G with TAB1 to be 0.78 and 0.61 respectively, 
however this was due to the underestimation of the TAB1 peptide concentration made after 
dissolving the peptide in the buffer. ITC is an extremely sensitive biophysical tool where the 
concentrations of the proteins have to be exact, which otherwise will produce a wrong result. 
TAB1 peptide lack enough of the tyrosine/tryptophan residues, which nanodrop relies on when 
measuring the protein concentration. As a result, the protein concentration we entered into the 
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program to calculate the stoichiometry was undervalue to the actual concentration of protein 
used in the experiment and this resulted in the lower n number.  We concluded both the 
WTp38α and the mutant p38αT185G was binding to TAB1 in a 1:1 manner with stoichiometry 
(n) of 1, and the crystal structure clearly confirms that. The ITC data confirmed that the T185G 
mutation did not hamper the p38αT185G’s ability to interact with TAB1.  
 
After confirming the interaction between mutant p38αT185G and TAB1, we resolved the crystal 
structure of the p38αT185G-TAB1 complex. The crystal structure confirmed the lack of 
threonine at 185 residue, which was replaced by glycine as seen in figure 5.3.5.1a/b. When 
TAB1 binds to the WTp38α, the Tyr182-Thr185 extends to form an alpha-helical segment that 
swings the activation loop towards the catalytic site. The formation of the extended helical 
segment is stabilized by the hydrogen bond formation between the Thr185 and the Asp150. In 
the crystal structure of p38αT185G and TAB1, the Gly185 and Asp150 were unable to form a 
hydrogen bond as expected and the Gly185 appeared to be further away from Asp150 (Fig 
5.3.2b). As a result of this, the Tyr182-Thr185 appeared more relaxed and did not extend to 
form a helical segment. The lack of the extended helical segment should prevent the swing of 
the activation loop towards the catalytic site and prevent the T-G-Y autophosphorylation. 
However, due to the high B-factor, the T-G-Y part of the activation loop could not be resolved 
in the crystal structure, which means the activation loop was too mobile for it to be crystallized. 
This supports the first part of our hypothesis that the lack of the hydrogen bond between the 
Thr185 and Asp150 means there was not enough energy required to hold the activation loop 
near the catalytic site, which otherwise would have been resolved in the crystal structure. The 
activation loop did not relax completely either as in the monomeric WTp38α form due to the 
lattice constraint from the adjacent p38αT185G monomer. The crystal structure confirms that 
p38αT185G mutant cannot form hydrogen bond between the side chains of Thr185 and Asp150, 




The ITC data showed that the mutant p38αT185G was able to bind to TAB1 similar to the 
WTp38α, and the crystal structure of the p38αT185G with TAB1 confirmed this. The crystal 
structure also illustrated that the lack of hydrogen bond between Asp150 and Thr185 
destabilized the activation loop and with these encouraging initial findings, we next investigated 
whether this would reflect in a lack of T-G-Y autophosphorylation.   
 
 
4.4.2 Thr185 plays a crucial role in the TAB1 induced p38α’s auto-activation mechanism 
To test our hypothesis, we carried out an in-vitro kinase assay with p38αT185G and TAB1 
peptide (384-412) and analysed its activation status at 4 different time points. The western blot 
in 4.3.6 shows that in the presence of TAB1 peptide, the WTp38α was phosphorylated at the T-
G-Y motif at all 4 time points, whereas the mutant p38αT185G was not. Only a weak phospho 
p38α signal was seen at the 4 hour time point with p38αT185G in the presence of TAB1. The 
result suggests that the p38αT185G cannot be activated by TAB1, which supports our 
hypothesis. To gather further evidence, we decided to test our hypothesis in a living system with 
a mammalian cell line HEK293 cells. We transfected the HEK293 cells with WTp38α and the 
mutant p38αT185G in the presence of TAB1. 24 hours later, we analysed the cells with western 
blotting and probed with phospho p38 antibody. The co-transfection of WTp38α and TAB1 
significantly increased the phospho p38 signal (Fig 4.3.7) which supports the original study that 
TAB1 causes p38α activation (Ge et al, 2002). This increment was inhibited by 10µM 
SB203580 treatment which confirms the mode of TAB1-induced activation to be auto-
activation. The co-transfection of p38αT185G and TAB1 did not cause a similar increase in the 
phospho p38 signal and was significantly lower than the phospho p38α signal seen with the 
WTp38α. The lower phospho p38 signal on the endogenous band in p38αT185G sample was 
however a surprise, a result which was consistent throughout the project and rest of the projects 
in the lab. It’s an anomaly we cannot explain at this time and requires further investigation. This 
signal was also completely abolished by SB203580 treatment. The result suggests that TAB1 is 
unable to cause autoactivation of p38αT185G similar to the WTp38α. Next, we decided to test 
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our hypothesis using a more physiologically relevant stimulus of ischaemia which is a well-
known stimulus that induces TAB1-mediated p38α activation (Li et al, 2005; Tanno et al, 
2006). We transfected the HEK293 cells with WTp38α or p38αT185G, then subjected them 
with simulated ischaemia using an ischaemia buffer for 10 minutes. 10 minute incubation time 
was chosen as previous experiments in the lab had indicated it to be the time-point at which 
phospho p38 signal was the highest. 24hours after transfection, the cells were treated with 
ischaemia buffer for 10 minutes and analysed by western blotting. The western blot showed that 
the simulated ischaemia caused a significant increase in phospho p38 signal in cells transfected 
with WTp38α compared to the baseline control, but not in the cells transfected with p38αT185G 
(Fig4 .3.8). The signal was completely inhibited by the 10µM SB203580 treatment. One of the 
main components of ischaemia buffer is sodium dithionite, which causes oxidative stress that 
also activate p38, however, it has been shown to be via ASK1-MKK3/6 pathway (Nagai et al, 
2007). Additionally, inhibition by SB203580 suggests that ischaemia buffer is causing 
autoactivation not transactivation. The result suggests that the TAB1 induced autoactivation is 
impaired in the mutant p38αT185G recapitulating the results from previous IVK and TAB1 
transfection experiments. The 3 independent experiments have given the same outcome which 
suggests that the p38αT185G’s autoactivation mechanism is impaired, i.e. the hydrogen bond 
between the Thr185 and Asp150 is crucial in mediating autoactivation of p38α caused by 
TAB1.   
 
4.4.3 Thr185 does not play a role in MKK3/6 mediated p38α trans-activation mechanism.  
The data collected so far suggests that the hydrogen bond formation between Thr185 and 
Asp150 is a key step for a successful p38α autoactivation. We wanted to find out whether it had 
a similar role in p38α’s alternative activation mode of transphosphorylation caused by upstream 
kinases. We carried out an in-vitro kinase assay with p38αT185G and constitutively active 
MKK6dd for 2 hours. The IVK result showed that MKK6 caused a huge phospho p38α signal in 
both WTp38α and the mutant p38αT185G as seen in figure 4.3.9. The result indicated that the 
transactivation mode of p38α is not impaired in the mutant p38αT185G suggesting the hydrogen 
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bond between Thr185 and Asp150 is not important in the transphosphorylation of p38α. We 
also tested this in HEK293 cells by transfecting WTp38α or p38αT185G with MKK3. 24 hours 
after transfection, the co-transfection of WTp38α and MKK3 caused a huge phospho p38α 
signal, as expected. Similarly, the co-transfection of p38αT185G and MKK3 also caused a 
similar level of phospho p38 signal (Fig 4.3.10) suggesting that the p38αT185G is able to be 
activated by MKK3 similar to the WTp38α. The result supports the outcome from the IVK 
assay, suggesting that the trans-activation mode of p38α caused by MKK3/6 is not affected by 
Thr185. The result is not a surprise as MKK3/6 docks to p38α’s canonical binding domain to 
phosphorylate the T-G-Y motif and Thr185 is not thought to play any part. In the autoactivation 
mechanism, TAB1 binding leads to structural changes that increases ATP affinity and promotes 
autophosphorylation. The hydrogen bond formation is the part of that structural change which 
makes it crucial for autoactivation process. However, when MKK3/6 binds to p38α, the 
significant structural changes takes place after MKK3/6 phosphorylates the T-G-Y motif on the 
activation loop. The phosphorylation of the T-G-Y motif is the significant change that alters 
p38α’s structure, which relieves steric blocking, increases ATP affinity, and facilitates substrate 
binding, which makes p38α kinetically active.  
 
4.4.4 Thr185 does not impact p38α’s catalytic activity 
We also carried out tests to investigate if Thr185 was important in p38α’s catalytic activity. 
p38α is a serine/threonine kinase that catalyses its targets by transferring the γ-phosphate from 
the bound ATP onto substrates. We ran an in-vitro kinase assay with active WTp38α or active 
p38αT185G and activating transcription factor -2 (ATF2), a well-known substrate of p38α. 
After 30 minutes of IVK reaction, ATF2 was equally activated by both the WTp38α and the 
mutant p38αT185G as seen by the phospho ATF2 signal in figure 4.3.11. The result suggests 
that the Thr185 does not impact p38α’s kinetic activity. We also carried out this experiment in 
the HEK293 cells by co-transfecting the cells with WTp38α or p38αT185G and TAB1, which is 
another downstream substrate of p38α. 24 hours later, the co-transfection of WTp38α and TAB1 
increased the phospho TAB1 signal as expected (Fig 4.3.12). Similarly, the co-transfection of 
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the mutant p38αT185G and TAB1 also produced a similar phospho TAB1 signal suggesting 
that p38αT185G’s ability to phosphorylate its target has not been impaired.  
 
In the in-vitro kinase reaction carried out in 4.3.11, there was an equal amount of active 
WTp38α and mutant p38αT185G, however in the HEK293 cells, there was less active 
p38αT185G in the cells compared to the active WTp38α as seen in western blot figure 4.3.12. 
The lower amount of active p38αT185G was due to its impaired autoactivation mechanism 
caused by TAB1 we discussed earlier, and with that we expected more TAB1 activation in the 
cells transfected with WTp38α compared to the cells transfected with the mutant p38αT185G.  
There are a couple of explanations for this; one being although we transfected the mutant 
p38αT185G in the cells, there is still the presence of endogenous WTp38α that can 
phosphorylate TAB1, another explanation is that there are other kinases in the cells 
phosphorylating TAB1 such as TAK1, ERK1, and JNK (Mendoza et al, 2008; Wolf et al, 
2011). The IVK and transfection data seem to suggest that the mutation of Thr185 does not 
affect p38α’s kinetic activity.  
 
4.4.5 The T185G mutation makes a difference at lower enzyme concentrations. 
From the discussion in 4.4.3 and 4.4.4, we concluded that Thr185 neither plays a role in its 
activation by upstream kinases nor its kinetic activity to phosphorylate substrates. However, the 
IVK assays were carried out with high enzyme concentration which not only makes it very 
different from the physiological environment of the cells but it can also give rise to artefactual 
stoichiometry that may give misleading results when trying to compare the enzymatic activity. 
To address this, we repeated our IVK assays by titrating the enzyme concentration down from 
0.6µM to 2nM. The IVK result confirmed that there was no difference in MKK6’s ability to 
phosphorylate mutant p38αT185G compared to the WTp38α at high nanomolar concentrations. 
However, from the 20nM range MKK6 was unable to phosphorylate p38αT185G as well as it 
was able to phosphorylate WTp38α and the difference became more marked with lower enzyme 
concentration. Similarly, we repeated this experiment with p38αT185G and ATF2 by titrating 
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active p38αT185G with the same concentrations as MKK6. Again at high nanomolar 
concentration there was no difference between WTp38α and p38αT185G in their abilities to 
activate ATF2. However, from 60nM concentration, p38αT185G was unable to phosphorylate 
ATF2 as well as the WTp38α. Just like with the MKK6, the difference between the WTp38α 
and the mutant p38αT185G was more marked at the lower concentrations and from 6nM 
concentrations p38αT185G was almost unable to activate ATF2. The result suggests that the 
mutation has indeed affected the p38αT185G’s functionality at lower nanomolar concentration. 
Exactly how the T185G mutation has caused this effect, and how it would translate 
physiologically is however, difficult to explain at this point and requires further investigation 
with in-vivo models. 
 
The result gathered in this chapter suggests that Thr185 plays a significant role in the TAB1 
induced autoactivation of p38α. Thr185 does not seem to play a role in the classical activation 
pathway nor does it seem to affect its kinetic activity, however at very low nanomolar 
















5 Could Thr185 play a role in p38α’s cellular location? 
 
5.1 Introduction  
In the last chapter we studied the role of Thr185 in TAB1-mediated p38α autoactivation and 
concluded that Thr185 plays a significant role in the process. The findings suggest that there 
could be an alternative method, beside the use of small molecules, to target the TAB1-p38α 
complex. In this chapter we shift our attention to the potential role of Thr185 in determining 
p38α’s cellular localization.   
 
In 2008, Kristina Lorenz and her group published a paper in Nature Medicine to show that the 
autophosphorylation of Thr188 in ERK1/2 directs ERK into the nucleus to phosphorylate its 
target in cardiac hypertrophy (Lorenz et al, 2008). They suggested a signalling cascade 
involving the following components the Raf-MEK-ERK kinase cassette, phosphorylation of the 
ERK’s TEY motif, dimerization of ERK1/2, followed by binding of the β/γ subunit from Gq 
protein which finally leads to the autophosphorylation of Thr188 that triggers ERK’s 
translocation into the nucleus. From the last chapter we know that Thr185 of p38α plays a role 
in p38α autoactivation; based on the ERK paradigm we pondered if Thr185 could play a similar 
role in p38α’s cellular localization too. The underlying rationale is that p38 is a close relative of 
ERK in the MAPK family and the corresponding residue of Thr188 in ERK is Thr185 in p38α. 
Belonging to the same kinase family, ERK and p38 share a very similar tertiary structure, as 
seen in figure 5.1A, which suggests complementary function. Furthermore, the interaction of 
ERK with β/γ subunit from Gq protein is similar to the interaction of p38α with TAB1. And 
finally, the signalling event in ERK occurs during cardiac hypertrophy and TAB1-p38α 
signalling occurs during the pathological stress of myocardial ischaemia. These compelling 
similarities between ERK and p38 in regards to the signalling role played by Thr188 and 



























Figure 5.1A The Crystal structure of ERK2 and p38α: The crystal structure highlights the similarity 
between the two MAPKs’ family member ERK (left) and p38α (right). Both have two main lobes of N-
terminus and C-terminus with an interposed, long activation loop. Below the crystal structure is the 
alignment of the ERK2 and p38α sequence which highlights Thr188 in ERK2 and Thr185 in p38 (yellow), 







We hypothesise that p38α’s interaction with TAB1 leads to the autophosphorylation of Thr185 
residue and that causes the localization of p38α into the nucleus where it phosphorylates its 














Figure 5.1 B The signalling role of Thr188 in ERK2 and Thr185 in p38α: The schematic diagram 
illustrates the signalling role played by Thr188 in ERK (left) and Thr185 in p38α (right). The schematic 
cartoon of ERK signalling is taken directly from the Kristina Lorenz’s paper published in Nature 












5.2 Specific Methods  
 
5.2.1 pCDNA constructs for mammalian cell over expression  
pCDNA3 was used as the plasmid vector for expression in mammalian cells. The plasmid 
contains cytomegalovirus immediate early (CMV) promoter and SV40 polyadenylation 
sequence for high level expression in mammalian cells.  It has an ampicillin resistance gene for 
selective cloning. WTp38α, p38αT185G, p38αT185D and WT TAB1 were cloned into this 
plasmid.  
 
p38αT185G and p38αT185D were cloned in two stages. The overlapping C-terminus and N-
terminus halves of p38α were produced in separate PCR reactions using an external primer and 
complementing internal primer containing the desired mutation. The PCR products from these 
reactions were then combined to form the template for a second PCR reaction with external 
primers to produce the full length p38α mutants.  
 
External Primers for p38α  
p38α Forward Length: 5’ ATGGATCCAG AAAACCTGTA CTTCCAAGGA ATGTCGCAGG 
AGAGGCCCAC GTTC 3’ 
p38α Reverse Length: 5’ CGGTCATGCT GCAGTTATCA GGACTCCATT TCTTCTTGGT 
CAAGGGGTGG TG 3’  
Internal Primers with desired mutations 
p38αT185G Forward: 5’ CTA CGT GGC CGG TAG GTG GTA CAG 3’ 
p38αT185G Reverse: 5’ CCT GTC ATT TCA TCA TCT G 3’ 
p38αT185D Forward: 5’ CTA CGT GGC CGA TAG GTG GTA CAG 3’ 






Table 5.2.1Plasmids used for mammalian cell transfection 
 
5.2.2 HELA cells   
HELA cells are an immortal cell line derived from the cervical cancer cells of Henrietta Lacks. 
They were derived by isolating one tumour cell and expanding it to generate the cell line. 
George Gey who derived the cell in 1951 named the cell line after Henrietta Lacks, HELA 
(Scherer, 1953). HELA cells are the oldest and one of the most commonly used cell lines in 
biological and medical research. The vaccine for polio was developed by growing polio virus in 
these cells (Brownlee, 1955).  
 
Just like HEK293 cells, HELA cells are easy to transfect to express the protein of interest and 
they contain all the machinery required for post-translational modifications. HELA cells were 
grown in T75 flask with full growth medium (Dulbecco’s modified Eagle’s medium, 





Resistance  Tag Expected 
molecular weight 
(kDa) 
Details & Source 
 
WT p38α pCDNA3 Ampicillin HA 40 Full length WTp38α (DR Y 
Wang, UCLA, USA) 
p38αT185G pCDNA3 Ampicillin HA 40 Full length mutant p38 
(Cloned from WTp38α) 
p38αT185D pCDNA3 Ampicillin HA 40 Full length mutant p38 
(Cloned from WTp38α) 
WT TAB1 pCDNA3 Ampicillin CFP 83 Full length WT TAB1 
(Gian De Nicola) 
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5% CO2 in a water saturated incubator. The cells were split onto another T75 flask for culture 
and 6-well plate for the experiments once they were 80% confluent.   
 
5.2.3 Cellular fractionation 
The cellular fractionation of HEK293 cells was carried out using a kit from Thermo-Fisher 
Scientific (78833). The fractionation was carried out 24 hours after transfection. The cells were 
washed with PBS and harvested with 200µl of trypsin-EDTA. The cells were centrifuged at 
320g for 5 minutes and supernatant was carefully removed leaving the pellet as dry as possible. 
200µl of CER I reagent (with protease inhibitor) from the kit (78833) was used to resuspend the 
cells by vortexing on the highest setting for 15 minutes and incubated on ice for 10 minutes. 
11µl of CER II was added into the tube and vortexed for 5 seconds. The cells were incubated for 
1 minute and vortexed again for 5 seconds before being centrifuged for 5 minutes at 16000g. 
The supernatant (which contains the cytoplasmic fraction) was transferred immediately into a 
pre-chilled tube on ice. The pellet was re-suspended with 100µl of ice cold NER reagent (with 
protease inhibitor) and vortexed for 15 seconds every 10 minutes for a total of 40 minutes. The 
tube was centrifuged at 16000g for 10 minutes and the supernatant (which contains the nuclear 
fraction) was transferred into a pre-chilled tube. The cytoplasmic and nuclear extracts were 
stored at -80
o
C for analysis by western blotting.  
 
5.2.4 Western blot 
The cytoplasmic and nuclear extracts were run on SDS PAGE and transferred onto PVDF 
membrane as described previously in chapter 2 and probed with total p38α antibody (1/1000) 
and GAPDH antibody (1/1000). GAPDH antibody was used as a marker for the efficiency of 
fractionation between the cytoplasmic and nuclear extracts. Rabbit secondary antibody 






For immunocytochemistry, HELA cells were seeded in a 6-well plate with sterile coverslips and 
transfected once they were 70% confluent. 24hrs later, the transfection media was aspirated off 
and cells were washed with cold PBS. The cells were fixed with 4% paraformaldehyde in PBS 
for 10 minutes followed by two 5 minutes wash with PBS. 1ml of 0.2% v/v Triton X-100 in 
PBS was used to permeabilise the cells for 20 minutes at room temperature. The cells were 
washed 2 times with PBS for 5 minutes each. They were then blocked with 0.2% Triton X-100, 
2% w/v BSA in PBS for 2 hour at room temperature. After blocking, the cells were probed with 
anti-HA-mouse (CST) antibody at 1/200 dilution in 2% w/v BSA-PBS overnight at 4
o
C. Anti-
HA antibody was used because both WTp38α and p38αT185G were cloned with a 
hemagglutinin tag.  
 
The following day, the cells were washed with cold PBS three times for 5 minutes each. The 
cells were incubated with anti-mouse CY3 conjugated secondary antibody at 1/200 dilution for 
2 hours. The plates were protected from light with aluminium foil from this stage onwards. 
After 2hrs incubation, the cells were washed with cold PBS for three 5 minute washes. The 
cover slips were taken out and air-dried for 30 minutes. 3 drops of Vectashield (DAPI) solution 
was placed on the coverslip and mounted on the microscope slide. The coverslip was fixed onto 
the slide with nail varnish, left to dry and stored at 4
O
C in the dark before being analysed by 
confocal microscopy.  
 
5.2.6 Ischaemic Buffer 
The ischaemic buffer was made up as described in Chapter 2. 24hrs after transfection, cells were 
washed with warm PBS and 2ml of warm ischaemia buffer was added onto the cells. For cells 
exposed to pharmacological inhibitors, 10µM of SB203580 was added onto the cells 30 minutes 
prior to the addition of ischaemia buffer. After 10 minutes of exposure to ischaemia buffer, cells 
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were quickly washed with PBS and collected with 150µl of 2X SDS buffer and analysed by 
western blotting.  
 
5.2.7 In-vitro kinase  
An in-vitro kinase assay was performed as described previously in chapter 2. In brief, WTp38α 
at 3 µM, TAB1 (371-416) peptide at 15µM, and 0.855µg of MKK6 were used in an IVK 
reaction for 2 hours at 37
o
C in 1X kinase buffer (25mM Tris/HCl, pH7.5, 5mM β-
glycerolphosphate, 2mM dithiothreitol, 0.1mM Na3VO4 and 1mM MgCl2). 5µl of 10mM ATP 
was added to the incubation mixture to start the reaction at 37
o
C. 2X sample buffer was added to 
the sample to terminate the reaction, heated to 95
o
C for 10 minutes and 5µl was used to run on 
SDS-gel for western blot analysis. 
 
5.2.8 Mass spectrometry  
5µl of IVK product were run on 10% SDS gel for 1 hour 30 minutes and stained with coomassie 
for 1 hour at room temperature to visualise the protein bands. The band of interest was excised 
by cutting close to the edge of the band, chopped into 2mm
2
 pieces and transferred into an 
eppendorf tube. The gel pieces were washed with 100mM Ambic buffer for 5 minutes. The gel 
pieces were washed with acetonitrile two times and dried in a speed vacuum for 5 minutes. The 
gels were rehydrated with 10mM DTT and heated at 56
o
C for 30 minutes. The DTT was 
discarded and gels were washed with acetonitrile again two times and dried in a speed vacuum 
for 5 minutes. 55mM Iodoacetamide (IAA) was added and incubated for 20 minutes in the dark 
at ambient temperature. The supernatant was discarded and washed with 100mM of Ambic 
buffer two times for 5 minutes. The supernatant was discarded and gels dehydrated again with 
acetonitrile as previously and dried off in a speed vacuum for 5 minutes. 13ng/µl of trypsin was 
used to rehydrate the gel pieces in a minimal volume just sufficient to cover the gel pieces at 
4
o
C for 20 minutes. Unabsorbed trypsin was discarded and a minimum volume of 50mM Ambic 
(20-20µl) was added to cover the gel pieces and keep them wet during enzyme cleavage. The 
gel pieces are incubated at 37
o
C for 2 hours then overnight at room temperature. The following 
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day the supernatant was decanted from gel pieces and collected into a new eppendorf tube. The 
gel pieces were washed with 50mM Ambic for 5 minutes at 37
o
C, decanted and pooled into the 
same eppendorf from previous step (This process is repeated again). The peptide extract was 


























5.3 Results  
 
5.3.1 TAB1 induces Thr185 phosphorylation  
 
The IVK reaction was carried out by Dr Denise Eva Martin and Mass spectrometry analysis 
was performed by Steven Lynham.  
 
To test our hypothesis, the first thing we needed to determine was if TAB1 caused the 
phosphorylation of Thr185. To investigate this, we carried out an in-vitro kinase assay with 
WTp38α and TAB1, and WTp38α and MKK6 in a kinase buffer at 37OC as described in section 
5.2.7. As we did not have an antibody against p-Thr185, we ran the IVK product on an SDS-
PAGE gel, coomassied the gel, cut the p38 band out, which was then analysed by MS/MS 
Tandem mass spectrometry. The result from mass spectrometry showed the presence of 
phosphorylation at residue Thr185 in the IVK sample with WTp38α and TAB1 but not in the 
sample with WTp38α and MKK6 (Fig 5.3.1). The result suggested that TAB1 promotes the 
phosphorylation of Thr185 but MKK6 does not. It was an encouraging finding as it supported 
























5.3.1A TAB1 induces Thr185 phosphorylation: The western blot shows the IVK product probed with 
phospho p38α (Thr180/Tyr182) antibody. TAB1 caused a small increase in phospho p38α signal, 
whereas MKK6 caused a huge increase in phospho p38 signal. A duplicate gel was run with same 







































5.3.1B TAB1 induces Thr185 phosphorylation: The upper panel shows the raw spectra produced from 
the IVK product of WTp38α + TAB1 which were cut out from the SDS gel after they were stained with 
coomassie. The spectra shows the confirmation of phosphorylation of Thr185 with a phosphopeptide with 
m/z 796.31
2+
. A CNL was detected from the parent ion at m/z 747.47
2+
. A loss of phosphoric acid was not 
detected from the database assigned y2-ion however, there was a loss of 98 Da detected from the y4 and 
y5-ions. As there is not a residue that could be phosphorylated at y3, this evidence confirms the correct 
assignment to the threonine at T185. The table below summarizes the mass-spec result from IVK products 
with relative intensity observed at each residue.  The phospho-p38 signal at Thr185 was only detected in 
the IVK product of WTp38+TAB1 (red) although the signal was low compared to the phospho signal at 
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5.3.2 The effect of phosphorylation of Thr185 on p38α’s cellular localization  
The data above suggested that TAB1 but not MKK6 induces phosphorylation of Thr185. Next 
we wanted to investigate whether this TAB1 induced phosphorylation of Thr185 could cause 
p38α’s movement into the nucleus. To test this we carried out cellular fractionation with 
WTp38α, p38αT185G mutant which cannot be phosphorylated at Thr185 and p38αT185D 
mutant which mimics phosphorylation at Thr185.  
 
HEK293 cells were transfected with TAB1 and WTp38α, p38αT185G, or p38αT185D. 24hrs 
after transfection we carried out fractionation of the cells to separate the cellular and nuclear 
fractions as described in section 5.2.3. After fractionation, we analysed the cellular and nuclear 
extracts by western blotting and probed the samples with total p38 and GAPDH antibody. As 
seen in the figure 5.3.2, there was a similar level of p38α achieved in WTp38α, p38αT185G, 
and p38αT185D transfected cells in both cytosolic and nuclear fractions. The cytoplasmic 
fraction had a higher expression of p38α across all samples compared to the nuclear fraction, 
but there was no difference between the samples. To support our hypothesis, the level of p38α 
in p38αT185D transfected cells should have been greater in the nuclear fraction than 
cytoplasmic fraction compared to WTp38α transfected cells, but it was not. The co-transfection 
of the all p38α forms’ with TAB1 caused a reduction of p38α in the nuclear fraction in all 
samples suggesting TAB1 promotes p38α’s localization into the cytoplasm, but again there was 
no difference between the samples. This result is contrary to our hypothesis, since the 
transfection of WTp38α+TAB1 should have caused the expression of p38α to increase in the 
nuclear fraction and the transfection of p38αT185G+TAB1 to cause no change, however, in 
both cases the p38α level in nuclear fraction went down suggesting Thr185 does not play a role 


















5.3.2 Phosphorylation of Thr185does not affect p38α’s cellular localization: The western blot figure 
shows the fractionation of HEK293 cells transfected with TAB1 and WTp38α, p38αT185G, or 
p38αT185D. Fractions were probed with total p38 antibody (top) and GAPDH (bottom). There was no 
difference in the cytoplasmic and nuclear expression level of p38α between WTp38α, p38αT185G and 
p38αT185D samples. Co-expression with TAB1 caused a reduction in the expression level of p38 in the 
nuclear fraction from all cells transfected with WTp38α, p38αT185G, and p38αT185D, but there was no 




5.3.3 Thr185 does not affect p38α’s cellular localization  
The cellular fractionation experiment in 5.3.2 showed no difference in the differential location 
of WTp38α, p38αT185G or p38αT185D in cells with or without TAB1, suggesting the 
phosphorylation of Thr185 plays no role in p38α’s cellular localization. We wanted to 
investigate whether this negative result may result from the artificial nature of TAB1 co-
expression, so we used the more physiologically relevant stimulus of simulated ischaemia. To 
achieve this, we transfected the HEK293 cells with WTp38α and p38αT185G, then subjected 
them to simulated ischaemia using ischaemic buffer. Under control conditions, we saw similar 
expression of p38α between WTp38α and p38αT185G forms. After 10 minutes of exposure to 
ischaemia buffer, the expression level of p38α decreased in the nuclear fraction in both WTp38α 
and p38αT815G transfected cell which was reversed by the SB203580 treatment. Again this 
result is not compatible with our hypothesis. To support our hypothesis, ischaemia buffer should 
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have increased the expression of WTp38α, but not p38αT815G, in the nuclear fraction. The 
result mirrors the outcome from experiment in 5.3.2 which indicates that Thr185 does not play a 










5.3.3 Thr185 does not affect p38α’s cellular localization: The western blot figure shows the HEK293 
cells transfected with WTp38α and p38αT185G, subjected to 10 minutes of simulated ischaemia prior to 
harvest and cellular fractionation.  Membranes were probed with total p38 antibody (top) or GAPDH 
(bottom). There were similar levels of p38α in both WTp38α and p38αT185G transfections, with greater 
expression in the cytoplasmic fraction compared to the nuclear fraction. After 10 minutes of simulated 
ischaemia, p38α levels went down in nuclear fraction in both WTp38α and p38T185G, which was 




5.3.4 Thr185 does not impact p38α’s cellular localization in HELA cells 
The cellular fractionation data in HEK293 cells demonstrated that Thr185 has no impact on 
p38α’s cellular localization so we investigated our hypothesis in a different cell line. We used 
another mammalian cell line to test if the result would persist and carried out 
immunocytochemistry in HELA cells. We used an over-expression system to transfect 
WTp38α+TAB1 and p38αT185G+TAB1 in HELA cells. 24hrs after transfection, cells were 
fixed and prepared for immunostaining as described in section 5.2.5 and observed using a 
confocal microscope. The confocal images showed no difference between HELA cells 
transfected with WTp38α+TAB1 and p38αT185G+TAB1. p38α appeared to reside throughout 
the cell in all samples with no marked difference between WTp38α+TAB1, and 
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p38αT185G+TAB1 expressing cells. The expression of p38α was greater in the cytoplasm 
compared to the nucleus; however it was the same for both samples. The immunofluorescence 
data seems to mirror the cellular fractionation data from HEK293 cells, and confirm Thr185 




















5.3.4 Immunofluorescence in HELA cells: The HELA cells were transfected with WTp38α+TAB1 (left 
top/bottom)) and p38αT185G+TAB1 (right top/bottom), fixed and stained with anti-HA antibody (p38 is 
HA tagged) and detected with Mouse-Cy3 secondary antibody as described in section 5.2.6. The 
expression of p38α (HA tag) was observed in the green channel which showed no difference between 
WTp38α+TAB1 and p38αT185G+TAB1 samples. The p38α expression was greater in cytoplasm than in 







5.4 Discussion  
 
In this chapter we investigated if Thr185 played any role in the cellular localization of p38α.  
 
5.4.1 TAB1 induces Thr185 phosphorylation  
Based on the ERK theory described in the introduction, we proposed that the interaction with 
TAB1 results in p38α autophosphorylation not only at the T-G-Y motif but also at the Thr185 
residue. The Thr185 phosphorylation then causes the p38α to localize into the nucleus to 
phosphorylate its nuclear targets. As we did not have a good p-Thr185 antibody, we decided to 
use mass spectrometry analysis as a readout tool to find whether Thr185 gets phosphorylated or 
not. We ran an IVK assay with p38α in the presence of TAB1 or MKK6. The TAB1 augmented 
p38α phosphorylation as seen in western blot (Fig 5.3.1A) but not as much as MKK6, which 
caused a huge increase in phospho p38 signal. The mass spectrometry analysis of the same 
samples showed that Thr185 was phosphorylated in the presence of TAB1, but not in the 
presence of MKK6 (Fig 5.3.1B). The result revealed that although MKK6 phosphorylated p38α 
at T-G-Y motif, it did not phosphorylate p38α at residue Thr185. This suggests that the first 
component of our hypothesis may be correct and TAB1 interaction causes the Thr185 
phosphorylation. However, the phosphorylation signal seen at Thr185 was very low compared 
to the phosphorylation signal seen at Thr180/Tyr182, as represented by the total ion current 
(TIC) intensity of 40450 and 432400/73120 respectively. Furthermore, compared to the TIC 
intensity observed at Thr180/Tyr182 caused by MKK6 of 52680000/531100, the 
phosphorylation at Thr185 appears to be extremely minute, which makes it uncertain whether 
such a low signal could have any impact on the regulation of p38α’s vital functionality such as 
its cellular location. Nevertheless, the initial findings were encouraging enough and we 
proceeded onto investigate the second part of our hypothesis which was whether the phospho 




5.4.2 Thr185 does not cause p38α to localize into the nucleus  
After the mass spectrometry data suggested TAB1 causes Thr185 phosphorylation, we went on 
to investigate whether this would impact p38α’s cellular location. To test this, we created a 
p38α mutant that cannot be phosphorylated at Thr185 in p38αT185G, and another mutant that 
mimics p38α phosphorylation at Thr185 in p38αT185D. We transfected WTp38α, p38αT185G, 
and p38αT185D in HEK293 cells and 24 hours later analysed their cellular location with 
cellular fractionation. With our proposed hypothesis we expected the expression of p38αT185D 
to be greater in the nucleus compared to the expression of WTp38α and p38αT185G. However, 
contrary to our prediction we observed a similar expression of all forms of p38αs’, with greater 
expression of p38α in the cytoplasm than in the nucleus. The result suggests that the 
phosphorylation of Thr185 does not cause p38α to localize into the nucleus. Similarly, we also 
expected the cells co-transfected with WTp38α and TAB1, and p38αT185D and TAB1 to 
produce a greater p38α expression in the nucleus compared to the cells co-transfected with 
p38αT185G and TAB1. However co-transfection of all forms of p38αs’ with TAB1 produced 
similar p38α expression, with almost complete disappearance of p38α from the nuclear fraction. 
The western blot showed that TAB1 causes p38α to localize into the cytoplasm from the nucleus 
and Thr185 does not seem to play a role in it. 
 
We also carried out immunocytochemistry in HELA cells to investigate whether 
phosphorylation of Thr185 induced p38α’s movement into the nucleus. We co-transfected 
HELA cells with TAB1 and WTp38α or p38αT185G. 24hours after transfection we stained the 
cells with anti-HA antibody, as transfected p38α were HA tagged. The immunofluorescence 
images illustrated similar p38α expression pattern between the WTp38α and p38αT185G. Both 
WTp38α and p38αT185G appeared to be heavily expressed in the cytoplasm compared to the 
nucleus with no difference between them. The result showed that TAB1 did not cause p38α to 
translocate into the nucleus which is similar to the outcome we achieved from the cellular 




5.4.3 Ischaemia buffer changes p38α’s cellular location  
Previous results from cell fractionation and immunofluorescence suggest that the TAB1 induced 
Thr185 phosphorylation does not cause p38α translocation into the nucleus. However, the 
system we used could have been too artificial with co-transfection of TAB1, which perhaps 
contributed to the negative result. To address this, we transfected WTp38α and p38αT185G in 
HEK293 cells, and instead of co-transfecting TAB1 we used a more physiologically relevant 
stimulus in simulated ischaemia. Ischaemia is a well-known stimulus that induces TAB1 to 
interact with p38α to cause its autoactivation (Tanno et al, 2006; Ge et al, 2002; Li et al, 2005). 
24hours after transfecting WTp38α, and p38αT185G, the cells were exposed to ischaemia buffer 
for 10 minutes. The transfection of WTp38α and p38αT185G produced similar expression 
levels as before with greater expression of p38α in the cytoplasm than in the nucleus. 10 
minutes of simulated ischaemia reduced the expression of p38α in the nuclear fraction in both 
WTp38α and p38αT185G transfected cells, contrary to what we predicted. To support our 
hypothesis the ischaemia buffer should have induced TAB1 to phosphorylate p38α at Thr185 
that would increase its expression in the nucleus. But the result suggests that TAB1’s interaction 
with p38α promotes the p38α’s localization into the cytoplasm. It supports the previous result in 
5.3.2 which suggests that association with TAB1 seems to drive p38α out of the nucleus into the 
cytoplasm. Cells transfected with p38αT185G produced the same result indicating Thr185 does 
not play a role in nuclear translocation. Interestingly this effect caused by simulated ischaemia 
was reversed by 10µM SB203580 treatment. It means that rather than Thr185, it’s the 
phosphorylation of T-G-Y motif, i.e p38α activation status that seems to affect p38α’s cellular 
location. This supports several studies in the literature that claim that p38 activation status, 
stimulus involved, and its environment determines its cellular location (Brand et al, 2002; Ito et 
al, 2010; Gong et al, 2010; Wood et al, 2009; ). Repeating our experiment with p38α mutant 
that cannot be activated should provide a better understanding. Another explanation is p38α’s 
cellular localization is dependent on one of its substrates, as SB203580 makes p38α catalytically 
inactive. In fact there is evidence for this in the literature; following phosphorylation of mitogen 
activated protein kinase –activated protein kinase 2 by p38, it formed a complex with p38 to 
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drive it out of the nucleus (Ben-Levy et al, 1998).  One puzzling observation was that although 
the p38α expression disappeared in the nuclear fraction with ischaemia buffer in cells 
transfected with p38αT185G, the expression did not increase in the cytoplasmic fraction. More 
cell death in the cells treated with ischaemia buffer could explain the result but the GAPDH 
level was not altered indicating that this is unlikely. Additionally, this conundrum was not 
observed in cells transfected with WTp38α which makes is even harder to explain, and further 
experiments are required to investigate this.  
 
5.4.4 Conclusion  
To summarise, although TAB1 appears to cause phosphorylation of Thr185, that 
phosphorylation does not seem to cause p38α to translocate into the nucleus. The cell 
fractionation and immunofluorescence data from the transfection and simulated ischaemia 
experiments suggest that Thr185 plays no role in p38α cellular location, instead it appears to be 
the activation status of p38α that does. However, the mass spectrometry analysis of IVK product 
showed that the phosphorylation event at Thr185 is minimal relative to the phosphorylation 
event at the T-G-Y motif. And we cannot confirm whether the TAB1 transfection or ischaemia 
buffer has caused p38α phosphorylation at Thr185 in the HEK293 and HELA cells, due to the 
lack of an anti-p-Thr185 antibody. So, further experiments are required with evidence of Thr185 
phosphorylation in these cells before we conclude that Thr185 has no impact on p38α’s cellular 
location. Another important point to consider is that although we have ectopically transfected 
WTp38α and p38αT185G, there is still endogenous p38α present in the cells which can 
influence the result. The endogenous p38α could make the ectopic p38α functionally redundant 
which could produce a negative result. One thing that appears to be concrete though, is that 
TAB1 seems to promote p38α localization in the cytoplasm. Both ectopically expressed TAB1, 
and endogenous TAB1 activated via ischaemia buffer seemed to cause nuclear export of p38α, 
which is in line with previous finding from Lu and co-workers who showed that TAB1 
promotes p38α autophosphorylation and prevents its nuclear localization (Lu et al, 2005). 
However there are also studies in the literature which suggests that once activated, p38 goes into 
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the nucleus to phosphorylate transcription factors (Wood et al, 2009). In conclusion, the 
evidence gathered in this chapter suggests that although TAB1 may seem to cause the 
phosphorylation of Thr185, this phosphorylation does not appear to be the signal that drives 
p38α into the nucleus. Hence, the Thr185 of p38α does not have a similar function as the 
Thr188 of ERK2 with regards to nuclear localization, and this may be because of a lack of 
























6 Characterization of TAB1 KI mice and preliminary data  
 
6.1 Introduction  
In previous chapters, I have extensively discussed the autoactivation mechanism of p38α 
induced by TAB1. During an ischaemic event in the heart, TAB1 interacts with p38α through a 
bipartite binding motif involving the canonical and non-canonical sites. This binding event is 
thought to cause the approximation of the N-terminal and C-terminal lobes of p38α. This 
structural rearrangement brings Glu71 and Lys53 in close proximity to each other to form a salt 
bridge, typical of an active kinase, which facilitates ATP binding. This is accompanied by the 
parallel movement of the activation loop (Leu171-Val183) which swings towards the catalytic 
site, and Tyr182-Thr185 form an extension of an α-helical segment, which is stabilised by the 
hydrogen bond between the side chains of Thr185 and Asp150 of the HRD domain. This new 
helical extension at the C-terminal portion of the activation loop brings Thr180/Tyr182 10Å 
closer to the bound ATP which we believe promotes ATP γ-phosphate transfer onto the T-G-Y 
motif to cause autophosphorylation, resulting in p38α’s autoactivation in cis. 
 
There is overwhelming evidence in the literature that the TAB1-induced mode of p38α 
activation aggravates myocardial injury during cardiac ischaemia (Barancik, 2000; Li, 2005; 
Ma, 1999; Kaiser, 2004; Mackay, 1999; Nagarkatti, 1998; Schneider, 2001; Tanno, 2003). As a 
result, preventing the interaction of p38α and TAB1 would be therapeutically desirable. Based 
on the findings in chapter 3, we know that TAB1 interacts with p38α in a bipartite manner at the 
canonical and non-canonical site. We created a mutant TAB1 containing four point mutations; 
V390A, Y392A (which binds to the non-canonical site), V408G and M409A (which binds to 
the canonical site), and showed that these residues are necessary for the interaction, as mutation 
of these residues prevented TAB1 binding to p38α and prevented its consequent autoactivation. 
We showed this using recombinant proteins in in-vitro kinase assays and using an over-
expression system in a mammalian cell line. However, we have not yet tested this in an in-vivo 
138 
 
model to determine the effect this would have physiologically. From the studies in our lab and a 
plethora of studies in the literature, we predict that preventing the TAB1-induced p38α 
autoactivation in the ischaemic heart should reduce myocardial injury in an in-vivo model.   
 
To test this, we created a gene-targeted mouse with the four point mutations in TAB1 
(V390A/Y392A/V408G/M409A). We commissioned a global knock-in TAB1 mouse from 
























6.2 Specific methods  
 
6.2.1 Generation of TAB KI mice  
The TAB1 KI mice were created by Cyagen Biosciences. In brief, the mTAB1 gene 
(NM_025609.2) was identified on mouse chromosome 15. The gene contains eleven exons with 
the ATG start codon in exon 1 and the TAG stop codon in exon 11. The four amino acids to be 
mutated (V390, Y392, V408, M409) are located in exon 10. The mutations V390A, Y392A, 
V408G, and M409A were introduced into exon 10 by site-directed mutagenesis with the 
QuickChange
TM
 Site-Directed Mutagenesis Kit. In the targeted vector, the Neo cassette was 
flanked by LoxP sites and diphtheria toxin A (DTA) was used for negative selection. The 
constitutive KI allele was obtained by Cre-recombination and C57BL/6 ES cells were used for 
gene targeting.  
 
 1 MAAQRRSLLQ SEQQPSWTDD LPLCHLSGVG SASNRSYSAD GKGTESHPPE 
51 DNWLKFRSEN NCFLYGVFNG YDGNRVTNFV AQRLSAELLL GQLNTEHTEA 
101 DVRRVLLQAF DVVERSFLES IDDALAEKAS LQSQLPEGVP QHQLPPQYQK 
151 ILERLKALER EISGGAMAVV AVLLNSKLYV ANVGTNRALL CKSTVDGLQV 
201 TQLNMDHTTE NEDELFRLSQ LGLDAGKIKQ MGVICGQEST RRIGDYKVKY 
251 GYTDIDLLSA AKSKPIIAEP EIHGAQPLDG VTGFLVLMSE GLYKALEAAH 
301 GPGQANQEIA AMIDTEFAKQ TSLDAVAQAV VDRVKRIHSD TFASGGERAK 
351 FCPRHEDMTL LVRNFGYPLG EMSQPTPTPA PGGRVYPVSV PYSSAQSTSK 
401 TSVTLSLVMP SQGQMVNGSH SASTLDEATP TLTNQSPTLT LQSTNTHTQS 
451 SSSSSDGGLF RSRPAHSLPP GEDGRVEPYV DFAEFYRLWS VDHGEQSVMT 
501 AP 















    
      
       
 



































Figure 6.2.1 Overview of the targeting strategy to produce TAB KI mice: The diagram illustrates the 
targeting strategy to generate the TAB1 KI mice. The DNA sequences for 4 amino acids to be mutated 
reside in exon 10 and were mutated by site-directed mutagenesis. The constitutive KI allele was obtained 











Constitutive KI allele 
(After Cre recombination) 
8
                                                                                 







EMSQP TPTPA PGGRV YPVSV PYSSA QSTSK TSVTL SLVMP SQGQM V  
 Replaced with EMSQP TPTPA PGGRV YPVSA PASSA QSTSK TSVTL SLGAP SQGQM V 
 
EMSQP TPTPA PGGRV YPVSA PASSA QSTSK TSVTL SLGAP SQGQM V 
 
 EMSQP TPTPA PGGRV YPVSA PASSA QSTSK TSVTL SLGAP SQGQM V 
1
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6.2.2 Breeding  
All experiments were carried out in accordance with the United Kingdom Home Office 
Guidance on the operation of Animals (Scientific Procedures) Act 1986.  
 
5 heterozygous (Hets) (2 males and 3 females) mice were received from Cyagen Bioscience and 
housed in the Biological Service Unit (BSU) at St Thomas’ Hospital campus, King’s College 
London. The care of the colony, feeding, setting up the breeding, weaning, ear sampling, and 
culling were done by the BSU staff under our instructions. The mouse litters were ear clipped at 
21 days of age and used for analysis by PCR to confirm the genotype of each mouse prior to 
their use in breeding or in experiments.    
 
6.2.3 Genotyping 
6.2.3.1 DNA isolation and purification  
Ear clips from mice were processed to collect the genomic DNA using a DNeasy Blood & 
Tissue kit (69506) from Qiagen. The ear clip was re-suspended in 180µl of Buffer ATL (lysis 
buffer), 20µl of proteinase K solution and incubated at 56
o
C for 1 hour. After the ear clip 
dissolved completely in the buffer, 200µl of Buffer AL was added and mixed by vortexing. 
200µl of ethanol was added, mixed by vortex and poured into DNeasy Mini Spin column in a 
2ml collection tube, and centrifuged at 6,000g for 1 minute. The DNeasy Mini Spin column was 
transferred into a new 2ml collection tube, washed with 500µl of Buffer AW1 (wash buffer) and 
centrifuged for 1 minute at 6,000g. The DNeasy Mini Spin column was transferred into a new 
2ml column, washed with 500µl of Buffer AW2 (wash buffer) and centrifuged at 20,000g for 3 
minute. The DNeasy Mini Spin column was transferred into a 1.5ml eppendorf tube and DNA 
was eluted with 50µl of nuclease free water by centrifuging at 6,000g for 1 minute.  The DNA 
was stored at -20
o






6.2.3.2 Polymerase Chain Reaction (PCR) 
Once genomic DNA was collected, PCR was carried out using primers provided by Cyagen 
Biosciences. As seen in figure below (Fig 6.2.3.2A), the forward and reverse primers (black 
arrows) are on either side of the LoxP site which is only present in the KI allele, therefore the KI 









Figure 6.2.3.2A Primers for PCR reaction to genotype the mice: The diagram illustrates the forward 
and reverse primers (black arrows) for genotyping. 
  
 
Forward primer: GCTGGCCTTGCTCAACTCCAG 




Mutated allele: 405bp 



















Figure 6.2.3.2B Genotyping of TAB KI and WT mice: The image shows the PCR product run on an 
agarose gel. The KI product appears around 405bp, the WT product appears around 261bp and the Hets 
harbour one of each allele with bands appearing at both molecular weights. 
 
The PCR products used for genotyping do not contain the site where the mutations have been 
introduced in exon 10, and as a result these PCR products cannot be sequenced to screen for the 
mutations. Therefore, new primers (blue arrows on figure below) were designed to flank exon 









Figure 6.2.3.2C Primers to amplify the region containing the mutated sites: The diagram illustrates the 
forward and reverse primers (blue arrows) to amplify the DNA sequence containing the 4 residues that 







Forward primer: GGCTGGCCTTGCTCAACTCCA 




Mutated allele: 1170bp 
WT allele: 1026bp 
 











Figure 6.2.3.2D PCR to sequence the TAB KI allele and the WT allele: The image shows the PCR 
product run on an agarose gel. The KI product appears around 1170bp, the WT product appears around 
1026bp. The PCR products were excised from the agarose gel, purified, and sent for sequencing to 
confirm the presence of mutated residues in the KI sample. 
 
 
The PCR reaction mix was prepared as set out in table A below. A master mix was prepared 
which contained nuclease free water, forward and reverse primers, and TAQ polymerase with 
dNTPs. The master mix was aliquoted into PCR tubes and DNA was added before starting the 
PCR reaction. The PCR reaction for genotyping and sequencing the KI allele was run on the 























Table 6.2.3.2B PCR setting for genotyping: Table shows the settings used to run the PCR for genotyping.    
 
Table 6.2.3.2C PCR setting for sequencing: Table shows the settings used to run the PCR to amplify the 
gene section for sequencing the mutated sites.     
 
Component Volume (µl) 
ddH2O 9.4 
Forward Primer 0.8 
Reverse Primer 0.8 





C) Time (min) Number of cycles 
Initial denaturation 94
o
C 3 1 
Denaturation 94
o














Time (min) Number of cycles 
Initial denaturation 94
o
C 3 1 
Denaturation 94
o









C 5 1 
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6.2.3.3 Agarose gel electrophoresis 
Once the PCR was completed, the PCR products for genotyping (250-405bp) were prepared to 
run on a 2% agarose gel electrophoresis. 4µl of 6X gel loading dye was added to the PCR 
product, and 5µl was loaded into the gel. The electrophoresis was run at a constant voltage of 
100 volts for 1 hour and visualised using a UV dual intensity transilluminator (UVP). 
 
6.2.4 Langendorff Perfusion of isolated mouse hearts 
 
All Langendorff experiments were performed by Dr Rekha Bassi, and I assisted her with 
perfusion and blinding to mouse genotype.  
 
Langendorff perfusion of isolated mouse hearts was carried out on 10 week old male mice. Mice 
were anesthetized and anti-coagulated by intraperitoneal injection with pentobarbital 
(300mg/kg) and heparin (150 units). The body weight was measured and the heart was rapidly 
excised and placed in an ice cold modified KREBS-Henseleit buffer (K-HB) (See chapter 2 for 
constituents). The excess fatty tissue was carefully removed to reveal the aorta between the 
thymus and trachea. The aorta was then cannulated with a 23G blunt ended/grooved stainless 
steel needle. The hearts were perfused at a constant pressure of 80mmHg with KREBs buffer, 
equilibrated with 95% O2 and 5% CO2 and maintained at a constant temperature of 37+/- 0.3
o
C. 
The temperature of the heart was maintained at 37
o
C by immersing the heart 1/3 in a water 
jacketed chamber.  
 
A fluid-filled compliant balloon was inserted into the left ventricular cavity by carefully 
removing the left atrial appendage and the balloon passed through the mitral valve. The balloon 
was attached to a catheter with a pressure transducer coupled to a 4S Powerlab (AD 
Instruments, UK) that monitored and recorded contractile function; left ventricular systolic and 
diastolic pressures and left ventricular developed pressure (LVDP) and coronary flow.  Once in 
position and secured with clamps, the balloon was gently inflated until the end diastolic pressure 
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measured between 1 and 10mmHg. The hearts were electrically paced at 600bpm with a 
0.05mm silver wire (Advent, UK). The wire and the aortic cannula were attached to an SD9 
stimulator (Grass Instruments, USA) delivering a square wave pulses of 5ms duration and 1V 
amplitude.  
 
The Langendorff technique was used to carry out two different experiments 
 
1. Activation of p38α during ischaemia.  
2. Measurement of infarct size resulting from ischaemia.  
 







Figure 6.2.4A Schematic representation of mouse heart perfusion to investigate p38α activation caused 
by ischaemia: The isolated hearts were subjected to 40 minutes of stabilization with KREBs buffer, 
followed by 10 minutes of global zero-flow ischaemia. The control hearts were subjected to continuous 
perfusion of KREBs buffer for 50 minutes. At the end, the hearts were snap frozen in liquid nitrogen and 
stored at -80
o






Figure 6.2.4B Schematic representation of mouse heart perfusion to investigate SB sensitive-p38α 
activation caused by ischaemia: The isolated hearts were subjected to 40 minutes of stabilization with 
KREBs buffer, followed by 10 minutes of global ischaemia. The control hearts were subjected to 
continuous perfusion with KREBs buffer for 50 minutes. At the 30 minute time-point during stabilization, 
10µM SB203580 was added to the KREBs buffer. At the end of all protocols, the hearts were snap frozen 
in liquid nitrogen and stored at -80
o













Figure 6.2.4C Schematic representation of mouse heart perfusion to investigate infarct size caused by 
ischaemia: The isolated hearts were subjected to 40 minutes of stabilization with KREBs buffer, followed 
by 30 minutes of global ischaemia and 2 hours of reperfusion. The control hearts were subjected to 
continuous perfusion with KREBs buffer for 3 hours. At the end of both protocols the hearts were 
prepared for TTC staining to measure the infarct size. 
 
 
6.2.5 Infarct size assessment 
After the hearts were perfused using the Langendorff technique, they were stained with 
triphenyl tetrazolium chloride (TTC) to measure the infarct size. TTC is a redox indicator that 
differentiates metabolically active tissue from inactive/dead tissue. TTC, a white compound, is 
reduced to a red TPF (1,3,5-triphenylformazan) by the activity of dehydrogenase enzymes 
present within cells in viable tissue. However, in dead tissues these enzymes are degraded and 
denatured, and as a result TTC cannot be reduced and remains white.  
 
The hearts were perfused with 5ml of warm 1% TTC in PBS for 5 min. The heart was then 
completely immersed in 1% TTC solution and incubated at 37
o
C for 10 minutes. After 10 
minutes incubation, the heart was blotted dry, the atria were removed, and remnants weighed 




After TTC staining, the hearts were fixed and sectioned to measure the infarct size. The hearts 
were fixed by placing in 2.5% gluteraldehyde for 1 minute and mounted in 5% agarose in PBS 
with the apex uppermost. The agarose embedded heart blocks were sectioned from apex to base 
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in 0.75mm slices using a vibratome (Series 1000, Agar Scientific, UK). The heart slices were 
placed in a 6-well plate in PBS and scanned at a high resolution by placing them on a flat bed 
scanner compressed between perspex plates (separation gap = 0.75mm). The images were then 
analysed using the ImageJ software to quantify the infarct volume as a percentage of total LV 
volume. The experiments and analyses were carried out by an investigator that was blind to the 
mouse genotype.  
 
6.2.6 Homogenization of hearts  
The hearts were removed from -80
o
C storage and thawed on ice. Once pat dried on a paper 
towel, hearts were weighed before being homogenized with 100mg/ml of homogenization 
buffer in a mortar using a pestle. Homogenization buffer was made up of 20mM HEPES, pH 
7.4, 150mM NaCl, 1mM EDTA, 1mM EGTA, 1mM Na2VO4, 5mM NaF, 1mM DTT, 0.5% 
(v/v) Triton X-100 and 1X Protease Inhibitor Tablet (Roche)/50ml buffer. The hearts were 
homogenized for 3 minutes by the shearing force generated at the interface of the mortar and 
pestle. Homogenate was transferred to 1.5ml eppendorf tube and centrifuged at 10,000g for 10 
minutes at 4
o
C. The supernatant was collected and stored at -80
o
C to analyse by western 
blotting. The liver and thymus were also homogenized in the same manner.  
 
6.2.7 Isolation of MEFs 
A pregnant mouse 13 or 14 d.p.c (day post-coitum) was culled by neck dislocation. The uterine 
horn was dissected out, briefly rinsed in 70% ethanol, and placed on a petri dish with sterile 
PBS. Individual embryos were isolated and carefully removed from its embryonic sac. The 
embryo was separated from placenta, and head and red organ were dissected off. The heads 
were stored at 4
0
C and used for genotyping each embryo. Then with a sterile razor blade, the 
embryo was minced finely until it was possible to pipette with a 1ml pipette tip. 1ml of 0.25% 
trypsin/EDTA was used to collect the minced embryo and transferred into a falcon tube to 
incubate at 37
o
C for 20 minutes.  During incubation, cells were pipetted up and down 
thoroughly every 5 minutes to help with the digestion. 9ml of full growth medium (Dulbecco’s 
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modified Eagle’s medium containing 584mg/l L-glutamine, 10% v/v foetal bovine serum, 1% 
v/v penicillin/streptomycin) was added into the falcon tube to neutralize the trypsin. The cells 
were passed through 0.75µm cell strainer and centrifuged at 500g for 5 minutes. The 
supernatant was removed and pellet was re-suspended in 2ml full growth medium and plated 
onto a gelatine pre-coated 6-well plate (plates were coated with 0.2% gelatine in PBS for 2 
hours prior to addition of cells). After 24hrs, the cells are usually 80-90% confluent and 
























6.3 Results  
 
6.3.1 Testing TAB1 antibodies 
The first experiment we carried out was to test the expression of mutated TAB1 protein in the 
KI mouse and whether the TAB1 antibody would be able to pick it up. To investigate this, we 
sacrificed a KI mouse and harvested the key organs where TAB1 is most abundant; heart, liver, 
and thymus. The organs were homogenized using mortar and pestle as described in 6.2.6. After 
homogenization, the supernatant was run on western blot and probed with the Total TAB1 
antibody (Santacruz) and compared against the WT protein. The antibody picked up two bands 
around 60kDa and 50kDa which we believe are the alpha and beta isoforms respectively, of the 
TAB1 protein. The antibody detected a strong signal with the WT protein and a very faint signal 
with the KI protein as seen on the western blot below (Fig 6.3.1A). One interesting observation 
was the fact that the KI protein appeared to run slightly lower than the WT protein in all of the 
organs. The WT protein is only slightly heavier (54.581kDa) than the KI protein (54.359kDa), 
and the western blot seems to confirm this but it is still surprising to see that shift on the gel 





















Figure 6.3.1A Testing anti-TAB1 antibody: The western blot shows the homogenate from the heart, liver 
and thymus probed with Total TAB1 antibody from Santacruz. The antibody was able to pick up both the 
alpha (60kDa) and beta (50kDa) isoforms of the TAB1 protein. The WT protein appeared to run higher 
than the KI protein in all organs confirming the fact that the WT TAB1 is slightly heavier than the KI 
TAB1. On the right hand is the ectopically expressed TAB1 protein in 293 cells run as a positive control.   
 
 
Next, we used another total TAB1 antibody (obtained from Phil Cohen’s group in Dundee) to 
probe the same samples again to test if we would be able to reproduce the result. The western 
blot figure shows that the second TAB1 antibody was also able to detect the WT protein more 
easily than the KI protein (Fig 6.3.1B). Similarly, WT TAB1 appeared to run slightly higher 
than the KI protein although the difference in the shift appeared less compared to the Santacruz 
antibody depicted in figure 6.3.1A. These results confirm that TAB1 antibody can detect the 
total TAB1 protein in the KI mouse albeit weakly compared to the WT, and the expression of 
TAB1 is not markedly affected by the mutation. Later in the project, we received a new fresh 
TAB1 antibody from Phil Cohen which showed no difference in the expression of TAB1 and 
the shift on the western blot between the WT and the KI samples. We concluded that the result 
in 6.3.1A/B were due to antibodies being old, and proceeded with using the new antibody from 














Figure 6.3.1B Testing proprietary anti-TAB1 antibody: The western blot figure shows the homogenate 
from heart, liver and thymus probed with Total TAB1 antibody from Dundee. The antibody was able to 
pick up both the alpha (60kDa) and beta (50kDa) isoforms of the TAB1 protein.  
 
 
6.3.2 p38α activation in KI ischaemic hearts  
To investigate the TAB1-induced activation of p38α in the KI mice, we carried out Langendorff 
perfusion on the hearts. The hearts were subjected to 40 minutes of stabilization with KREBs 
buffer followed by 10 minutes of ischaemia, as described in section 6.2. The heart homogenates 
were analysed by western blotting and probed with phospho p38 antibody to examine the 
activation of p38α. Contrary to our expectation, 10 minutes of global ischaemia caused 
activation of p38α in the KI mouse. As seen in western blot 6.3.2, following ischaemia there 
was a significant increase in the phospho p38 signal at the T-G-Y motif compared to the control. 
This could be attributed to the activation of MKK3, which appeared to be higher in the KI 
hearts, perhaps compensating for the disabled TAB1 pathway. In the WT hearts, ischaemia 
caused a significant increase in the phospho p38α signal as expected, but interestingly the 
increment in the phospho p38 signal compared to the control seemed to be less than in the KI 
hearts. An intriguing observation was the fact that the p38α activation at baseline seemed to be 
greater in the WT hearts compared to the KI hearts. Also, the phospho TAB1 signal did not 
change with ischaemia in the WT hearts. The phospho TAB1 signal in the KI hearts was not 
detectable as expected as TAB1 cannot dock to p38α. Our results suggest that p38α activation, 




























Figure 6.3.2 Western blot analysis of TAB1 KI and WT hearts at baseline and during global 
ischaemia: The western blot shows the heart homogenates probed with phospho p38 (T-G-Y), total p38, 
phospho MKK3, phospho TAB1 and Total TAB1 antibody.  The graph above shows the quantification of 
blots with significant difference in p38α activation between the control and ischaemic hearts for both 
genotypes, however no significant difference in p38α activation was observed between the WT and KI 







6.3.3 p38α auto-activation in KI ischaemic hearts  
The experiment above suggests that p38α activation during ischaemia is not impaired in the KI 
hearts, contrary to our prediction. To test the mode of p38α activation in the KI hearts during 
ischaemia, we carried out Langendorff perfusion on the KI hearts in the presence of SB203580. 
SB203580 is an ATP-mimetic and should inhibit the autophosphorylation of p38α. As seen in 
the western blot figure below, there was a varied level of p38α activation in different hearts in 
the presence of SB with ischaemia. In all hearts, the p38α activation appeared to be inhibited by 
the SB treatment, some more than others. However this effect was also seen in the presence of 
DMSO, the control solvent in which SB203580 was dissolved, indicating that the effect 
observed may not be due to the SB203580 alone. The result suggests that SB203580 in this 
experiment might have not blocked the activation of p38α indicating the mode of p38α 
activation was not by autoactivation. The most likely interpretation is that p38α is being 













Figure 6.3.3 Western blot analysis of TAB1 KI hearts at baseline and during global ischaemia in the 
presence of SB203580: The western blot shows the KI heart homogenates probed with phospho p38 (T-






6.3.4 Morphometric characteristics and hemodynamic function 
The Morphometric characteristics of the WT and KI mice are illustrated in the graphs below. 10 
week old male mice were used for experiments with n=12 in each group of WT and KI. The WT 
appeared to be heavier with a mean weight of 28.1g compared to the KI mice whose mean 
weight was 26.3g.  Similarly, the isolated hearts were also weighed, and the KI hearts tended to 
be heavier with a mean weight of 138mg compared to the WT hearts with a mean weight of 












Figure 6.3.4A Morphometric characteristics: The graphs show the body weight and the heart weight of 
the WT and KI mice selected for experiments. There was a significant difference in the body weight 
between the WT and KI mice with WT slightly heavier than the KI. There was no significant difference 
between the WT and KI mice in heart weight. (n=12, unpaired t-test with p<0.05) 
 
The WT and KI mice were grouped into two subgroups of control and ischaemia in a random 
fashion, and the ischaemia-reperfusion protocol was implemented which is described in 6.2.  
  
1. WT Control (6) 
2. WT Ischaemia (6) 
3. KI Control (5) 
4. KI Ischaemia (7) 
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The coronary flow, end diastolic pressure and left ventricular pressure were recorded just before 
the induction of ischaemia at 40 minutes, then during 5, 10, 20 and 30 minutes of global 
ischaemia, and finally at the end after 120 minutes of reperfusion. The coronary flow, as 
expected went down to zero with ischaemia and returned back to towards the baseline level at 
the end of reperfusion in both genotypes. The end diastolic pressure went up with ischaemia in 
both WT and KI hearts with significant difference from baseline appearing after 10 minutes of 
ischaemia. There was a significant difference between the WT and the KI hearts only at the 10 
minute time-point of ischaemia. The left ventricular pressure went down after induction of 
ischaemia with a significant difference in both WT and KI hearts but there was no significant 















































Figure 6.3.4B Hemodynamics of the perfused hearts: The graphs above show the coronary flow, EDP, 
and LVP of the isolated perfused hearts under ischaemia-reperfusion protocol which consists of 40 
minutes of stabilization, and 30 minutes of ischaemia/aerobic perfusion, followed by 120 minutes of 
reperfusion. The measurements were taken at following times; just prior to ischaemia (40 minutes), 
during 30 minutes of ischaemia (45, 50, 60, 70 minutes) and then finally at the end of reperfusion (190 
minute). (Graphs were analysed by Two-way ANOVA with post-hoc Tukey test, p<0.05, *=against 




 6.3.5 Infarct size in the TAB1 KI and WT hearts  
 
To assess myocardial infarction in WT and KI hearts resulting from ischaemia, the Langendorff 
technique was performed with an ischaemia-reperfusion protocol. The hearts were subjected to 
40 minutes of stabilization, followed by either 30 minutes of global ischaemia or continuous 
aerobic perfusion, which was then followed by 120 minutes of reperfusion. At the end of the 
experiment, the hearts were stained with TTC for infarct assessment as described in section 6.2. 
After the analysis, to our surprise the infarction caused by ischaemia tended to be greater in the 
KI hearts compared to the WT hearts (Fig 6.3.5A), although there was no significant difference 
between the two genotypes. Ischaemia caused a significant increase in the infarction to the heart 
in both WT and KI as expected. However, interestingly the infarction caused by prolonged 
aerobic perfusion tended to be less in the KI hearts compared to the WT hearts; which correlates 





































Figure 6.3.5A Graph illustrating the infarct size assessment in TAB KI and WT hearts during 190 min 
of perfusion with and without 30 minutes of global ischaemia: 30 minutes of global ischaemia caused 
extensive infarction in both WT and KI hearts. At the baseline, the KI hearts tended to have less infarction 
compared to the WT hearts, whereas with ischaemia the KI hearts tended to have more infarction 
compared to the WT hearts. There was no significant difference in infarct size between genotypes. Graphs 


























Figure 6.3.5B Image shows the heart sections scanned for infarct analysis: The heart sections 
(0.75mm) are representative images of the WT and KI mice after TTC staining, scanned for infarct 




6.3.6 p38α autoactivation in mouse embryonic fibroblasts 
We used fibroblasts isolated from the WT and KI embryos as a tool to investigate the effect of 
ischaemia on p38α activation. The fibroblasts were subjected to simulated ischaemia using the 
ischaemic buffer as described in chapter 4. The WT and KI cells were incubated in serum 
starved growth medium for 2 hours prior to the addition of ischaemic buffer. To induce 
ischaemia, the serum-free medium was aspirated and replaced with 2ml of simulated ischaemia 
buffer. The cells were incubated in the buffer for 20 minutes, washed with PBS, collected with 
2X SDS buffer and analysed by western blotting. As seen in western blot below, the ischaemic 
buffer slightly increased the phospho p38 signal in the WT cells and SB203580 treatment 
completely abolished the phospho p38 signal. In the KI cells, the phospho p38 signal was very 
high at baseline and the ischaemia buffer did not increase the signal further. However, the 
SB203580 treatment greatly reduced the signal. The high phospho p38 signal seen in the control 
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cells could be the reason ischaemic buffer was unable to cause further increase as the signal was 


















Figure 6.3.6 Mouse embryonic fibroblasts subjected to simulated ischaemia: Western blot shows the 
effect of simulated ischaemia buffer on the WT and the KI cells. The phospho-p38 signal in the WT cells 
under basal condition was low and the addition of ischaemia buffer appeared to increase it slightly which 
was then reversed by the addition of 10µM SB203580. The phospho p38 signal in the KI cells was very 
high under basal condition and the addition of ischaemia buffer did not increase the signal further. The 











6.4 Discussion  
 
6.4.1 Expression of TAB1 protein in the KI mice 
To investigate the TAB1-induced p38α activation caused by ischaemia, we created transgenic 
TAB1 KI mice with four point mutations in the TAB1 protein (V390A, Y392A, V408G, and 
M409A) which prevents TAB1 from interacting with p38α. The four mutated residues reside on 
the C-terminal end of TAB1 in the p38α binding domain, and prior to the start of our 
investigation, we needed to confirm that the mutation did not affect the expression of the protein 
in the KI mice. To test this, we homogenized 3 organs; heart, liver, and thymus, and compared 
the expression of TAB1 in the KI and the WT mice.  
 
The commercially available anti-TAB1 antibody from Santacruz detected a stronger TAB1 band 
in the WT organs compared to the KI organs suggesting that the TAB1 expression is higher in 
the WT mice than in the KI mice (Fig 6.3.1A). The anti-TAB1 antibody from Phil Cohen’s 
group in Dundee reproduced similar result (Fig 6.3.1B) providing further evidence that there is 
more TAB1 expression in the WT mice. The result suggests that the four point mutations 
introduced at the C-terminal end of the TAB1 protein has diminished its expression in the cells. 
The other explanation could be that the antibody is not able to recognize the KI TAB1 as 
efficiently because of the mutations. The 4 point mutations could have altered the folding of the 
protein and its structure ever so slightly that the antibodies’ affinity may have gone down. 
However, when we probed the Langendorff perfused hearts with the new fresh batch of TAB1 
antibody from the Cohen group, there was no difference in the expression of TAB1 between the 
WT and the KI mice. In addition, the MEFs probed with the same antibody produced no 
difference in the TAB1 expression level between the WT and KI either (Fig 6.3.6). So, the 
result produced in 6.3.1 could be due to the fact that those two antibodies were old and not as 
good, and might have degraded, but we need to test the samples in 6.3.1 with the fresh TAB1 
antibody from Cohen’s group before we conclude this. Another interesting result in 6.3.1 was 
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that the TAB1 from the WT mice appeared to run higher than the TAB1 from the KI mice. This 
was produced by both Santacruz and the Cohen group’s old TAB1 antibody. The result 
confirmed that the WT TAB1 (54.581kDa) is heavier than the KI TAB1 (54.359kDa). However 
the difference in molecular weight is a mere 0.222kDa and it is very surprising to see a shift in 
the western blot for such small difference. The result would be more plausible if the WT TAB1 
was to undergo more post-translational modifications such as phosphorylation and 
ubiquitination than the KI TAB1 that would make it heavier. The new batch of TAB1 antibody 
from the Cohen group did not produce the shift between the WT and KI TAB1 band with both 
running at same molecular weight. To conclude, although the old antibodies detected a small 
difference in the expression of the WT and KI TAB1, the new fresh antibody did not detect any 
differences. From these results, we conclude that the expression of the mutated TAB1 in the KI 
mice is not impaired, and it should not affect our investigation to compare its function between 
the WT and the KI mice.  
 
 6.4.2 p38α activation in the KI mice  
 
6.4.2.1 p38α activation is not impaired in the KI mice 
After confirming that the mutated TAB1 protein is expressed in the KI mice, we investigated 
the TAB1-induced activation of p38α caused by ischaemia. We carried out Langendorff 
perfusion of the WT and KI hearts and subjected them to 40 minutes of stabilization followed 
by 10 minutes of global ischaemia. These hearts were then homogenised and analysed by 
western blotting to look at the activation of p38α. As the TAB1 protein in the KI mice has its 4 
residues involved in binding to p38α mutated, we expected a lack of p38 activation in the KI 
mice during ischaemia. However, as seen in western blot 6.3.2 there was a clear activation of 
p38α in the KI hearts. In fact, p38α activation appeared to be more in the KI mice compared to 
the WT mice. In the WT hearts, ischaemia caused an increase in p38α activation as expected but 
to see p38α activation in the KI hearts was a surprise. Interestingly, there was also more MKK3 
activation in the KI hearts compared to the WT hearts which could help to explain the phospho 
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p38 signal seen in the KI hearts. p38α is a vital signalling protein and it seems the MKK 
pathway may have been switched on to compensate for the lack of TAB1 pathway. 
Additionally, we know that MKK3/6 activates p38α significantly more strongly than the TAB1 
activates p38α, and it could explain the stronger phospho p38 signal we see in the KI hearts 
compared to the WT hearts where there is minimum active MKK3. Intriguingly in a reversal 
study where MKK3 pathway was knocked out, the p38α activation induced by tumour necrosis 
factor (TNF)-α (activator of canonical pathway) did not seem to be compensated via the TAB1 
pathway (Tanno et al, 2003).   
 
The p38α activation at the baseline condition appeared to be less in the KI hearts compared to 
the WT hearts. This result suggests that in heart the TAB1-induced p38α autoactivation pathway 
could also play a role in baseline condition in addition to the ischaemic event. There was no 
change in the phospho TAB1 signal with ischaemia in the WT hearts. The result was surprising 
as with increased activation of p38α following ischaemia, we expected the phospho TAB1 
signal to go up as well, since it is the downstream target of p38α. The phospho TAB1 signal in 
the KI hearts could not be detected either at baseline or during ischaemia. This was expected as 
the mutated TAB1 in the KI mice is unable to bind to p38α and as a result TAB1 cannot dock to 
p38α and become phosphorylated.   
 
6.4.2.2 p38α auto-activation is impaired in the KI mice  
The result in 6.3.2 showed that p38α gets activated during ischaemia in the KI hearts as opposed 
to our prediction. It suggests that the canonical MKK pathway may be compensating for the 
lack of TAB1 pathway. To confirm this, we carried out Langendorff perfusion of the KI hearts 
that were subjected to global ischaemia in the presence of SB203580. SB203580 is an ATP-
mimetic inhibitor that competes with ATP for p38α’s catalytic site and as a result inhibits the 
p38α’s activation caused via TAB1 (Cohen, 1997; Young et al, 1997). SB203580 does not 
inhibit enzymes involved in the canonical pathway so it does not prevent the activation of p38α 
via trans-activation mechanism (Kumar et al, 1999). If p38α activation is inhibited in the 
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presence of SB203580, it means that p38α must be getting activated via the TAB1-induced 
autoactivation mechanism. The western blot analysis in 6.3.3 showed that in the KI hearts 
treated with 10µM SB203580, the phospho p38 signal was reduced in some hearts by various 
degrees. The result suggests that SB203580 is preventing the p38 auto-activation during 
ischaemia, i.e. p38α must be getting activated via the TAB1 pathway. However, that is not 
possible, as TAB1 cannot bind to p38α in the KI animal, and the only other known 
autoactivation mechanism of p38α not involving TAB1 is specific to T-cells (Salvador et al, 
2005). In the presence of DMSO, the vehicle solvent in which the SB203580 was dissolved, 
p38α activation was also reduced; producing very similar result to the SB203580 treated hearts. 
This result indicates that it was not in fact the SB203580 that caused the inhibition of p38α 
activation, but DMSO. However, DMSO itself should not inhibit the p38 activation. It is 
something we cannot explain at this stage and it requires further tests, for example running the 
experiments with water-soluble SB203580 and also running the experiments alongside WT 
hearts. To conclude, the results so far suggest that the p38α auto-activation in the KI hearts 
seems to be impaired but the p38α trans-activation is not, as the canonical MKK pathway 
appears to take over for the lack of the TAB1 pathway.  
 
6.4.3 Infarct volume assessment in the KI hearts  
As discussed in previous chapters and the introduction of this chapter, the TAB1-induced p38α 
autoactivation in ischaemic heart aggravates the lethal injury to the heart. p38α autoactivation 
causes biochemical signalling in the myocardium that drives the damage to the heart which 
results in myocardial death and heart failure (Barancik et al, 2000; Ma et al, 1999; Martin et al, 
2015). From the results in 6.3.2 and 6.3.3, we know p38α activation is not affected in the TAB1 
KI mice, as the canonical pathway takes over the impaired TAB1 pathway. The p38α activation 
that causes the damage in ischaemic heart takes place via the TAB1 pathway not the canonical 
pathway, however p38α is activated nevertheless. Whether the contrasting mode of p38α   
activation from two different pathways reflects in phosphorylation of different substrates to 
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produce distinct outcomes is not known. We tested this by carrying out Langendorff perfusion 
of these hearts with ischaemia-reperfusion protocol and quantifying the infarct sizes.  
 
The result in 6.3.6 showed that ischaemia caused a significant infarction in the KI hearts similar 
to the WT hearts. In fact the average infarct volume in the KI hearts tended to be greater (60%) 
than in the WT hearts (50%). The result suggests that the KI hearts are not protected during 
ischaemia contrary to our prediction. The result is not entirely surprising considering our 
previous results which showed p38α activation is not impaired in the KI hearts, and the findings 
from previous study which has shown that only a complete inhibition of p38α elicits a 
protective phonotype (Kumphune et al, 2010). In fact the infarction result correlates with the 
p38α activation result in 6.3.2 where we observed greater p38α activation in the KI hearts which 
produced a higher infarction from ischaemia in 6.3.5. Similarly, in the control hearts of the KI 
mice, we observed less infarction compared to the control hearts of the WT mice, which also 
correlates with the p38α activation result in 6.3.2 where we observed less p38α activation in the 
KI baseline hearts compared to the WT baseline hearts. However, the infarction of around 
average of 25% in the WT control hearts is a surprise. Under the aerobic perfusion, the 
infarction should be at minimal level as seen in the KI control hearts. The 2 out of 6 hearts in 
the WT control showed big infarction which could have resulted from individual experimental 
error on those particular hearts, so repeating the experiment with another 2 control WT hearts 
would be a good future experiment. Nevertheless, the infarction study has confirmed that p38α 
is the main determinant that orchestrates the catastrophic biochemical signalling in the heart 
which contributes to infarction and heart failure.  
 
To summarise, our results have demonstrated that p38α activation during ischaemia aggravates 
the injury to the heart, to support hundreds of other studies in the literature (Barancik et al, 
2000; Ma et al, 1999; Mackay et al, 1999; Liu et al, 2005; Kaiser et al, 2004). However, our 
study at this stage has suggested one novel finding, which is, the mode of p38α activation does 
not seem to determine the detrimental outcome as long as p38α is activated. After 20 years of 
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failure in clinical trials, the circumstance selective inhibition of p38α had provided a promising 
outlook and looked to be the way forward in p38α therapeutics. We hoped to contribute to that 
research with our study of TAB1 KI mice and aimed to achieve selective inhibition of TAB1 
pathway during ischaemia that would translate into protective phenotype of the heart. However, 
the results so far from the TAB1 KI mice seem to suggest that even if the TAB1 pathway is 
targeted, the MKK3/6 pathway could be switched on to activate p38α to cause damage in the 
ischaemic heart. But having said that, this is a preliminary data collected from one ex-vivo 
technique and we need to carry out significant amount of further studies on these animals before 
coming to any conclusion. Additionally, knocking out TAB1 pathway genetically is completely 
different to selectively inhibiting TAB1 pathway using an inhibitor. Using a drug to inhibit the 




















 7 General discussions and future work  
 
p38α is a serine/threonine kinase belonging to a family of MAPKs which plays a vital role in a 
myriad of cellular cascades. Also known as stress activated protein kinase (SAPK), several 
studies in the literature in past twenty years have shown that ischaemic stress in myocardium 
causes an activation of p38α, which exacerbates the injury (Tanno et al, 2003; Nagarkatti et al, 
1998; Ren et al, 2005). Significantly, the studies have also established that inhibiting the 
activation of p38α prevents the injury to the heart (Barancik et al, 2000; Cain et al, 1999; Martin 
et al, 2001; Kumphune et al, 2009; See et al, 2004). As a result, a huge amount of time and 
resources have been poured into elucidating p38α’s activation mechanism that accelerates injury 
to the heart in ischaemic heart disease. Several p38α inhibitors have been tested but 
unfortunately none have passed through the phase III stage of clinical trials, attributed to severe 
side effects (Martin et al, 2012; Marber et al, 2011). In early 2000, Ge and co-workers made a 
major observation and discovered the activation mechanism of p38α during ischaemia, which 
surprisingly was not via the classical activation pathway but via a scaffold protein known as 
TAB1 (Ge et al, 2002). This finding has become critical in the development of a new type of 
p38α inhibitor that bypasses the activation of p38α via classical activation pathway but inhibits 
the p38α activation induced by TAB1. This, in theory, should reduce the incidence of side 
effects seen with the p38α inhibitors in the clinical trials by avoiding a blanket inhibition. 
However, in order to develop such a drug, a better understanding of the activation of p38α by 
TAB1 is required in atomic detail. This was the aim of my thesis in which I investigated the 








































Figure 7 p38α activation pathways: The cartoon describes the activation pathways of p38α. The 
classical activation pathway involving the TAK1/MKK3&6/p38α cascade helps to maintain proper 
cellular function and physiological homeostasis. The TAB1/p38α pathway is activated during ischaemia 
and aggravates myocardial injury. The therapeutic strategy is to prevent the TAB1-mediated p38α 
activation pathway, without affecting the classical activation pathway. (The black arrow indicates 
activation, the red arrow indicates inhibition). 
 
 
7.1 Chapter 4  
7.1.1 Summary  
In chapter 3, using an in-vitro kinase assay and the living system of a mammalian cell line, I 
confirmed the TAB1-mediated activation mode of p38α. I showed that TAB1 caused 
autoactivation of p38α which was sensitive to an ATP-mimetic inhibitor, SB203580. This 
supported the original findings from Ge et al in 2002. With that confirmation, I went on to 
address the main aim of my thesis; to study the structural details of TAB1-mediated p38α 
activation. In 2013 our lab resolved the crystal structure of a p38α-TAB1 complex which 
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revealed many key findings of the autoactivation mechanism of p38α (De Nicola et al, 2013). 
The significant findings were; TAB1 interacts with p38α in a bipartite manner, interaction leads 
to structural changes that increase affinity for ATP, the activation loop swings towards the 
catalytic site bringing Thr180 in proximity to the bound ATP which facilitates the T-G-Y 
autophosphorylation. On a closer inspection of the crystal structure, we observed that the C-
terminal end of the activation loop (Tyr182-Thr185) extended to form an α-helical segment, 
which caused the activation loop to swing towards the catalytic site. This extension appeared to 
be stabilized by the formation of a hydrogen bond between the side chains of Thr185 and 
Asp150. Based on this observation, we hypothesised that if this hydrogen bond between Thr185 
and Asp150 was disrupted then this would deprive the system of the free energy that is required 
to hold the activation loop in this new orientation and disturb the structural changes that favour 
autophosphorylation of the T-G-Y motif. To test this hypothesis, we created a mutant 
p38αT185G and compared its biophysical and biochemical properties with WTp38α. Using an 
in-vitro kinase assay and several stimuli in the living system of HEK293 cells, we produced 
robust data to show that the hydrogen bond between the side chains of Thr185 and Asp150 does 
indeed play a significant role in the structural changes induced by TAB1 and without it the 
autoactivation of p38α is impaired. We showed this with purified recombinant protein in in-
vitro kinase assay (Fig 4.3.6) and by transfecting p38αT185G in to HEK293 cells with TAB1 
(Fig 4.3.7). Additionally, we also showed that ischaemia, a prominent activator of TAB1-
mediated activation of p38α, was unable to cause autoactivation of p38αT185G. These results 
collectively support our hypothesis that the autoactivation of p38αT185G is impaired, and it was 
not due to the inability of the mutant p38αT185G to bind and interact with TAB1. We verified 
this using ITC and showed that p38αT185G was indeed able to interact with TAB1 similar to 
the WTp38α. Finally, we resolved the crystal structure of the p38αT185G-TAB1 complex 
which confirmed the interaction and the lack of hydrogen bond between residues 185 and 150. 
This in-turn caused the C-terminal end of the activation loop (Tyr182-Thr185) to be more 
relaxed, which in-turn destabilized and prevented the swing of activation loop toward the 
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catalytic site. Due to this, the activation loop was too mobile which was depicted by the high B 
factor and could not be resolved in the crystal structure (Fig 4.3.5).  
 
7.1.2 Implications  
The results gathered in chapter 4 highlighted a key feature; that the hydrogen bond between 
Thr185 and Asp150 plays a vital role in the successful activation of p38α induced by TAB1. 
Unfortunately however, a hydrogen bond cannot be targeted by a drug or an inhibitor, so this is 
not an observation that can be easily translated to disrupt p38α activation during ischaemia in-
vivo. Nevertheless we know that the hydrogen bond stabilizes the extension of the C-terminal 
end of the activation loop (Tyr182-Thr185), one of the key structural changes that takes place 
during the activation mechanism, and this region can perhaps be targeted for disruption. A 
definite line of future work would be to create a transgenic mouse based on this mutation. Our 
results suggest that the mutation has not impacted p38α’s ability to interact with TAB1, which 
means it is highly likely that its ability to bind to other binding partners is not affected either. 
Although the classical activation mechanism, and the catalytic ability, of the p38αT185G 
mutant appeared to be disrupted at low nanomolar concentrations, we speculate the higher 
differential sensitivity of the auto-activation mechanism would provide a high therapeutic index. 
These results suggest that the transgenic mice should be viable and healthy without any major 
complications. Once created, the hearts from these mice could be investigated under ischaemic 
stress to assess p38α’s activation status and whether they present a protective phenotype. If the 
results are positive, this model can be exploited in several ways to elucidate p38α’s role in 
ischaemia. For example, any difference in the activation of substrates compared to WT mice can 
be investigated to compile potential hits for p38α’s substrates that are activated during 
ischaemia. The p38αT185G knock-in mice therefore have the potential to both validate our 





7.2 Chapter 5 
7.2.1 Summary  
In chapter 5 I investigated if Thr185 also played a role in determining p38α’s cellular location. 
The underlying rationale behind this prediction was related to the role of Thr188, the 
corresponding residue in ERK2, in determination of cellular location (Lorenz et al, 2008). In 
pathological cardiac hypertrophy, autophosphorylation of Thr188 drives ERK2 into the nucleus 
to phosphorylate pro-hypertrophic genes which exacerbate hypertrophy. p38α is a close family 
member of ERK2 and we wondered whether TAB1-mediated autophosphorylation extends to 
Thr185 and that in turn translocates p38α during ischaemia. We showed using mass 
spectrometry analysis that TAB1 induced phosphorylation at Thr185, however, this did not 
result in p38α localizing to the nucleus. We found no different in the cellular location of 
WTp38α compared to p38αT185G, suggesting that phosphorylation of Thr185 had no impact on 
p38α’s cellular location. Therefore, Thr185 of p38α does not have a similar functional role to 
the Thr188 of ERK2.   
 
7.2.2 Implications  
Our hypothesis was based on the 50% shared homology between p38α and ERK2 that 
warranted this investigation (Cargnello et al, 2011). However, despite the similarity, one major 
difference between them with regards to their regulation of cellular location was that; ERK2 has 
a nuclear localization signal, whereas p38α does not. Therefore our negative result is not a total 
surprise. The regulation of p38α’s cellular location has been the subject of debate with several 
studies publishing contrasting results as discussed in 5.4. So, more work needs to be done in this 
area, but based on our study, we can conclude that Thr185 does not play a major role in 






7.3 Chapter 6 
7.3.1 Summary  
The final chapter contains the preliminary data collected from the TAB1 KI mice, where four 
residues (V390A/Y392A/V408G/M409A) in TAB1 involved in the interaction with p38α have 
been mutated. As a result, TAB1 is unable to bind to and auto-activate p38α in the TAB1 KI 
mice. Using a Langendorff technique, we perfused the KI hearts and subjected them to 10 
minutes of ischaemia to determine the p38α activation status. To our surprise, ischaemia caused 
similar p38α activation in the KI hearts to that observed in the WT hearts. The result was 
completely the opposite of what was expected. We also observed a greater activation of MKK3 
by the classical activation pathway in the KI hearts compared to the WT hearts, and concluded 
that the MKK3/6 pathway appeared to be compensating for the lack of the TAB1 pathway. If 
this is indeed the case, it would not be a total surprise since p38α is a vital signalling molecule, 
especially in a stressful environment such as ischaemia. The key question was whether this 
activation of p38α via a different activation pathway resulted in a similar detrimental outcome. 
To find out, we subjected Langendorff-perfused hearts to an ischaemia-reperfusion protocol. 
After 30 minutes of ischaemia and 2 hours of reperfusion, we observed that the ischaemia 
tended to cause more substantial infarction in the KI hearts compared to the WT hearts. This 
result correlated with the activation level of p38α, as higher phospho p38α level was observed in 
the KI hearts compared to the WT hearts. The result suggested that the injury to the heart is 
determined by the level of p38α activation and the mechanism of activation may have no impact 
on it. It is an interesting result because MKK3/6 activates p38α significantly more strongly than 
TAB1. So, the fact that p38α get activated via TAB1 during ischaemia could be an adaptive 
mechanism to protect the cell, thereby minimizing the activation of p38α and consequent injury 






7.3.2 Implications  
To observe p38α activation and greater infarction in the TAB1 KI hearts compared to the WT 
hearts was a very disappointing outcome. We created the TAB1 KI mice in the hope that it 
would produce a protective phenotype during ischaemia by preventing the detrimental TAB1-
mediated p38α activation pathway. However, such is the elegance of a cellular system to adapt 
for survival that the MKK3/6 pathway seems to have been switched on to maintain the activity 
of p38α, which further demonstrates p38α’s importance as a signalling protein. Ironically, this 
compensative mechanism has led to greater infarction resulting from higher p38α activation by 
MKK3/6. However, this does not mean we cannot target the TAB1 pathway with a drug. Using 
an inhibitor to target p38α-TAB1 pathway is not going to evoke the same cellular response as 
genetically ablating the pathway, i.e. a small molecule that targets TAB1-p38α complex will not 
necessarily cause an activation of the classical MKK3/6 pathway. Furthermore, our observations 
may reflect the germline KI of p38α and the compensatory activation of MKK3/6 may not 
happen with short-term inhibition of the association between TAB1 and p38α that would be 
achieved with a small molecule. So, the work to create a drug to prevent TAB1 and p38α 
interaction must continue. Additionally, the data presented in this chapter are preliminary from 
an ex-vivo technique. A more relevant in-vivo technique, such as transverse aortic constriction 
(TAC) should be performed to further validate the observation. Similarly, these mice can be 












The aim of this thesis was to study the TAB1-mediated autoactivation of p38α in the hope we 
can reveal key structural features that are vital to this process. I investigated the structural 
features, and consequence of activating and disrupting this pathway. Determining how exactly 
p38α mediates its signalling to aggravate myocardial injury is a challenging task. So many 
variables- such as different isoforms of p38, signalling networks, feedback loops, status of 
MKK3/6 and TAB1, p38 cell location, availability of substrates- will have an impact on p38α 
signalling. In this thesis, the two models I investigated, p38αT185G and TAB1 KI 
(V390A/Y392A/V408G/M409A) have provided promising preliminary results in respect to 
understanding the p38α signalling in more details and how to target TAB1-mediated p38α 
activation. However, it warrants further investigations so that we can achieve the ultimate aim of 
reducing myocardial ischaemic injury caused by p38α that may contribute to heart failure, the 































Figure 7.4 Targeting TAB1-mediated p38α activation:  The p38αT185G and the TAB1 KI model can be 
exploited to unravel p38α’s functionality during ischaemia that contributes to myocardial injury. The 
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